U.S. patent application number 16/143202 was filed with the patent office on 2019-08-29 for pyridine and pyrazine derivative for the treatment of cf.
The applicant listed for this patent is NOVARTIS AG. Invention is credited to Urs BAETTIG, Kamlesh Jagdis Bala, Emma Budd, Lee Edwards, Catherine Howsham, Glyn Alan Hughes, Darren Mark LE GRAND, Katrin Spiegel.
Application Number | 20190262324 16/143202 |
Document ID | / |
Family ID | 44647718 |
Filed Date | 2019-08-29 |
![](/patent/app/20190262324/US20190262324A1-20190829-C00001.png)
![](/patent/app/20190262324/US20190262324A1-20190829-C00002.png)
![](/patent/app/20190262324/US20190262324A1-20190829-C00003.png)
![](/patent/app/20190262324/US20190262324A1-20190829-C00004.png)
![](/patent/app/20190262324/US20190262324A1-20190829-C00005.png)
![](/patent/app/20190262324/US20190262324A1-20190829-C00006.png)
![](/patent/app/20190262324/US20190262324A1-20190829-C00007.png)
![](/patent/app/20190262324/US20190262324A1-20190829-C00008.png)
![](/patent/app/20190262324/US20190262324A1-20190829-C00009.png)
![](/patent/app/20190262324/US20190262324A1-20190829-C00010.png)
![](/patent/app/20190262324/US20190262324A1-20190829-C00011.png)
View All Diagrams
United States Patent
Application |
20190262324 |
Kind Code |
A1 |
BAETTIG; Urs ; et
al. |
August 29, 2019 |
Pyridine and Pyrazine Derivative for the Treatment of CF
Abstract
The present invention provides pyridine and pyrazine derivatives
which restore or enhance the function of mutant and/or wild type
CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic
bronchitis, chronic obstructive pulmonary disease, asthma,
respiratory tract infections, lung carcinoma, xerostomia and
keratoconjunctivitis sire, or constipation (IBS, IBD, opioid
induced). Pharmaceutical compositions comprising such derivatives
are also encompassed.
Inventors: |
BAETTIG; Urs; (Reinach,
CH) ; Bala; Kamlesh Jagdis; (Horsham, GB) ;
Budd; Emma; (Horsham, GB) ; Edwards; Lee;
(Horsham, GB) ; Howsham; Catherine; (Horsham,
GB) ; Hughes; Glyn Alan; (Horsham, GB) ; LE
GRAND; Darren Mark; (West Sussex, GB) ; Spiegel;
Katrin; (Horsham, GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
NOVARTIS AG |
Basel |
|
CH |
|
|
Family ID: |
44647718 |
Appl. No.: |
16/143202 |
Filed: |
September 26, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15156528 |
May 17, 2016 |
10117858 |
|
|
16143202 |
|
|
|
|
14521843 |
Oct 23, 2014 |
9365552 |
|
|
15156528 |
|
|
|
|
13923349 |
Jun 20, 2013 |
|
|
|
14521843 |
|
|
|
|
13544182 |
Jul 9, 2012 |
8476269 |
|
|
13923349 |
|
|
|
|
13047319 |
Mar 14, 2011 |
8247436 |
|
|
13544182 |
|
|
|
|
61441853 |
Feb 11, 2011 |
|
|
|
61315509 |
Mar 19, 2010 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 31/00 20180101;
A61P 37/08 20180101; C07D 413/12 20130101; A61P 11/06 20180101;
A61K 31/4545 20130101; A61P 11/12 20180101; C07D 405/04 20130101;
A61P 1/02 20180101; C07D 213/81 20130101; C07D 241/26 20130101;
C07D 413/04 20130101; C07D 401/12 20130101; C07D 213/38 20130101;
A61P 1/10 20180101; A61P 19/04 20180101; A61K 31/443 20130101; C07D
403/12 20130101; A61P 11/08 20180101; A61K 31/497 20130101; A61P
27/02 20180101; A61P 29/00 20180101; A61K 31/44 20130101; A61K
45/06 20130101; A61K 31/4412 20130101; A61K 31/4965 20130101; C07D
405/12 20130101; A61K 31/444 20130101; A61P 35/00 20180101; A61K
31/4418 20130101; A61K 31/5377 20130101; A61K 31/4439 20130101;
C07D 401/04 20130101; A61P 11/00 20180101 |
International
Class: |
A61K 31/44 20060101
A61K031/44; A61K 31/4412 20060101 A61K031/4412; A61K 31/4418
20060101 A61K031/4418; A61K 31/4965 20060101 A61K031/4965; A61K
31/497 20060101 A61K031/497; A61K 31/5377 20060101 A61K031/5377;
A61K 31/443 20060101 A61K031/443; A61K 31/4439 20060101
A61K031/4439; A61K 31/444 20060101 A61K031/444; A61K 31/4545
20060101 A61K031/4545; C07D 401/12 20060101 C07D401/12; C07D 213/38
20060101 C07D213/38; C07D 403/12 20060101 C07D403/12; C07D 241/26
20060101 C07D241/26; C07D 405/04 20060101 C07D405/04; C07D 413/12
20060101 C07D413/12; C07D 413/04 20060101 C07D413/04; C07D 405/12
20060101 C07D405/12; C07D 401/04 20060101 C07D401/04; C07D 241/28
20060101 C07D241/28; C07D 213/81 20060101 C07D213/81; A61K 45/06
20060101 A61K045/06 |
Claims
1. A compound of Formula I ##STR00116## or pharmaceutically
acceptable salts thereof, wherein: A is N or CR.sup.4a; R.sup.1 is
H; C.sub.1-C.sub.8 alkyl optionally substituted by one or more
halogen atoms; C.sub.2-C.sub.8 alkenyl; C.sub.2-C.sub.8 alkynyl;
C.sub.3-C.sub.10 cycloalkyl; C.sub.5-C.sub.10 cycloalkenyl;
--C.sub.1-C.sub.4 alkyl-C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.8
alkoxy optionally substituted by one or more halogen atoms;
halogen; SO.sub.2NR.sup.8R.sup.9; SO.sub.2R.sup.10;
S--C.sub.1-C.sub.8alkyl optionally substituted by one or more
halogen atoms; S--C.sub.6-C.sub.14 aryl; CN; NR.sup.11R.sup.12;
C(O)NR.sup.13R.sup.14; NR.sup.13SO.sub.2R.sup.15;
NR.sup.13C(O)R.sup.15, CO.sub.2R.sup.15, --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; or --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; wherein
the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are each
optionally substituted by one or more Z substituents; R.sup.2 is
C.sub.1-C.sub.4 haloalkyl; R.sup.3 and R.sup.4a are each
independently H or C.sub.1-C.sub.8 alkyl optionally substituted by
one or more halogen atoms; R.sup.4 is H, or C.sub.1-C.sub.8 alkyl
optional substituted with one or more halogen; R.sup.5 is
--(CH.sub.2).sub.m--NR.sup.17R.sup.18, --(CH.sub.2).sub.m--OR';
C.sub.1-C.sub.8 alkoxy optionally substituted by one or more
halogen atoms; --(C.sub.0-C.sub.4 alkyl)-CO.sub.2R.sup.15;
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl or -3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; wherein
the --(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl and
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group are
each optionally substituted by one or more Z substituents; R.sup.6
is C.sub.1-C.sub.8 alkyl optionally substituted by one or more
halogen atoms; C.sub.3-C.sub.10 cycloalkyl; --C.sub.1-C.sub.4
alkyl-C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.8 alkoxy optionally
substituted by one or more halogen atoms; OH; CN; halogen;
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl; or
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group,
wherein the heterocyclic group contains at least one heteroatom
selected from N, O and S; wherein the cycloalkyl, cycloalkenyl,
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl and
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group are
each optionally substituted by one or more Z substituents; or
R.sup.6 is H, and R.sup.5 is --(CH.sub.2).sub.m--NR.sup.17R.sup.18,
--(CH.sub.2).sub.m--OR', C.sub.1-C.sub.8 alkoxy optionally
substituted by one or more halogen atoms; --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; or
--(C.sub.0-C.sub.4 alkyl)-CO.sub.2R.sup.15, wherein
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl and
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group
groups are each optionally substituted by one or more Z
substituents; or R.sup.4 and R.sup.6 together with the carbon atoms
to which they are bound form a 3 to 8 membered carbocyclic ring
system; or R.sup.4 and R.sup.5 together form an oxo group (C.dbd.O)
and R.sup.6 is C.sub.1-C.sub.4 alkyl optionally substituted by one
or more halogen atoms; C.sub.1-C.sub.4 alkoxy optionally
substituted by one or more halogen atoms; --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; or --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S, wherein
the aryl and heterocyclyl groups are each optionally substituted by
one or more Z substituents; or R.sup.5 and R.sup.6 together with
the carbon atoms to which they are bound a 5 to 8 membered
heterocyclic ring system containing one or more heteroatoms
selected from N, O and S, wherein the ring system is optionally
substituted by one or more Z substituents; or R.sup.4 and R.sup.5
and R.sup.6 together with the carbon atoms to which they are bound
form a 5 to 8 membered heterocyclic ring system containing one or
more heteroatoms selected from N, O and S, wherein the ring system
is optionally substituted by one or more Z substituents; R' is H,
or C.sub.1-C.sub.8 alkyl optional substituted with one or more
halogen; m is 0, 1, 2 or 3; R.sup.8, R.sup.11, R.sup.13 and
R.sup.17 are each independently H, C.sub.1-C.sub.8 alkyl optionally
substituted by one or more halogen atoms, C.sub.3-C.sub.10
cycloalkyl or --(C.sub.1-C.sub.4 alkyl)-C.sub.3-C.sub.8 cycloalkyl;
R.sup.9, R.sup.10, R.sup.12, R.sup.14, R.sup.15, R.sup.16 and
R.sup.18 are each independently H; C.sub.1-C.sub.8 alkyl optionally
substituted by one or more halogen atoms; C.sub.2-C.sub.8 alkenyl;
C.sub.2-C.sub.8 alkynyl; C.sub.3-C.sub.10 cycloalkyl;
C.sub.5-C.sub.10 cycloalkenyl; --C.sub.1-C.sub.4
alkyl-C.sub.3-C.sub.8 cycloalkyl; --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; or --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S, wherein
the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are each
optionally substituted by one or more Z substituents; or R.sup.8
and R.sup.9, R.sup.11 and R.sup.12, R.sup.13 and R.sup.14, and
R.sup.17 and R.sup.18 together with the nitrogen atom to which they
are attached may form a 4 to 14 membered heterocyclic group
optionally substituted by one or more Z substituents; Z is
independently OH, aryl, O-aryl, benzyl, O-benzyl, C.sub.1-C.sub.6
alkyl optionally substituted by one or more OH groups or NH.sub.2
groups, C.sub.1-C.sub.6 alkyl optionally substituted by one or more
halogen atoms, C.sub.1-C.sub.6 alkoxy optionally substituted by one
or more OH groups or C.sub.1-C.sub.4 alkoxy,
NR.sup.18(SO.sub.2)R.sup.21, (SO.sub.2)NR.sup.19R.sup.21,
(SO.sub.2)R.sup.21, NR.sup.18C(O)R.sup.21, C(O)NR.sup.19R.sup.21,
NR.sup.18C(O)NR.sup.19R.sup.21, NR.sup.18C(O)OR.sup.19,
NR.sup.19R.sup.21, C(O)OR.sup.19, C(O)R.sup.19, SR.sup.19,
OR.sup.19, oxo, CN, NO.sub.2, halogen or a 3 to 14 membered
heterocyclic group, wherein the heterocyclic group contains at
least one heteroatom selected from N, O and S; R.sup.19 and
R.sup.21 are each independently H; C.sub.1-C.sub.8 alkyl;
C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.4 alkoxy-C.sub.1-C.sub.4
alkyl; (C.sub.0-C.sub.4 alkyl)-aryl optionally substituted by one
or more groups selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkoxy and halogen; (C.sub.0-C.sub.4 alkyl)-3- to 14-membered
heterocyclic group, the heterocyclic group including one or more
heteroatoms selected from N, O and S, optionally substituted by one
or more groups selected from halogen, oxo, C.sub.1-C.sub.6 alkyl
and C(O)C.sub.1-C.sub.6 alkyl; (C.sub.0-C.sub.4 alkyl)-O-aryl
optionally substituted by one or more groups selected from
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy and halogen; and
(C.sub.0-C.sub.4 alkyl)-O-3- to 14-membered heterocyclic group, the
heterocyclic group including one or more heteroatoms selected from
N, O and S, optionally substituted by one or more groups selected
from halogen, C.sub.1-C.sub.6 alkyl or C(O)C.sub.1-C.sub.6 alkyl;
wherein the alkyl groups are optionally substituted by one or more
halogen atoms, C.sub.1-C.sub.4 alkoxy, C(O)NH.sub.2,
C(O)NHC.sub.1-C.sub.6 alkyl or C(O)N(C.sub.1-C.sub.6 alkyl).sub.2;
or R.sup.19 and R.sup.21 together with the nitrogen atom to which
they attached form a 5- to 10-membered heterocyclic group, the
heterocyclic group including one or more further heteroatoms
selected from N, O and S, the heterocyclic group being optionally
substituted by one or more substituents selected from OH; halogen;
aryl; 5- to 10-membered heterocyclic group including one or more
heteroatoms selected from N, O and S; S(O).sub.2-aryl;
S(O).sub.2--C.sub.1-C.sub.6 alkyl; C.sub.1-C.sub.6 alkyl optionally
substituted by one or more halogen atoms; C.sub.1-C.sub.6 alkoxy
optionally substituted by one or more OH groups or C.sub.1-C.sub.4
alkoxy; and C(O)OC.sub.1-C.sub.6 alkyl, wherein the aryl and
heterocyclic substituent groups are themselves optionally
substituted by C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl or
C.sub.1-C.sub.6 alkoxy.
2. The compound according to claim 1, wherein A is CR.sup.4a.
3. The compound according to claim 1, wherein R.sup.1 is
C.sub.1-C.sub.8 alkyl optionally substituted by one or more halogen
atoms; C.sub.1-C.sub.8 alkoxy optionally substituted by one or more
halogen atoms; halogen; NR.sup.11R.sup.12, C.sub.6-C.sub.14 aryl;
or --(C.sub.0-C.sub.4 alkyl)-5 to 6 membered heterocyclic group,
wherein the heterocyclic group contains at least one heteroatom
selected from N, O and S, wherein the aryl and heterocyclic groups
are each optionally substituted by one or more Z substituents.
4. The compound according to claim 1, wherein R.sup.1 is
C.sub.1-C.sub.4 alkyl optionally substituted by one or more halogen
atoms; C.sub.1-C.sub.4 alkoxy optionally substituted by one or more
halogen atoms; or halogen.
5. The compound according to claim 1, wherein R.sup.1 is aryl,
wherein aryl is phenyl optionally substituted by one or more Z
substituents.
6. The compound according to claim 1, wherein R.sup.2 is
CF.sub.3.
7. The compound according to claim 1, wherein R.sup.4 is H or
C.sub.1-C.sub.4 alkyl optionally substituted by one or more halogen
atoms; R.sup.5 is C.sub.1-C.sub.4 alkoxy optionally substituted by
one or more halogen atoms; --(CH.sub.2).sub.m--NR.sup.7R.sup.8,
--(CH.sub.2).sub.m--OR'; or --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S, wherein
the aryl heterocyclyl groups is optionally substituted by one or
more Z substituents; R.sup.6 is C.sub.1-C.sub.4 alkyl optionally
substituted by one or more halogen atoms; C.sub.1-C.sub.4 alkoxy
optionally substituted by one or more halogen atoms; or
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl wherein the aryl is
optionally substituted by one or more Z substituents; or R.sup.4
and R.sup.6 together with the carbon atoms to which they are bound
form a 3 to 6 membered carbocyclic ring system; or R.sup.5 and
R.sup.6 together with the carbon atoms to which they are bound form
a 5 to 8 membered heterocyclic ring system containing one or more
heteroatoms selected from N, O and S, wherein the ring system is
optionally substituted by one or more Z substituents; m is 0 or 1;
R.sup.17 and R.sup.18 are each independently H; C.sub.1-C.sub.8
alkyl optionally substituted by one or more halogen atoms.
8. The compound according to claim 1, wherein A is CR.sup.4a;
R.sup.1 is C.sub.1-C.sub.4 alkyl optionally substituted by one or
more halogen atoms; or C.sub.1-C.sub.4 alkoxy optionally
substituted by one or more halogen atoms; R.sup.2 is CF.sub.3;
R.sup.3 is H, CH.sub.3 or CF.sub.3; R.sup.4 is H or Me; R.sup.4a is
H; R.sup.5 is --NR.sup.17R.sup.18 or OH, and R.sup.6 is
C.sub.1-C.sub.4 alkyl optionally substituted by one or more halogen
atoms.
9. The compound according to claim 1, represented by formula II,
##STR00117## or a pharmaceutically acceptable salt; wherein A is N
or CR.sup.4a; R.sup.a is H or C.sub.1-C.sub.4 alkyl; R.sup.1 is
C.sub.1-C.sub.8 alkyl optionally substituted by one or more halogen
atoms; C.sub.1-C.sub.8 alkoxy optionally substituted by one or more
halogen atoms; halogen; NR.sup.11R.sup.12, C.sub.6-C.sub.14 aryl;
or --(C.sub.0-C.sub.4 alkyl)-5 to 6 membered heterocyclic group,
wherein the heterocyclic group contains at least one heteroatom
selected from N, O and S, wherein the aryl and heterocyclic groups
are each optionally substituted by one or more Z substituents;
R.sub.3 is H or CH.sub.3; R.sup.101 is ##STR00118##
##STR00119##
10-12. (canceled)
13. A pharmaceutical composition, comprising: the compound
according to claim 1 and one or more pharmaceutically acceptable
excipients.
14. A pharmaceutical combination, comprising: a first active
comprising the compound according to claim 1 and a second active
selected from osmotic agents, ENaC blockers, anti-inflammatory
agents, bronchodilatory agents, antihistamine agents, anti-tussive
agents, antibiotic agents and DNase drug substances, wherein the
first and second actives may be in the same or different
pharmaceutical composition.
15. A method for treating CFTR mediated condition or disease,
comprising: administering an effective amount of at least one
compound according to claim 1 to a subject in need of such
treatment.
Description
[0001] This application is a continuation of U.S. application Ser.
No. 15/156,528, filed May 17, 2016, which is a continuation of U.S.
application Ser. No. 14/521,843, filed Oct. 23, 2014, which is a
continuation of U.S. application Ser. No. 13/923,349, filed Jun.
20, 2013, which is a continuation of U.S. application Ser. No.
13/544,182, filed Jul. 9, 2012, which issued as U.S. Pat. No.
8,476,269, which is a continuation of U.S. application Ser. No.
13/047,319, filed on Mar. 14, 2011, which issued as U.S. Pat. No.
8,247,436, which claims benefit under 35 U.S.C. .sctn. 119(e) of
U.S. Provisional Application No. 61/315,509, filed Mar. 19, 2010,
and U.S. Provisional Application No. 61/441,853, filed on Feb. 11,
2011, the contents of which are incorporated herein by reference in
their entirety.
[0002] This invention relates to pyridine and pyrazine compounds,
their preparation and use as pharmaceuticals.
[0003] Cystic fibrosis (CF) is a fatal genetic disease caused by
mutations in the gene encoding the CF transmembrane conductance
regulator (CFTR), a protein kinase A (PKA)-activated epithelial
anion channel involved in salt and fluid transport in multiple
organs, including the lung. Most CF mutations either reduce the
number of CFTR channels at the cell surface (e.g., synthesis or
processing mutations) or impair channel function (e.g., gating or
conductance mutations) or both. There are currently no approved
therapies that target CFTR directly. The present invention
discloses compounds which restore or enhance the function of mutant
and/or wild type CFTR to treat cystic fibrosis, primary ciliary
dyskinesia, chronic bronchitis, chronic obstructive pulmonary
disease, asthma, respiratory tract infections, lung carcinoma,
xerostomia and keratoconjunctivitis sire, or constipation (IBS,
IBD, opioid induced).
[0004] In one aspect, the invention provides compounds according to
Formula I:
##STR00001##
or pharmaceutically acceptable salts thereof, wherein:
A is N or CR.sup.4a;
[0005] R.sup.1 is H; C.sub.1-C.sub.8 alkyl optionally substituted
by one or more halogen atoms; C.sub.2-C.sub.8 alkenyl;
C.sub.2-C.sub.8 alkynyl; C.sub.3-C.sub.10 cycloalkyl;
C.sub.5-C.sub.10 cycloalkenyl; --C.sub.1-C.sub.4
alkyl-C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.8 alkoxy optionally
substituted by one or more halogen atoms; halogen;
SO.sub.2NR.sup.8R.sup.9; SO.sub.2R.sup.10; S--C.sub.1-C.sub.8alkyl
optionally substituted by one or more halogen atoms;
S--C.sub.6-C.sub.14 aryl; CN; NR.sup.11R.sup.12;
C(O)NR.sup.13R.sup.14; NR.sup.13SO.sub.2R.sup.15;
NR.sup.13C(O)R.sup.15, CO.sub.2R.sup.15, --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; or --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; wherein
the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are each
optionally substituted by one or more Z substituents; R.sup.2 is
C.sub.1-C.sub.4 haloalkyl; R.sup.3 and R.sup.4a are each
independently H or C.sub.1-C.sub.8 alkyl optionally substituted by
one or more halogen atoms; R.sup.4 is H, or C.sub.1-C.sub.8 alkyl
optional substituted with one or more halogen; R.sup.5 is
--(CH.sub.2).sub.m--NR.sup.17R.sup.18, --(CH.sub.2).sub.m--OR';
C.sub.1-C.sub.8 alkoxy optionally substituted by one or more
halogen atoms; --(C.sub.0-C.sub.4 alkyl)-CO.sub.2R.sup.15;
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl or -3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; wherein
the --(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl and
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group are
each optionally substituted by one or more Z substituents; R.sup.6
is C.sub.1-C.sub.8 alkyl optionally substituted by one or more
halogen atoms; C.sub.3-C.sub.10 cycloalkyl; --C.sub.1-C.sub.4
alkyl-C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.8 alkoxy optionally
substituted by one or more halogen atoms; OH; CN; halogen;
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl; or
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group,
wherein the heterocyclic group contains at least one heteroatom
selected from N, O and S; wherein the cycloalkyl, cycloalkenyl,
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl and
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group are
each optionally substituted by one or more Z substituents; or
R.sup.6 is H, and R.sup.5 is --(CH.sub.2).sub.m--NR.sup.17R.sup.18,
--(CH.sub.2).sub.m--OR', C.sub.1-C.sub.8 alkoxy optionally
substituted by one or more halogen atoms; --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; or
--(C.sub.0-C.sub.4 alkyl)-CO.sub.2R.sup.15, wherein
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl and
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group
groups are each optionally substituted by one or more Z
substituents; or R.sup.4 and R.sup.6 together with the carbon atoms
to which they are bound form a 3 to 8 membered carbocyclic ring
system; or R.sup.4 and R.sup.5 together form an oxo group (C.dbd.O)
and R.sup.6 is C.sub.1-C.sub.4 alkyl optionally substituted by one
or more halogen atoms; C.sub.1-C.sub.4 alkoxy optionally
substituted by one or more halogen atoms; --(C.sub.0-C.sub.4
alkyl)-CO.sub.6--C.sub.14 aryl; or --(C.sub.0-C.sub.4 alkyl)-3 to
14 membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S, wherein
the aryl and heterocyclyl groups are each optionally substituted by
one or more Z substituents; or R.sup.5 and R.sup.6 together with
the carbon atoms to which they are bound a 5 to 8 membered
heterocyclic ring system containing one or more heteroatoms
selected from N, O and S, wherein the ring system is optionally
substituted by one or more Z substituents; or R.sup.4 and R.sup.5
and R.sup.6 together with the carbon atoms to which they are bound
form a 5 to 8 membered heterocyclic ring system containing one or
more heteroatoms selected from N, O and S, wherein the ring system
is optionally substituted by one or more Z substituents; R' is H,
or C.sub.1-C.sub.8 alkyl optional substituted with one or more
halogen; m is 0, 1, 2 or 3; R.sup.8, R.sup.11, R.sup.13 and
R.sup.17 are each independently H, C.sub.1-C.sub.8 alkyl optionally
substituted by one or more halogen atoms, C.sub.3-C.sub.10
cycloalkyl or --(C.sub.1-C.sub.4 alkyl)-C.sub.3-C.sub.8 cycloalkyl;
R.sup.9, R.sup.10, R.sup.12, R.sup.14, R.sup.15, R.sup.16 and
R.sup.18 are each independently H; C.sub.1-C.sub.8 alkyl optionally
substituted by one or more halogen atoms; C.sub.2-C.sub.8 alkenyl;
C.sub.2-C.sub.8 alkynyl; C.sub.3-C.sub.10 cycloalkyl;
C.sub.5-C.sub.10 cycloalkenyl; --C.sub.1-C.sub.4
alkyl-C.sub.3-C.sub.8 cycloalkyl; --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; or --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S, wherein
the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are each
optionally substituted by one or more Z substituents; or R.sup.8
and R.sup.9, R.sup.11 and R.sup.12, R.sup.13 and R.sup.14, and
R.sup.17 and R.sup.18 together with the nitrogen atom to which they
are attached may form a 4 to 14 membered heterocyclic group
optionally substituted by one or more Z substituents; Z is
independently OH, aryl, O-aryl, benzyl, O-benzyl, C.sub.1-C.sub.6
alkyl optionally substituted by one or more OH groups or NH.sub.2
groups, C.sub.1-C.sub.6 alkyl optionally substituted by one or more
halogen atoms, C.sub.1-C.sub.6 alkoxy optionally substituted by one
or more OH groups or C.sub.1-C.sub.4 alkoxy,
NR.sup.18(SO.sub.2)R.sup.21, (SO.sub.2)NR.sup.19R.sup.21,
(SO.sub.2)R.sup.21, NR.sup.18C(O)R.sup.21, C(O)NR.sup.19R.sup.21,
NR.sup.18C(O)NR.sup.19R.sup.21, NR.sup.18C(O)OR.sup.19,
NR.sup.19R.sup.21, C(O)OR.sup.19, C(O)R.sup.19, SR.sup.19,
OR.sup.19, oxo, CN, NO.sub.2, halogen or a 3 to 14 membered
heterocyclic group, wherein the heterocyclic group contains at
least one heteroatom selected from N, O and S; R.sup.19 and
R.sup.21 are each independently H; C.sub.1-C.sub.8 alkyl;
C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.4 alkoxy-C.sub.1-C.sub.4
alkyl; (C.sub.0-C.sub.4 alkyl)-aryl optionally substituted by one
or more groups selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkoxy and halogen; (C.sub.0-C.sub.4 alkyl)-3- to 14-membered
heterocyclic group, the heterocyclic group including one or more
heteroatoms selected from N, O and S, optionally substituted by one
or more groups selected from halogen, oxo, C.sub.1-C.sub.6 alkyl
and C(O)C.sub.1-C.sub.6 alkyl; (C.sub.0-C.sub.4 alkyl)-O-aryl
optionally substituted by one or more groups selected from
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy and halogen; and
(C.sub.0-C.sub.4 alkyl)-O-3- to 14-membered heterocyclic group, the
heterocyclic group including one or more heteroatoms selected from
N, O and S, optionally substituted by one or more groups selected
from halogen, C.sub.1-C.sub.6 alkyl or C(O)C.sub.1-C.sub.6 alkyl;
wherein the alkyl groups are optionally substituted by one or more
halogen atoms, C.sub.1-C.sub.4 alkoxy, C(O)NH.sub.2,
C(O)NHC.sub.1-C.sub.6 alkyl or C(O)N(C.sub.1-C.sub.6 alkyl).sub.2;
or R.sup.19 and R.sup.21 together with the nitrogen atom to which
they attached form a 5- to 10-membered heterocyclic group, the
heterocyclic group including one or more further heteroatoms
selected from N, O and S, the heterocyclic group being optionally
substituted by one or more substituents selected from OH; halogen;
aryl; 5- to 10-membered heterocyclic group including one or more
heteroatoms selected from N, O and S; S(O).sub.2-aryl;
S(O).sub.2--C.sub.1-C.sub.6 alkyl; C.sub.1-C.sub.6 alkyl optionally
substituted by one or more halogen atoms; C.sub.1-C.sub.6 alkoxy
optionally substituted by one or more OH groups or C.sub.1-C.sub.4
alkoxy; and C(O)OC.sub.1-C.sub.6 alkyl, wherein the aryl and
heterocyclic substituent groups are themselves optionally
substituted by C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl or
C.sub.1-C.sub.6 alkoxy.
[0006] Various embodiments of the invention are described herein.
It will be recognized that features specified in each embodiment
may be combined with other specified features to provide further
embodiments.
[0007] In an embodiment of the invention as described anywhere
herein, A is N.
[0008] In an embodiment of the invention as described anywhere
herein, A is CR.sup.4a.
[0009] In an embodiment of the invention as described anywhere
herein, R.sup.1 is selected from H; C.sub.1-C.sub.8 alkyl
optionally substituted by one or more halogen atoms;
C.sub.1-C.sub.8 alkoxy optionally substituted by one or more
halogen atoms; halogen; C.sub.6-C.sub.14 aryl; --(C.sub.0-C.sub.4
alkyl)-3 to 14 membered heterocyclic group, wherein the
heterocyclic group contains at least one heteroatom selected from
N, O and S; and NR.sup.11R.sup.12, wherein the aryl and
heterocyclic groups are each optionally substituted by one or more
Z substituents.
[0010] In an embodiment of the invention as described anywhere
herein, R.sup.1 is C.sub.1-C.sub.4 alkyl optional substituted by
one or more halogen atoms. For example, --CH.sub.3 or CF.sub.3.
[0011] In an embodiment of the invention as described anywhere
herein, R.sup.1 is C.sub.1-C.sub.4 alkoxy optional substituted by
one or more halogen atoms. For example, --OCH.sub.3 or
--OCF.sub.3.
[0012] In an embodiment of the invention as described anywhere
herein, R.sup.1 is aryl, wherein aryl is phenyl optionally
substituted by one or more Z substituents, specific example are
4-fluorophenyl, 4-chloro-2-methylphenyl, or 2,4-dichlorophenyl.
[0013] In an embodiment of the invention as described anywhere
herein, R.sup.1 is 6 membered heterocyclyl group, wherein 6
membered heterocyclyl group is pyridyl optionally substituted by
one or more Z substituents, specific example is
1-methyl-4-pyridyl.
[0014] In an embodiment of the invention as described anywhere
herein, R.sup.1 is Br, --CH.sub.3, --CF.sub.3, --OCH.sub.3,
--OCF.sub.3, 4-fluorophenyl, 4-chloro-2-methylphenyl, or
2,4-dichlorophenyl.
[0015] In an embodiment of the invention as described anywhere
herein, R.sup.2 is CF.sub.3CF.sub.2--, (CF.sub.3).sub.2CH--,
CH.sub.3--CF.sub.2--, CF.sub.3CF.sub.2--, CF.sub.3, CF.sub.2H--,
CH.sub.3--CCl.sub.2--, CF.sub.3CFCClH--, CBr.sub.3,
CBr.sub.2H--CF.sub.3CF.sub.2CHCF.sub.3 or
CF.sub.3CF.sub.2CF.sub.2CF.sub.2--.
[0016] In an embodiment of the invention as described anywhere
herein, R.sup.2 is CF.sub.3.
[0017] In an embodiment of the invention as described anywhere
herein, R.sup.3 is H or methyl.
[0018] In a further embodiment of the invention as described
anywhere herein, R.sup.4a is H.
[0019] An embodiment of the invention, as defined above provides a
compound, where R.sup.5 provides a heteroatom two carbons from the
amide nitrogen, wherein the heteroatom is oxygen or nitrogen.
[0020] An embodiment of the invention as defined above provides a
compound according to Formula I, wherein [0021] R.sup.4 is H,
C.sub.1-C.sub.4 alkyl optionally substituted by one or more halogen
atoms or not present; [0022] R.sup.5 is C.sub.1-C.sub.4 alkoxy
optionally substituted by one or more halogen atoms;
--(CH.sub.2).sub.m--NR.sup.17R.sup.18; --(CH.sub.2).sub.m--OR''',
or OH; [0023] m is 0, or 1; [0024] R.sup.6 is C.sub.1-C.sub.4 alkyl
optionally substituted by one or more halogen atoms;
C.sub.1-C.sub.4 alkoxy optionally substituted by one or more
halogen atoms; OH; CN; halogen; --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; or --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S, wherein
the aryl and heterocyclyl groups are each optionally substituted by
one or more Z substituents; or [0025] R.sup.4 and R.sup.5 together
form an oxo group (C.dbd.O); or [0026] R.sup.5 and R.sup.6 together
with the carbon atoms to which they are bound form a 5 to 8
membered heterocyclic ring system containing one or more
heteroatoms selected from N, O and S, wherein the ring system is
optionally substituted by one or more Z substituents; [0027]
R.sup.17 and R.sup.18 are each independently H; or C.sub.1-C.sub.4
alkyl optionally substituted by one or more halogen atoms.
[0028] An embodiment of the invention as defined above provides
compounds according to Formula I, wherein [0029] A is CR.sup.4a.
[0030] R.sup.1 is halogen, C.sub.1-C.sub.4 alkyl optionally
substituted by one or more halogen atoms, or C.sub.1-C.sub.4 alkoxy
optionally substituted by one or more halogen atoms; [0031] R.sup.2
is C.sub.1-C.sub.4 haloalkyl; [0032] R.sup.3 is H; [0033] R.sup.4
is H or Me; [0034] R.sup.4a is H; [0035] R.sup.5 is
--(CH.sub.2).sub.m--NR.sup.17R.sup.18; --(CH.sub.2).sub.m--OR'; or
OH; [0036] m is 0, or 1; [0037] R.sup.6 is C.sub.1-C.sub.4 alkyl
optionally substituted by one or more halogen atoms; or [0038]
R.sup.5 and R.sup.6 together with the carbon atoms to which they
are bound form a 5 to 6 membered heterocyclic ring system
containing one or more heteroatoms selected from N, O and S,
wherein the ring system is optionally substituted by one or more Z
substituents; and [0039] R.sup.17 and R.sup.18 are each
independently H; or C.sub.1-C.sub.4 alkyl optionally substituted by
one or more halogen atoms.
[0040] An embodiment of the invention as defined above provides
compounds according to Formula I, wherein [0041] A is CR.sup.4a.
[0042] R.sup.1 is halogen, C.sub.1-C.sub.4 alkyl optionally
substituted by one or more halogen atoms, or C.sub.1-C.sub.4 alkoxy
optionally substituted by one or more halogen atoms; [0043] R.sup.2
is C.sub.1-C.sub.4 haloalkyl; [0044] R.sup.3 is H; [0045] R.sup.4a
is H; [0046] R.sup.4 and R.sup.5 together form an oxo group
(C.dbd.O); and [0047] R.sup.6 is C.sub.1-C.sub.4 alkyl optionally
substituted by one or more halogen atoms; C.sub.1-C.sub.4 alkoxy
optionally substituted by one or more halogen atoms;
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl; or
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group,
wherein the heterocyclic group contains at least one heteroatom
selected from N, O and S, wherein the aryl and heterocyclyl groups
are each optionally substituted by one or more Z substituents.
[0048] An embodiment of the invention as defined above provides
compounds according to Formula I, wherein [0049] A is CR.sup.4a.
[0050] R.sup.1 is C.sub.1-C.sub.4 alkyl optionally substituted by
one or more halogen atoms; [0051] R.sup.2 is C.sub.1-C.sub.4
haloalkyl; [0052] R.sup.3 is H; [0053] R.sup.4 is H or Me; [0054]
R.sup.4a is H; [0055] R.sup.5 is
--(CH.sub.2).sub.m--NR.sup.17R.sup.18; --(CH.sub.2).sub.m--OR'; or
OH; [0056] m is 0, or 1; [0057] R.sup.6 is C.sub.1-C.sub.4 alkyl
optionally substituted by one or more halogen atoms; or [0058]
R.sup.5 and R.sup.6 together with the carbon atoms to which they
are bound form a 5 to 6 membered heterocyclic ring system
containing one or more heteroatoms selected from N, O and S,
wherein the ring system is optionally substituted by one or more Z
substituents; and [0059] R.sup.17 and R.sup.18 are each
independently H; or C.sub.1-C.sub.4 alkyl optionally substituted by
one or more halogen atoms.
[0060] An embodiment of the invention as defined above provides
compounds according to Formula I, wherein [0061] A is CR.sup.4a;
[0062] R.sup.1 is C.sub.1-C.sub.4 alkoxy optionally substituted by
one or more halogen atoms; [0063] R.sup.2 is C.sub.1-C.sub.4
haloalkyl; [0064] R.sup.3 is H; [0065] R.sup.4 is H or Me; [0066]
R.sup.4a is H; [0067] R.sup.5 is
--(CH.sub.2).sub.m--NR.sup.17R.sup.18; --(CH.sub.2).sub.m--OR; or
OH; [0068] m is 0, or 1; [0069] R.sup.6 is C.sub.1-C.sub.4 alkyl
optionally substituted by one or more halogen atoms; or [0070]
R.sup.5 and R.sup.6 together with the carbon atoms to which they
are bound form a 5 to 6 membered heterocyclic ring system
containing one or more heteroatoms selected from N, O and S,
wherein the ring system is optionally substituted by one or more Z
substituents; and [0071] R.sup.17 and R.sup.18 are each
independently H; or C.sub.1-C.sub.4 alkyl optionally substituted by
one or more halogen atoms.
[0072] An embodiment of the invention as defined above provides
compounds according to Formula I, wherein [0073] A is CR.sup.4a.
[0074] R.sup.1 is C.sub.1-C.sub.4 alkoxy optionally substituted by
one or more halogen atoms; [0075] R.sup.2 is C.sub.1-C.sub.4
haloalkyl; [0076] R.sup.3 is H; [0077] R.sup.4 is H or Me; [0078]
R.sup.4a is H; [0079] R.sup.5 is --NR.sup.17R.sup.18; or OH; [0080]
R.sup.6 is C.sub.1-C.sub.4 alkyl optionally substituted by one or
more halogen atoms; or [0081] R.sup.5 and R.sup.6 together with the
carbon atoms to which they are bound form a 5 to 6 membered
heterocyclic ring system containing one or more heteroatoms
selected from N, O and S, wherein the ring system is optionally
substituted by one or more Z substituents; and [0082] R.sup.17 and
R.sup.18 are each independently H; or C.sub.1-C.sub.4 alkyl
optionally substituted by one or more halogen atoms.
[0083] An embodiment of the invention as defined above provides
compounds according to Formula I, wherein [0084] A is CR.sup.4a.
[0085] R.sup.1 is C.sub.1-C.sub.4 alkyl optionally substituted by
one or more halogen atoms; [0086] R.sup.2 is C.sub.1-C.sub.4
haloalkyl; [0087] R.sup.3 is H; [0088] R.sup.4 is H or Me; [0089]
R.sup.4a is H; [0090] R.sup.5 is --NR.sup.17R.sup.18; or OH; [0091]
R.sup.6 is C.sub.1-C.sub.4 alkyl optionally substituted by one or
more halogen atoms; and [0092] R.sup.17 and R.sup.18 are each
independently H; or C.sub.1-C.sub.4 alkyl optionally substituted by
one or more halogen atoms.
[0093] An embodiment of the invention as defined above provides
compounds according to Formula I, wherein [0094] A is CR.sup.4a.
[0095] R.sup.1 is C.sub.1-C.sub.4 alkoxy optionally substituted by
one or more halogen atoms; [0096] R.sup.2 is C.sub.1-C.sub.4
haloalkyl; [0097] R.sup.3 is H; [0098] R.sup.4 is H or Me; [0099]
R.sup.4a is H; [0100] R.sup.5 is --NR.sup.17R.sup.18; or OH; [0101]
R.sup.6 is C.sub.1-C.sub.4 alkyl optionally substituted by one or
more halogen atoms; and [0102] R.sup.17 and R.sup.18 are each
independently H; or C.sub.1-C.sub.4 alkyl optionally substituted by
one or more halogen atoms.
[0103] In an embodiment of the invention as described anywhere
herein, wherein [0104] Z is independently OH, C.sub.1-C.sub.4 alkyl
optionally substituted by one or more OH groups or NH.sub.2 groups,
C.sub.1-C.sub.4 alkyl optionally substituted by one or more halogen
atoms, C.sub.1-C.sub.4 alkoxy optionally substituted by one or more
OH groups or C.sub.1-C.sub.4 alkoxy, NR.sup.19R.sup.21,
C(O)OR.sup.19, C(O)R.sup.19, SR.sup.19, OR.sup.19, CN, NO.sub.2, or
halogen; [0105] R.sup.19 and R.sup.21 are each independently H;
C.sub.1-C.sub.4 alkyl; C.sub.3-C.sub.6 cycloalkyl; or
C.sub.1-C.sub.4 alkoxy-C.sub.1-C.sub.4 alkyl, wherein all alkyls
are optionally substituted with halogens.
[0106] In an embodiment of the invention as described anywhere
herein, wherein [0107] Z is independently OH, C.sub.1-C.sub.4 alkyl
optionally substituted by one or more OH groups or NH.sub.2 groups,
C.sub.1-C.sub.4 alkyl optionally substituted by one or more halogen
atoms, C.sub.1-C.sub.4 alkoxy optionally substituted by one or more
OH groups or C.sub.1-C.sub.4 alkoxy, C(O)OR.sup.19, C(O)R.sup.19,
OR.sup.19, CN, or halogen; [0108] R.sup.19 is H; C.sub.1-C.sub.4
alkyl; C.sub.3-C.sub.6 cycloalkyl; or C.sub.1-C.sub.4
alkoxy-C.sub.1-C.sub.4 alkyl, wherein all alkyl are optionally
substituted with halogens.
[0109] In an embodiment of the invention as described anywhere
herein, wherein [0110] Z is independently, C.sub.1-C.sub.4 alkyl
optionally substituted by one or more halogen atoms,
C.sub.1-C.sub.4 alkoxy or halogen.
[0111] Another embodiment of the invention as defined above
provides compounds with substantially pure enantiomers with the R
configuration.
[0112] Another embodiment of the invention as defined above
provides compounds with substantially pure enantiomers with the S
configuration.
[0113] Certain compounds of Formula I include compounds of Formula
II:
##STR00002##
or a pharmaceutically acceptable salt thereof, wherein A, R.sup.1,
R.sup.2 and R.sup.3 have the definitions of Formula I and
R.sup.101 is
##STR00003##
[0115] In a further embodiment of Formula II of the invention
herein, A is CR.sup.4a, wherein R.sup.4a is H.
[0116] In a further embodiment of Formula II of the invention
herein, R.sup.1 is selected from H; C.sub.1-C.sub.4 alkyl
optionally substituted by one or more halogen atoms;
C.sub.1-C.sub.4 alkoxy optionally substituted by one or more
halogen atoms; halogen; C.sub.6-C.sub.14 aryl; --(C.sub.0-C.sub.4
alkyl)-3 to 14 membered heterocyclic group, wherein the
heterocyclic group contains at least one heteroatom selected from
N, O and S; and NR.sup.11R.sup.12, wherein the aryl and
heterocyclic groups are each optionally substituted by one or more
Z substituents.
[0117] In a further embodiment of Formula II of the invention
wherein, R.sup.1 is C.sub.1-C.sub.4 alkyl optional substituted by
one or more halogen atoms, C.sub.1-C.sub.4 alkoxy optionally
substituted by one or more halogen atoms; halogen; C.sub.6 aryl; or
6 membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S, wherein
the aryl and heterocyclic groups are each optionally substituted by
one or more Z substituents.
[0118] In a further embodiment of Formula II of the invention
wherein, R.sup.1 is C.sub.1-C.sub.4 alkyl optional substituted by
one or more halogen atoms, C.sub.1-C.sub.4 alkoxy optionally
substituted by one or more halogen atoms; or halogen.
[0119] In a further embodiment of Formula II of the invention
herein, R.sup.3 is H or methyl.
[0120] An embodiment of the invention as defined above provides
compounds according to Formula II, wherein [0121] A is CR.sup.4a;
[0122] R.sup.1 is halogen; [0123] R.sup.3 is H; [0124] R.sup.4a is
H; [0125] R.sup.101 is
##STR00004##
[0126] An embodiment of the invention as defined above provides
compounds according to Formula II, wherein [0127] A is CR.sup.4a;
[0128] R.sup.1 is C.sub.1-C.sub.4 alkyl optionally substituted by
one or more halogen atoms; [0129] R.sup.3 is H; [0130] R.sup.4a is
H; [0131] R.sup.101 is
##STR00005##
[0132] An embodiment of the invention as defined above provides
compounds according to Formula II, wherein [0133] A is CR.sup.4a;
[0134] R.sup.1 is C.sub.1-C.sub.4 alkoxy optionally substituted by
one or more halogen atoms; [0135] R.sup.3 is H; [0136] R.sup.4a is
H; [0137] R.sup.101 is
##STR00006##
[0138] An embodiment of the invention as defined above provides
compounds according to Formula II, wherein [0139] A is CR.sup.4a;
[0140] R.sup.1 is halogen, C.sub.1-C.sub.4 alkyl optionally
substituted by one or more halogen atoms, or C.sub.1-C.sub.4 alkoxy
optionally substituted by one or more halogen atoms; [0141] R.sup.3
is H; [0142] R.sup.4a is H; [0143] R.sup.101 is
##STR00007##
[0144] An embodiment of the invention as defined above provides
compounds according to Formula II, wherein [0145] A is CR.sup.4a.
[0146] R.sup.1 is halogen, C.sub.1-C.sub.4 alkyl optionally
substituted by one or more halogen atoms, or C.sub.1-C.sub.4 alkoxy
optionally substituted by one or more halogen atoms; [0147] R.sup.3
is H; [0148] R.sup.4a is H; [0149] R.sup.101 is
##STR00008##
[0150] An embodiment of the invention as defined above provides
compounds according to Formula II, wherein [0151] A is CR.sup.4a;
[0152] R.sup.1 is halogen, C.sub.1-C.sub.4 alkyl optionally
substituted by one or more halogen atoms, or C.sub.1-C.sub.4 alkoxy
optionally substituted by one or more halogen atoms; [0153] R.sup.3
is H; [0154] R.sup.4a is H; [0155] R.sup.101 is
##STR00009##
[0156] Another embodiment of the invention as defined above
provides compounds according to Formula I and Formula II,
represented by [0157]
3-amino-6-bromo-N-(imidazo[1,2-a]pyridin-2-ylmethyl)-5-(trifluoromethyl)p-
yrazine-2-carboxamide; [0158]
3-amino-6-bromo-N-((1-methyl-1H-imidazol-4-yl)methyl)-5-(trifluoromethyl)-
pyrazine-2-carboxamide; [0159]
3-amino-6-bromo-N-((1-methyl-1H-pyrazol-3-yl)methyl)-5-(trifluoromethyl)p-
yrazine-2-carboxamide; [0160]
3-amino-N-(2-(4-fluorophenyl)-2-oxoethyl)-6-(1-methyl-1H-indol-6-yl)-5-(t-
rifluoromethyl)picolinamide; [0161]
3-amino-6-bromo-N-((1-methyl-1H-imidazol-2-yl)methyl)-5-(trifluoromethyl)-
pyrazine-2-carboxamide; [0162] 3-amino-6-(6-(3-(dimethylamino)
propoxy)pyridin-3-yl)-N-(2-(4-fluorophenyl)-2-oxoethyl)-5-(trifluoromethy-
l) pyrazine-2-carboxamide; [0163]
(R)-3-amino-6-bromo-N-((4-methylpiperazin-2-yl)methyl)-5-(trifluoromethyl-
) pyrazine-2-carboxamide; [0164]
3-amino-6-bromo-N-((1-methyl-1H-imidazol-5-yl)methyl)-5-(trifluoromethyl)
pyrazine-2-carboxamide; [0165]
3-amino-6-(3-(N,N-dimethylsulfamoyl)phenyl)-N-(2-(4-fluorophenyl)-2-oxoet-
hyl)-5-(trifluoromethyl)picolinamide; [0166]
3-amino-6-bromo-N-isobutyl-N-methyl-5-(trifluoromethyl)pyrazine-2-carboxa-
mide; [0167]
3-amino-6-bromo-N-((1-methyl-1H-pyrazol-5-yl)methyl)-5-(trifluoromethyl)p-
yrazine-2-carboxamide; [0168]
(3-amino-6-bromo-5-(trifluoromethyl)pyrazin-2-yl)(4-methylpiperazin-1-yl)-
methanone; [0169]
3-amino-6-bromo-N-(2-(pyridin-4-yl)ethyl)-5-(trifluoromethyl)pyrazine-2-c-
arboxamide; [0170]
3-amino-N-(2-(4-fluorophenyl)-2-oxoethyl)-6-(1-oxo-1,2,3,4-tetrahydroisoq-
uinolin-6-yl)-5-(trifluoromethyl)picolinamide; [0171]
3-amino-6-(4-carbamoyl-2-methylphenyl)-N-(2-(4-fluorophenyl)-2-oxoethyl)--
5-(trifluoromethyl)picolinamide; [0172]
3-amino-6-bromo-N-(2-(pyridin-3-yl)ethyl)-5-(trifluoromethyl)pyrazine-2-c-
arboxamide; [0173]
3-amino-6-(3,4-dimethylphenyl)-N-(2-(4-fluorophenyl)-2-oxoethyl)-5-(trifl-
uoromethyl)picolinamide; [0174]
3-amino-N-benzyl-6-bromo-N-methyl-5-(trifluoromethyl)pyrazine-2-carboxami-
de; [0175]
(S)-3-amino-6-bromo-N-((1-ethylpyrrolidin-2-yl)methyl)-5-(trifl-
uoromethyl) pyrazine-2-carboxamide; or [0176]
3-amino-6-bromo-N-(imidazo[1,5-a]pyridin-1-ylmethyl)-5-(trifluoromethyl)
pyrazine-2-carboxamide.
[0177] Another embodiment of the invention as defined above
provides compounds according to Formula I, represented by [0178]
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0179]
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0180]
Methyl
3-(3-amino-6-bromo-5-(trifluoromethyl)picolinamido)propanoate;
[0181]
3-Amino-N-(benzo[d]isoxazol-3-ylmethyl)-6-bromo-5-(trifluoromethyl)
picolinamide; [0182]
3-Amino-6-(oxazol-2-yl)-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(t-
rifluoromethyl)picolinamide; [0183]
3-Amino-6-bromo-N-(3,3,3-trifluoro-2-methoxy-2-methylpropyl)-5-(trifluoro-
methyl)picolinamide; [0184]
3-amino-N-(2-hydroxy-3-methyl-2-(trifluoromethyl)butyl)-6-methoxy-5-(trif-
luoromethyl)picolinamide; [0185]
3-Amino-6-cyclopropyl-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(tri-
fluoromethyl)picolinamide; [0186]
3-Amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-(trifluoromethyl)propyl)-
-5-(trifluoro methyl) picolinamide; [0187]
5-amino-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-3-(trifluoromethyl)--
2,4'-bipyridine-6-carboxamide; [0188]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(3-methyl-2-oxo-butyl)-amide; [0189]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
[2-(4-fluoro-phenyl)-2-oxo-ethyl]-amide; [0190]
3-Amino-6-furan-2-yl-5-trifluoromethyl-pyrazine-2-carboxylic acid
[2-(2-methoxy-phenyl)-ethyl]-amide; [0191]
3-Amino-6-(1-methyl-1H-pyrazol-4-yl)-N-(3,3,3-trifluoro-2-hydroxy-2-methy-
lpropyl)-5-(trifluoromethyl) picolinamide; [0192]
3-amino-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5,6-bis(trifluoromet-
hyl) pyrazine-2-carboxamide; [0193]
N-(2-(1H-imidazol-2-yl)propyl)-3-amino-6-bromo-5-(trifluoromethyl)
pyrazine-2-carboxamide; [0194]
3-Amino-6-bromo-N-(2-morpholinoethyl)-5-(trifluoromethyl)pyrazine-2-carbo-
xamide; [0195]
(S)-3-amino-6-ethoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trif-
luoro methyl)picolinamide; [0196]
3-Amino-6-(pyrrolidin-1-yl)-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)--
5-(trifluoromethyl)picolinamide; [0197]
3-Amino-N-(2-amino-3,3,3-trifluoro-2-methylpropyl)-6-methoxy-5-(trifluoro-
methyl) picolinamide; or [0198]
3-Amino-6-methoxy-N-(3,3,3-trifluoro-2-(4-methoxybenzylamino)-2-methylpro-
pyl)-5-(trifluoromethyl)picolinamide.
[0199] It is understood that any and all embodiments of the present
invention may be taken in conjunction with any other embodiment to
describe additional embodiments of the present invention.
Furthermore, any elements of an embodiment are meant to be combined
with any and all other elements from any of the embodiments to
describe additional embodiments. It is understood by those skilled
in the art that combinations of substituents where not possible are
not an aspect of the present invention.
[0200] Especially preferred specific compounds of formula (I) or
formula (II) are those described hereinafter in the Examples.
Definitions
[0201] Terms used in the specification have the following meanings:
[0202] "Optionally substituted" means the group referred to can be
substituted at one or more positions by any one or any combination
of the radicals listed thereafter. [0203] "Optionally substituted
by one or more Z groups" denotes that the relevant group may
include one or more substituents, each independently selected from
the groups included within the definition of Z. Thus, where there
are two or more Z group substituents, these may be the same or
different. [0204] "Halo" or "halogen", as used herein, may be
fluorine, chlorine, bromine or iodine. [0205]
"C.sub.1-C.sub.8-Alkyl", as used herein, denotes straight chain or
branched alkyl having 1-8 carbon atoms. If a different number of
carbon atoms is specified, such as C.sub.6 or C.sub.3, then the
definition is to be amended accordingly, such as
"C.sub.1-C.sub.4-Alkyl" will represent methyl, ethyl, propyl,
isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. [0206]
"C.sub.1-C.sub.8-Alkoxy", as used herein, denotes straight chain or
branched alkoxy having 1-8 carbon atoms. If a different number of
carbon atoms is specified, such as C.sub.6 or C.sub.3, then the
definition is to be amended accordingly, such as
"C.sub.1-C.sub.4-Alkoxy" will represent methoxy, ethoxy, propoxy,
isopropoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy.
[0207] "C.sub.1-C.sub.4-Haloalkyl", as used herein, denotes
straight chain or branched alkyl having 1-4 carbon atoms with at
least one hydrogen substituted with a halogen. If a different
number of carbon atoms is specified, such as C.sub.6 or C.sub.3,
then the definition is to be amended accordingly, such as
"C.sub.1-C.sub.4-Haloalkyl" will represent methyl, ethyl, propyl,
isopropyl, butyl, isobutyl, sec-butyl and tert-butyl that have at
least one hydrogen substituted with halogen, such as where the
halogen is fluorine: CF.sub.3CF.sub.2--, (CF.sub.3).sub.2CH--,
CH.sub.3--CF.sub.2--, CF.sub.3CF.sub.2--, CF.sub.3, CF.sub.2H--,
CF.sub.3CF.sub.2CHCF.sub.3 or CF.sub.3CF.sub.2CF.sub.2CF.sub.2--.
[0208] "C.sub.3-C.sub.15-Cycloalkyl group", as used herein, denotes
a cycloalkyl group having 3- to 15-ring carbon atoms that is
saturated or partially saturated, such as a
C.sub.3-C.sub.8-cycloalkyl. Examples of C.sub.3-C.sub.15-cycolalkyl
groups include but are not limited to cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl or a bicyclic
group, such as bicyclooctyl, bicyclononyl including indanyl and
indenyl and bicyclodecyl. If a different number of carbon atoms is
specified, such as C.sub.6, then the definition is to be amended
accordingly. [0209] "aryl" or "C.sub.6-C.sub.15-Aromatic
carbocyclic group", as used herein, denotes an aromatic group
having 6- to 15-ring carbon atoms. Examples of
C.sub.6-C.sub.15-aromatic carbocyclic groups include, but are not
limited to, phenyl, phenylene, benzenetriyl, naphthyl, naphthylene,
naphthalenetriyl or anthrylene. If a different number of carbon
atoms is specified, such as C.sub.10, then the definition is to be
amended accordingly. [0210] "4- to 8-Membered heterocyclic group",
"5- to 6-membered heterocyclic group", "3- to 10-membered
heterocyclic group", "3- to 14-membered heterocyclic group", "4- to
14-membered heterocyclic group" and "5- to 14-membered heterocyclic
group", refers, respectively, to 4- to 8-membered, 5- to
6-membered, 3- to 10-membered, 3- to 14-membered, 4- to 14-membered
and 5- to 14-membered heterocyclic rings containing at least one
ring heteroatom selected from the group consisting of nitrogen,
oxygen and sulphur, which may be saturated, partially saturated or
unsaturated (aromatic). The heterocyclic group includes single ring
groups, fused ring groups and bridged groups. Examples of such
heterocyclic groups include, but are not limited to, furan,
pyrrole, pyrrolidine, pyrazole, imidazole, triazole, isotriazole,
tetrazole, thiadiazole, isothiazole, oxadiazole, pyridine,
piperidine, pyrazine, oxazole, isoxazole, pyrazine, pyridazine,
pyrimidine, piperazine, pyrrolidine, pyrrolidinone, morpholine,
triazine, oxazine, tetrahyrofuran, tetrahydrothiophene,
tetrahydrothiopyran, tetrahydropyran, 1,4-dioxane, 1,4-oxathiane,
indazole, quinoline, indazole, indole, 8-aza-bicyclo[3.2.1]octane
or thiazole.
[0211] A second aspect of the invention provides a compound of
Formula (I), (II) or (III) as defined anywhere herein for use as a
pharmaceutical.
[0212] A further aspect of the invention provides a compound of
Formula (I), (II) or (III) for use in the treatment of an
inflammatory or allergic condition, particularly an inflammatory or
obstructive airways disease or mucosal hydration. Such conditions
include, for example, cystic fibrosis, primary ciliary dyskinesia,
chronic bronchitis, chronic obstructive pulmonary disease, asthma,
respiratory tract infections, lung carcinoma, xerostomia and
keratoconjunctivitis sire, or constipation (IBS, IBD, opioid
induced).
[0213] A still further aspect of the present invention provides for
the use of a compound of formula (I), (II) or (III), as defined in
any of the aforementioned embodiments, in free or pharmaceutically
acceptable salt form, for the manufacture of a medicament for the
treatment of an inflammatory or allergic condition, particularly an
inflammatory or obstructive airways disease or mucosal
hydration.
[0214] An embodiment of the present invention provides for the use
of a compound of formula (I), (II) or (III), as defined in any of
the aforementioned embodiments, in free or pharmaceutically
acceptable salt form, for the manufacture of a medicament for the
treatment of an inflammatory or allergic condition selected from
cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis,
chronic obstructive pulmonary disease, asthma, respiratory tract
infections, lung carcinoma, xerostomia and keratoconjunctivitis
sire, or constipation (IBS, IBD, opioid induced).
[0215] An embodiment of the present invention provides method for
the prevention or treatment of a CFTR mediated condition or disease
comprising administering an effective amount of at least one
compound as described herein to a subject in need of such
treatment.
[0216] Such CFTR mediated condition or disease are selected from
cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis,
chronic obstructive pulmonary disease, asthma, respiratory tract
infections, lung carcinoma, xerostomia and keratoconjunctivitis
sire, or constipation (IBS, IBD, opioid induced).
[0217] Throughout this specification and in the claims that follow,
unless the context requires otherwise, the word "comprise", or
variations such as "comprises" or "comprising", should be
understood to imply the inclusion of a stated integer or step or
group of integers or steps but not the exclusion of any other
integer or step or group of integers or steps.
[0218] As used herein, the term "pharmaceutically acceptable salts"
refers to salts that retain the biological effectiveness and
properties of the compounds of this invention and, which typically
are not biologically or otherwise undesirable. In many cases, the
compounds of the present invention are capable of forming acid
and/or base salts by virtue of the presence of amino and/or
carboxyl groups or groups similar thereto.
[0219] Pharmaceutically acceptable acid addition salts can be
formed with inorganic acids and organic acids, e.g., acetate,
aspartate, benzoate, besylate, bromide/hydrobromide,
bicarbonate/carbonate, bisulfate/sulfate, camphorsulfornate,
chloride/hydrochloride, chlortheophyllonate, citrate,
ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate,
hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate,
laurylsulfate, malate, maleate, malonate, mandelate, mesylate,
methylsulphate, naphthoate, napsylate, nicotinate, nitrate,
octadecanoate, oleate, oxalate, palmitate, pamoate,
phosphate/hydrogen phosphate/dihydrogen phosphate,
polygalacturonate, propionate, stearate, succinate,
sulfosalicylate, tartrate, tosylate and trifluoroacetate salts.
[0220] Inorganic acids from which salts can be derived include, for
example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric
acid, phosphoric acid, and the like.
[0221] Organic acids from which salts can be derived include, for
example, acetic acid, propionic acid, glycolic acid, oxalic acid,
maleic acid, malonic acid, succinic acid, fumaric acid, tartaric
acid, citric acid, benzoic acid, mandelic acid, methanesulfonic
acid, ethanesulfonic acid, toluenesulfonic acid, and sulfosalicylic
acid.
[0222] Pharmaceutically acceptable base addition salts can be
formed with inorganic and organic bases.
[0223] Inorganic bases from which salts can be derived include, for
example, ammonium salts and metals from columns I to XII of the
periodic table. In certain embodiments, the salts are derived from
sodium, potassium, ammonium, calcium, magnesium, iron, silver,
zinc, and copper; particularly suitable salts include ammonium,
potassium, sodium, calcium and magnesium salts.
[0224] Organic bases from which salts can be derived include, for
example, primary, secondary, and tertiary amines, substituted
amines including naturally occurring substituted amines, cyclic
amines, basic ion exchange resins, and the like. Certain organic
amines include isopropylamine, benzathine, cholinate,
diethanolamine, diethylamine, lysine, meglumine, piperazine and
tromethamine.
[0225] The pharmaceutically acceptable salts of the present
invention can be synthesized from a parent compound, a basic or
acidic moiety, by conventional chemical methods. Generally, such
salts can be prepared by reacting free acid forms of these
compounds with a stoichiometric amount of the appropriate base
(such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the
like), or by reacting free base forms of these compounds with a
stoichiometric amount of the appropriate acid. Such reactions are
typically carried out in water or in an organic solvent, or in a
mixture of the two. Generally, use of non-aqueous media like ether,
ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable,
where practicable. Lists of additional suitable salts can be found,
e.g., in "Remington's Pharmaceutical Sciences", 20th ed., Mack
Publishing Company, Easton, Pa., (1985); and in "Handbook of
Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and
Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
[0226] Furthermore, the compounds of the present invention,
including their salts, can also be obtained in the form of their
hydrates, or include other solvents used for their
crystallization.
[0227] Compounds of the invention, i.e. compounds of formula (I),
(II) or (III) that contain groups capable of acting as donors
and/or acceptors for hydrogen bonds may be capable of forming
co-crystals with suitable co-crystal formers. These co-crystals may
be prepared from compounds of formula (I), (II) or (III) by known
co-crystal forming procedures. Such procedures include grinding,
heating, co-subliming, co-melting, or contacting in solution
compounds of formula (I), (II) or (III) with the co-crystal former
under crystallization conditions and isolating co-crystals thereby
formed. Suitable co-crystal formers include those described in WO
2004/078163. Hence the invention further provides co-crystals
comprising a compound of formula (I), (II) or (III).
[0228] As used herein, the term "isomers" refers to different
compounds that have the same molecular formula but differ in
arrangement and configuration of the atoms. Also as used herein,
the term "an optical isomer" or "a stereoisomer" refers to any of
the various stereo isomeric configurations which may exist for a
given compound of the present invention and includes geometric
isomers. It is understood that a substituent may be attached at a
chiral center of a carbon atom. Therefore, the invention includes
enantiomers, diastereomers or racemates of the compound.
"Enantiomers" are a pair of stereoisomers that are
non-superimposable mirror images of each other. A 1:1 mixture of a
pair of enantiomers is a "racemic" mixture. The term is used to
designate a racemic mixture where appropriate. "Diastereoisomers"
are stereoisomers that have at least two asymmetric atoms, but
which are not mirror-images of each other. The absolute
stereochemistry is specified according to the Cahn-Ingold-Prelog
R-S system. When a compound is a pure enantiomer the
stereochemistry at each chiral carbon may be specified by either R
or S. Resolved compounds whose absolute configuration is unknown
can be designated (+) or (-) depending on the direction (dextro- or
levorotatory) which they rotate plane polarized light at the
wavelength of the sodium D line. Certain of the compounds described
herein contain one or more asymmetric centers or axes and may thus
give rise to enantiomers, diastereomers, and other stereoisomeric
forms that may be defined, in terms of absolute stereochemistry, as
(R)- or (S)-. The present invention is meant to include all such
possible isomers, including racemic mixtures, optically pure forms
and intermediate mixtures. Optically active (R)- and (S)-isomers
may be prepared using chiral synthons or chiral reagents, or
resolved using conventional techniques. If the compound contains a
double bond, the substituent may be E or Z configuration. If the
compound contains a disubstituted cycloalkyl, the cycloalkyl
substituent may have a cis- or trans-configuration. All tautomeric
forms are also intended to be included.
[0229] Any asymmetric atom (e.g., carbon or the like) of the
compound(s) of the present invention can be present in racemic or
enantiomerically enriched, for example the (R)-, (S)- or
(R,S)-configuration. In certain embodiments, each asymmetric atom
has at least 50% enantiomeric excess, at least 60% enantiomeric
excess, at least 70% enantiomeric excess, at least 80% enantiomeric
excess, at least 90% enantiomeric excess, at least 95% enantiomeric
excess, or at least 99% enantiomeric excess in the (R)- or
(S)-configuration. Substituents at atoms with unsaturated bonds
may, if possible, be present in cis-(Z)- or trans-(E)-form.
[0230] Accordingly, as used herein a compound of the present
invention can be in the form of one of the possible isomers,
rotamers, atropisomers, tautomers or mixtures thereof, for example,
as substantially pure geometric (cis or trans) isomers,
diastereomers, optical isomers (antipodes), racemates or mixtures
thereof.
[0231] Any resulting mixtures of isomers can be separated on the
basis of the physicochemical differences of the constituents, into
the pure or substantially pure geometric or optical isomers,
diastereomers, racemates, for example, by chromatography and/or
fractional crystallization.
[0232] Any resulting racemates of final products or intermediates
can be resolved into the optical antipodes by known methods, e.g.,
by separation of the diastereomeric salts thereof, obtained with an
optically active acid or base, and liberating the optically active
acidic or basic compound. In particular, a basic moiety may thus be
employed to resolve the compounds of the present invention into
their optical antipodes, e.g., by fractional crystallization of a
salt formed with an optically active acid, e.g., tartaric acid,
dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O'-p-toluoyl
tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic
acid. Racemic products can also be resolved by chiral
chromatography, e.g., high pressure liquid chromatography (HPLC)
using a chiral adsorbent.
[0233] Since the compounds of the invention are intended for use in
pharmaceutical compositions it will readily be understood that they
are each preferably provided in substantially pure form, for
example at least 60% pure, more suitably at least 75% pure and
preferably at least 85%, especially at least 98% pure (% are on a
weight for weight basis). Impure preparations of the compounds may
be used for preparing the more pure forms used in the
pharmaceutical compositions; these less pure preparations of the
compounds should contain at least 1%, more suitably at least 5% and
preferably from 10 to 59% of a compound of the invention.
[0234] Compounds of the present invention are either obtained in
the free form, as a salt thereof, or as prodrug derivatives
thereof.
[0235] When both a basic group and an acid group are present in the
same molecule, the compounds of the present invention may also form
internal salts, e.g., zwitterionic molecules.
[0236] Any formula given herein is also intended to represent
unlabeled forms as well as isotopically labeled forms of the
compounds. Isotopically labeled compounds have structures depicted
by the formulas given herein except that one or more atoms are
replaced by an atom having a selected atomic mass or mass number.
Examples of isotopes that can be incorporated into compounds of the
invention include isotopes of hydrogen, carbon, nitrogen, oxygen,
phosphorous, fluorine, and chlorine, such as .sup.2H, .sup.3H,
.sup.11C, .sup.13C, .sup.14C, .sup.15N, .sup.18F .sup.31P,
.sup.32P, .sup.35S, .sup.36Cl, .sup.125I respectively. The
invention includes various isotopically labeled compounds as
defined herein, for example those into which radioactive isotopes,
such as .sup.3H, .sup.13C, and .sup.14C are present. Such
isotopically labeled compounds are useful in metabolic studies
(with .sup.14C), reaction kinetic studies (with, for example
.sup.2H or .sup.3H), detection or imaging techniques, such as
positron emission tomography (PET) or single-photon emission
computed tomography (SPECT) including drug or substrate tissue
distribution assays, or in radioactive treatment of patients. In
particular, an .sup.18F or labeled compound may be particularly
desirable for PET or SPECT studies. Isotopically labeled compounds
of this invention can generally be prepared by carrying out the
procedures disclosed in the schemes or in the examples and
preparations described below by substituting a readily available
isotopically labeled reagent for a non-isotopically labeled
reagent.
[0237] Further, substitution with heavier isotopes, particularly
deuterium (i.e., .sup.2H or D) may afford certain therapeutic
advantages resulting from greater metabolic stability, for example
increased in vivo half-life or reduced dosage requirements or an
improvement in therapeutic index. It is understood that deuterium
in this context is regarded as a substituent of a compound of the
formula (I), (II) or (III). The concentration of such a heavier
isotope, specifically deuterium, may be defined by the isotopic
enrichment factor. The term "isotopic enrichment factor" as used
herein means the ratio between the isotopic abundance and the
natural abundance of a specified isotope. If a substituent in a
compound of this invention is denoted deuterium, such compound has
an isotopic enrichment factor for each designated deuterium atom of
at least 3500 (52.5% deuterium incorporation at each designated
deuterium atom), at least 4000 (60% deuterium incorporation), at
least 4500 (67.5% deuterium incorporation), at least 5000 (75%
deuterium incorporation), at least 5500 (82.5% deuterium
incorporation), at least 6000 (90% deuterium incorporation), at
least 6333.3 (95% deuterium incorporation), at least 6466.7 (97%
deuterium incorporation), at least 6600 (99% deuterium
incorporation), or at least 6633.3 (99.5% deuterium
incorporation).
[0238] Isotopically-labeled compounds of formula (I), (II) or (III)
can generally be prepared by conventional techniques known to those
skilled in the art or by processes analogous to those described in
the accompanying Examples and Preparations using an appropriate
isotopically-labeled reagents in place of the non-labeled reagent
previously employed.
[0239] Pharmaceutically acceptable solvates in accordance with the
invention include those wherein the solvent of crystallization may
be isotopically substituted, e.g. D.sub.2O, d.sub.6-acetone,
d.sub.6-DMSO.
Synthesis
[0240] Generally, compounds according to Formula I, II or III can
be synthesized by the routes described in Scheme 1, 2 and 3 and the
Examples.
[0241] When A is CH the pyridinyl moiety may be synthesized
according to the general scheme 1 shown below.
##STR00010##
[0242] When A is nitrogen, the pyrazine moiety may be synthesized
according to the general scheme 2 shown below.
##STR00011##
[0243] The right hand side of the moiety is typically added via an
amide formation reaction as shown below in general scheme 3.
##STR00012##
[0244] HATU (2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl
uronium hexafluorophosphate Methanaminium) is a peptide coupling
agent. A skilled artisan would understand that other coupling
agents cold possibly work. The halogen group in the above schemes
can be replaced with other groups by choosing the appropriate
nucleophile and catalyst. Protection of the Aryl NH2 group may be
required and is represented by P. The schemes 4-7 below are some
representative examples.
##STR00013## ##STR00014##
[0245] The skilled person will appreciate that the general
synthetic routes detailed above show common reactions to transform
the starting materials as required. The specific reaction
conditions are not provided, but these are well known to those
skilled in the art and appropriate conditions considered to be
within the skilled person's common general knowledge.
[0246] The starting materials are either commercially available
compounds or are known compounds and can be prepared from
procedures described in the organic chemistry art.
[0247] Compounds of formula (I), (II) or (III), in free form, may
be converted into salt form, and vice versa, in a conventional
manner understood by those skilled in the art. The compounds in
free or salt form can be obtained in the form of hydrates or
solvates containing a solvent used for crystallisation. Compounds
of formula (I), (II) or (III) can be recovered from reaction
mixtures and purified in a conventional manner. Isomers, such as
stereoisomers, may be obtained in a conventional manner, e.g., by
fractional crystallisation or asymmetric synthesis from
correspondingly asymmetrically substituted, e.g., optically active,
starting materials.
[0248] The compounds of formula (I), (II) or (III) can be prepared,
e.g., using the reactions and techniques described below and in the
Examples. The reactions may be performed in a solvent appropriate
to the reagents and materials employed and suitable for the
transformations being effected. It will be understood by those
skilled in the art of organic synthesis that the functionality
present on the molecule should be consistent with the
transformations proposed. This will sometimes require a judgment to
modify the order of the synthetic steps or to select one particular
process scheme over another in order to obtain a desired compound
of the invention.
[0249] The various substituents on the synthetic intermediates and
final products shown in the following reaction schemes can be
present in their fully elaborated forms, with suitable protecting
groups where required as understood by one skilled in the art, or
in precursor forms which can later be elaborated into their final
forms by methods familiar to one skilled in the art. The
substituents can also be added at various stages throughout the
synthetic sequence or after completion of the synthetic sequence.
In many cases, commonly used functional group manipulations can be
used to transform one intermediate into another intermediate, or
one compound of formula (I), (II) or (III) into another compound of
formula (I), (II) or (III). Examples of such manipulations are
conversion of an ester or a ketone to an alcohol; conversion of an
ester to a ketone; interconversions of esters, acids and amides;
alkylation, acylation and sulfonylation of alcohols and amines; and
many others. Substituents can also be added using common reactions,
such as alkylation, acylation, halogenation or oxidation. Such
manipulations are well-known in the art, and many reference works
summarize procedures and methods for such manipulations. Some
reference works which gives examples and references to the primary
literature of organic synthesis for many functional group
manipulations, as well as other transformations commonly used in
the art of organic synthesis are March's Organic Chemistry,
5.sup.th Edition, Wiley and Chichester, Eds. (2001); Comprehensive
Organic Transformations, Larock, Ed., VCH (1989); Comprehensive
Organic Functional Group Transformations, Katritzky et al. (series
editors), Pergamon (1995); and Comprehensive Organic Synthesis,
Trost and Fleming (series editors), Pergamon (1991). It will also
be recognized that another major consideration in the planning of
any synthetic route in this field is the judicious choice of the
protecting group used for protection of the reactive functional
groups present in the compounds described in this invention.
Multiple protecting groups within the same molecule can be chosen
such that each of these protecting groups can either be removed
without removal of other protecting groups in the same molecule, or
several protecting groups can be removed using the same reaction
step, depending upon the outcome desired. An authoritative account
describing many alternatives to the trained practitioner is Greene
and Wuts, Protective Groups in Organic Synthesis, Wiley and Sons
(1999).
Pharmacological Activity
[0250] Having regard to their modulation of CFTR activity,
compounds of formula (I), in free or pharmaceutically acceptable
salt form, hereinafter alternately referred to as "agents of the
invention", are useful in the treatment of conditions which respond
to the modulation of CFTR activity, particularly conditions
benefiting from mucosal hydration such as cystic fibrosis.
[0251] Diseases mediated by modulation of CFTR activity, include
diseases associated with the regulation of fluid volumes across
epithelial membranes. For example, the volume of airway surface
liquid is a key regulator of mucociliary clearance and the
maintenance of lung health. The modulation of CFTR activity will
promote fluid accumulation on the mucosal side of the airway
epithelium thereby promoting mucus clearance and preventing the
accumulation of mucus and sputum in respiratory tissues (including
lung airways). Such diseases include respiratory diseases, such as
cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis,
chronic obstructive pulmonary disease (COPD), asthma, respiratory
tract infections (acute and chronic; viral and bacterial) and lung
carcinoma. Diseases mediated by modulation of CFTR activity also
include diseases other than respiratory diseases that are
associated with abnormal fluid regulation across an epithelium,
perhaps involving abnormal physiology of the protective surface
liquids on their surface, e.g., Sjogren's Syndrome, xerostomia (dry
mouth) or keratoconjunctivitis sire (dry eye). Furthermore,
modulation of CFTR activity in the kidney could be used to promote
diuresis and thereby induce a hypotensive effect.
[0252] Treatment in accordance with the invention may be
symptomatic or prophylactic.
[0253] Asthma includes intrinsic (non-allergic) asthma and
extrinsic (allergic) asthma, mild asthma, moderate asthma, severe
asthma, bronchitic asthma, exercise-induced asthma, occupational
asthma and asthma induced following bacterial infection. Treatment
of asthma is also to be understood as embracing treatment of
subjects, e.g., of less than 4 or 5 years of age, exhibiting
wheezing symptoms and diagnosed or diagnosable as "wheezy infants",
an established patient category of major medical concern and now
often identified as incipient or early-phase asthmatics. (For
convenience this particular asthmatic condition is referred to as
"wheezy-infant syndrome".)
[0254] Prophylactic efficacy in the treatment of asthma will be
evidenced by reduced frequency or severity of symptomatic attack,
e.g., of acute asthmatic or bronchoconstrictor attack, improvements
in lung function or improved airways hyperreactivity. It may
further be evidenced by reduced requirement for other, symptomatic
therapy, i.e., therapy for or intended to restrict or abort
symptomatic attack when it occurs, e.g., anti-inflammatory (e.g.,
cortico-steroid) or bronchodilatory. Prophylactic benefit in asthma
may, in particular, be apparent in subjects prone to "morning
dipping". "Morning dipping" is a recognized asthmatic syndrome,
common to a substantial percentage of asthmatics and characterized
by asthma attack, e.g., between the hours of about 4-6 am, i.e., at
a time normally substantially distant from any previously
administered symptomatic asthma therapy.
[0255] Chronic obstructive pulmonary disease includes chronic
bronchitis or dyspnea associated therewith, emphysema, as well as
exacerbation of airways hyperreactivity consequent to other drug
therapy, in particular, other inhaled drug therapy. The invention
is also applicable to the treatment of bronchitis of whatever type
or genesis including, e.g., acute, arachidic, catarrhal, croupus,
chronic or phthinoid bronchitis.
[0256] Dry eye disease is characterized by a decrease in tear
aqueous production and abnormal tear film lipid, protein and mucin
profiles. There are many causes of dry eye, some of which include
age, laser eye surgery, arthritis, medications, chemical/thermal
burns, allergies and diseases, such as cystic fibrosis and
Sjogren's Syndrome. Increasing anion secretion via CFTR would
enhance fluid transport from the corneal endothelial cells and
secretory glands surrounding the eye to increase corneal hydration.
This would help to alleviate the symptoms associated with dry eye
disease.
[0257] Sjogren's Syndrome is an autoimmune disease in which the
immune system attacks moisture-producing glands throughout the
body, including eye, mouth, skin, respiratory tissue, liver, vagina
and gut. Symptoms include dry eye, dry mouth and dry vagina, as
well as lung disease. The disease is also associated rheumatoid
arthritis, systemic lupus, systemic sclerosis and
polymypositis/dermatomyositis. Defective protein trafficking is
believed to cause the disease, for which treatment options are
limited. Modulators of CFTR activity may hydrate the various organs
affected by the disease and help to alleviate the associated
symptoms.
[0258] The suitability of CFTR activity modulators as a treatment
of a disease benefiting from mucosal hydration may be tested by
determining the movement of chloride ions in a suitable cell-based
assay. For example single cells or confluent epithelia,
endogenously expressing or engineered to overexpress CFTR can be
used to assess channel function using electrophysiological
techniques or ion flux studies. See methods described in: Hirsh et
al., J Pharm Exp Ther (2004); Moody et al., Am J Physiol Cell
Physiol (2005).
[0259] CFTR activity modulators, including the compounds of formula
(I), are also useful as co-therapeutic agents for use in
combination with other drug substances, such as anti-inflammatory,
bronchodilatory, antihistamine or anti-tussive drug substances,
particularly in the treatment of cystic fibrosis or obstructive or
inflammatory airways diseases such as those mentioned hereinbefore,
e.g., as potentiators of therapeutic activity of such drugs or as a
means of reducing required dosaging or potential side effects of
such drugs.
[0260] The compounds of Formula (I), (II) or (III) may be mixed
with the other drug substance in a fixed pharmaceutical composition
or it may be administered separately, before, simultaneously with
or after the other drug substance.
[0261] Accordingly, the invention includes as a further aspect a
combination of a CFTR activity modulator with osmotic agents
(hypertonic saline, dextran, mannitol, Xylitol), ENaC blockers, an
anti-inflammatory, bronchodilatory, antihistamine, anti-tussive,
antibiotic and/or DNase drug substance, wherein the CFTR activity
modulator and the further drug substance may be in the same or
different pharmaceutical composition.
[0262] Suitable antibiotics include macrolide antibiotics, e.g.,
tobramycin (TOBI.TM.).
[0263] Suitable DNase drug substances include dornase alfa
(Pulmozyme.TM.), a highly-purified solution of recombinant human
deoxyribonuclease I (rhDNase), which selectively cleaves DNA.
Dornase alfa is used to treat cystic fibrosis.
[0264] Other useful combinations of CFTR activity modulators with
anti-inflammatory drugs are those with antagonists of chemokine
receptors, e.g., CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7,
CCR-8, CCR-9 and CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5,
particularly CCR-5 antagonists, such as Schering-Plough antagonists
SC-351125, SCH-55700 and SCH-D; Takeda antagonists, such as
N-[[4-[[[6,7-dihydro-2-(4-methyl-phenyl)-5H-benzo-cyclohepten-8-yl]carbon-
yl]amino]phenyl]-methyl]tetrahydro-N,N-dimethyl-2H-pyran-4-amin-ium
chloride (TAK-770); and CCR-5 antagonists described in U.S. Pat.
No. 6,166,037 (particularly claims 18 and 19), WO 00/66558
(particularly claim 8), WO 00/66559 (particularly claim 9), WO
04/018425 and WO 04/026873.
[0265] Suitable anti-inflammatory drugs include steroids, in
particular, glucocorticosteroids, such as budesonide,
beclamethasone dipropionate, fluticasone propionate, ciclesonide or
mometasone furoate, or steroids described in WO 02/88167, WO
02/12266, WO 02/100879, WO 02/00679 (especially those of Examples
3, 11, 14, 17, 19, 26, 34, 37, 39, 51, 60, 67, 72, 73, 90, 99 and
101), WO 03/35668, WO 03/48181, WO 03/62259, WO 03/64445, WO
03/72592, WO 04/39827 and WO 04/66920; non-steroidal glucocorticoid
receptor agonists, such as those described in DE 10261874, WO
00/00531, WO 02/10143, WO 03/82280, WO 03/82787, WO 03/86294, WO
03/104195, WO 03/101932, WO 04/05229, WO 04/18429, WO 04/19935 and
WO 04/26248; LTD4 antagonists, such as montelukast and zafirlukast;
PDE4 inhibitors, such as cilomilast (Ariflo.RTM. GlaxoSmithKline),
Roflumilast (Byk Gulden), V-11294A (Napp), BAY19-8004 (Bayer),
SCH-351591 (Schering-Plough), Arofylline (Almirall Prodesfarma),
PD189659/PD168787 (Parke-Davis), AWD-12-281 (Asta Medica), CDC-801
(Celgene), SelCID(TM)CC-10004 (Celgene), VM554/UM565 (Vernalis),
T-440 (Tanabe), KW-4490 (Kyowa Hakko Kogyo), and those disclosed in
WO 92/19594, WO 93/19749, WO 93/19750, WO 93/19751, WO 98/18796, WO
99/16766, WO 01/13953, WO 03/104204, WO 03/104205, WO 03/39544, WO
04/000814, WO 04/000839, WO 04/005258, WO 04/018450, WO 04/018451,
WO 04/018457, WO 04/018465, WO 04/018431, WO 04/018449, WO
04/018450, WO 04/018451, WO 04/018457, WO 04/018465, WO 04/019944,
WO 04/019945, WO 04/045607 and WO 04/037805; adenosine A2B receptor
antagonists such as those described in WO 02/42298; and beta-2
adrenoceptor agonists, such as albuterol (salbutamol),
metaproterenol, terbutaline, salmeterol fenoterol, procaterol, and
especially, formoterol, carmoterol and pharmaceutically acceptable
salts thereof, and compounds (in free or salt or solvate form) of
formula (I) of WO 0075114, which document is incorporated herein by
reference, preferably compounds of the Examples thereof, especially
indacaterol and pharmaceutically acceptable salts thereof, as well
as compounds (in free or salt or solvate form) of formula (I) of WO
04/16601, and also compounds of EP 1440966, JP 05025045, WO
93/18007, WO 99/64035, USP 2002/0055651, WO 01/42193, WO 01/83462,
WO 02/66422, WO 02/70490, WO 02/76933, WO 03/24439, WO 03/42160, WO
03/42164, WO 03/72539, WO 03/91204, WO 03/99764, WO 04/16578, WO
04/22547, WO 04/32921, WO 04/33412, WO 04/37768, WO 04/37773, WO
04/37807, WO 04/39762, WO 04/39766, WO 04/45618, WO 04/46083, WO
04/80964, WO 04/108765 and WO 04/108676.
[0266] Suitable bronchodilatory drugs include anticholinergic or
antimuscarinic agents, in particular, ipratropium bromide,
oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), and
glycopyrrolate, but also those described in EP 424021, U.S. Pat.
Nos. 3,714,357, 5,171,744, WO 01/04118, WO 02/00652, WO 02/51841,
WO 02/53564, WO 03/00840, WO 03/33495, WO 03/53966, WO 03/87094, WO
04/018422 and WO 04/05285.
[0267] Suitable dual anti-inflammatory and bronchodilatory drugs
include dual beta-2 adrenoceptor agonist/muscarinic antagonists
such as those disclosed in USP 2004/0167167, WO 04/74246 and WO
04/74812.
[0268] Suitable antihistamine drug substances include cetirizine
hydrochloride, acetaminophen, clemastine fumarate, promethazine,
loratidine, desloratidine, diphenhydramine and fexofenadine
hydrochloride, activastine, astemizole, azelastine, ebastine,
epinastine, mizolastine and tefenadine, as well as those disclosed
in JP 2004107299, WO 03/099807 and WO 04/026841.
[0269] In accordance with the foregoing, the invention also
provides as a further aspect a method for the treatment of a
condition responsive to modulation of CFTR activity, e.g., diseases
associated with the regulation of fluid volumes across epithelial
membranes, particularly an obstructive airways disease, which
comprises administering to a subject, particularly a human subject,
in need thereof a compound of formula (I), (II) or (III), in free
form or in the form of a pharmaceutically acceptable salt.
[0270] In another aspect the invention provides a compound of
formula (I), (II) or (III), in free form or in the form of a
pharmaceutically acceptable salt, for use in the manufacture of a
medicament for the treatment of a condition responsive to
modulation of CFTR activity, particularly an obstructive airways
disease, e.g., cystic fibrosis and COPD.
[0271] The agents of the invention may be administered by any
appropriate route, e.g. orally, e.g., in the form of a tablet or
capsule; parenterally, e.g., intravenously; by inhalation, e.g., in
the treatment of an obstructive airways disease; intranasally,
e.g., in the treatment of allergic rhinitis; topically to the skin;
or rectally. In a further aspect, the invention also provides a
pharmaceutical composition comprising a compound of formula (I), in
free form or in the form of a pharmaceutically acceptable salt,
optionally together with a pharmaceutically acceptable diluent or
carrier therefor. The composition may contain a co-therapeutic
agent, such as an anti-inflammatory, broncho-dilatory,
antihistamine or anti-tussive drug as hereinbefore described. Such
compositions may be prepared using conventional diluents or
excipients and techniques known in the galenic art. Thus oral
dosage forms may include tablets and capsules. Formulations for
topical administration may take the form of creams, ointments, gels
or transdermal delivery systems, e.g., patches. Compositions for
inhalation may comprise aerosol or other atomizable formulations or
dry powder formulations.
[0272] When the composition comprises an aerosol formulation, it
preferably contains, e.g., a hydro-fluoro-alkane (HFA) propellant,
such as HFA134a or HFA227 or a mixture of these, and may contain
one or more co-solvents known in the art, such as ethanol (up to
20% by weight), and/or one or more surfactants, such as oleic acid
or sorbitan trioleate, and/or one or more bulking agents, such as
lactose. When the composition comprises a dry powder formulation,
it preferably contains, e.g., the compound of formula (I), (II) or
(III) having a particle diameter up to 10 microns, optionally
together with a diluent or carrier, such as lactose, of the desired
particle size distribution and a compound that helps to protect
against product performance deterioration due to moisture, e.g.,
magnesium stearate. When the composition comprises a nebulised
formulation, it preferably contains, e.g., the compound of formula
(I), (II) or (III) either dissolved, or suspended, in a vehicle
containing water, a co-solvent, such as ethanol or propylene glycol
and a stabilizer, which may be a surfactant.
[0273] Further aspects of the invention include: [0274] (a) a
compound of formula (I), (II) or (III) in inhalable form, e.g., in
an aerosol or other atomisable composition or in inhalable
particulate, e.g., micronised form; [0275] (b) an inhalable
medicament comprising a compound of formula (I), (II) or (III) in
inhalable form; [0276] (c) a pharmaceutical product comprising a
compound of formula (I) in inhalable form in association with an
inhalation device; and [0277] (d) an inhalation device containing a
compound of formula (I), (II) or (III) in inhalable form.
[0278] Dosages of compounds of formula (I), (II) or (III) employed
in practicing the present invention will of course vary depending,
e.g., on the particular condition to be treated, the effect desired
and the mode of administration. In general, suitable daily dosages
for administration by inhalation are of the order of 0.005-10 mg,
while for oral administration suitable daily doses are of the order
of 0.05-100 mg.
Pharmaceutical Use and Assay
[0279] Compounds of formula (I), (II) or (III) and their
pharmaceutically acceptable salts, hereinafter referred to
alternatively as "agents of the invention", are useful as
pharmaceuticals. In particular, the compounds are suitable CFTR
activity modulators and may be tested in the following assays.
Membrane Potential Assay
[0280] CFTR activity can be quantified by measuring the
transmembrane potential. The means for measuring the transmembrane
potential in a biological system can employ a number of methods
including electrophysiological and optical fluorescence-based
membrane potential assays.
[0281] The optical membrane potential assay utilises a negatively
charged potentiometric dye, such as the FLIPR membrane potential
dye (FMP) (see Baxter D F, Kirk M, Garcia A F, Raimondi A,
Holmqvist M H, Flint K K, Bojanic D, Distefano P S, Curtis R, Xie
Y. `A novel membrane potential-sensitive fluorescent dye improves
cell-based assays for ion channels.` J Biomol Screen. 2002
February; 7(1):79-85) which when extracellular is bound to a
quenching agent. Upon cellular depolarisation the negatively
charged dye redistributes to the intracellular compartment,
unbinding from the membrane impermeant quench agent, yielding an
increase in fluorescence. This change in fluorescence is
proportional to the change in transmembrane potential which can
result from the activity of CFTR. The changes in fluorescence can
be monitored in real time by an appropriately equipped fluorescence
detector such as the FLIPR (fluorometric imaging plate reader) in
96 or 384-well microtitre plates.
Cell Culture:
[0282] Chinese hamster ovary (CHO) cells stably expressing the
.DELTA.F508-CFTR channel were used for membrane potential
experiments. Cells were maintained at 37.degree. C. in 5% v/v
CO.sub.2 at 100% humidity in Modified Eagles medium (MEM)
supplemented with 8% v/v foetal calf serum, 100 g/ml methotrexate
and 100 U/ml penicillin/streptomycin. Cells were grown in 225
cm.sup.2 tissue culture flasks. For membrane potential assays cells
were seeded into 96 well plates at 40,000 cells per well, allowed
to adhere and then maintained at 26.degree. C. for 48 h to
facilitate channel insertion.
Potentiator Assay:
[0283] The membrane potential screening assay utilised a low
chloride ion containing extracellular solution (.about.5 mM)
combined with a double addition protocol. The first addition was of
buffer with or without test compound followed 5 minutes later by an
addition of forskolin (1-20 .mu.M)--this protocol favours maximum
chloride efflux in response to .DELTA.F508-CFTR activation. The
.DELTA.F508-CFTR mediated chloride ion efflux leads to a membrane
depolarisation which is optically monitored by the FMP dye.
Solutions:
[0284] Low chloride extracellular (mM): 120 Na-gluconate, 1.2
CaCl.sub.2, 3.3 KH.sub.2PO.sub.4, 0.8 K.sub.2HPO.sub.4, 1.2
MgCl.sub.2, 10.0 D-glucose, 20.0 HEPES, pH 7.4 with NaOH FMP dye:
made up as per manufacturers' instructions in low chloride
extracellular solution detailed above, at 10.times. final
concentration, and stored as 1 mL aliquots at -20.degree. C.
lonWorks Quattro assay: CFTR activity can also be quantified
electrophysiologically using the whole-cell configuration of the
patch clamp technique (Hamill et al Pflugers Acrhive 1981). This
assay directly measures the currents associated with chloride flow
through CFTR channels whilst either maintaining or adjusting the
transmembrane voltage. This assay can use either single glass
micropipettes or parallel planar arrays to measure CFTR activity
from native or recombinant cell systems. Currents measured using
parallel planar arrays can be quantified using an appropriately
equipped instrument such as the lonWorks Quattro (Molecular
Devices) or the Qpatch (Sophion). The Quattro system can measure
CFTR currents from either a single cell per recording well (HT
configuration) or alternatively from a population of 64 cells per
well (Population Patch Clamp PPC) (Finkel A, Wittel A, Yang N,
Handran S, Hughes J, Costantin J. `Population patch clamp improves
data consistency and success rates in the measurement of ionic
currents.` J Biomol Screen. 2006 August; 11(5):488-96).
Cell Culture:
[0285] Chinese hamster ovary (CHO) cells stably expressing the
.DELTA.F508-CFTR channel were used for lonWorks Quattro
experiments. Cells were maintained at 37.degree. C. in 5% v/v
CO.sub.2 at 100% humidity in D-MEM supplemented with 10% (v/v) FCS,
100 U/mL Penicillin/Streptomycin, 1% (v/v) NEAA, 1 mg/ml Zeocin and
500 ug/ml Hygromycin B. For experiments cells were grown in 225
cm.sup.2 tissue culture flasks until near confluence and then
cultured at 26.degree. C. for 48-72 h to facilitate channel
insertion. Cells were removed from the flask and resuspended in
either extracellular recording solution for immediate
experimentation or alternatively in growth medium supplemented with
10% v/v DMSO and frozen to -80.degree. C. as 1-2 mL aliquots for
use at a later date.
Potentiator Assay:
[0286] Cells, at a density of 1.5-3 million per mL, were placed on
the Quattro system, added to the planar patch array and seals
allowed to establish for 5-10 mins. After assessing seal
resistances (commonly >50 M.OMEGA.), whole-cell access was
obtained by perforation with 100 .mu.g/mL amphotericin B. Baseline
currents were measured by a pre-compound scan obtained by
application of a voltage ramp from -100 to +100 mV. This was
followed by addition of either buffer or test compound diluted in
the extracellular solution supplemented with 20 .mu.M forskolin, to
each of the 384 wells of the planar parch array. After incubation
step (5-20 minutes) the post-compound currents were measured again
by application of a voltage ramp from -100 to +100 mV. The
difference in currents between the pre- and post-compound scans
defined the efficacy of CFTR potentiation.
Solutions:
[0287] Extracellular solution (ECS): 145 mM NaCl, 4 mM CsCl, 5 mM
D-glucose, 10 mM TES, 1 mM CaCl.sub.2, 1 mM MgCl.sub.2, pH 7.4
NaOH
[0288] Intracellular buffer (ICS): 113 mM L-Aspartic acid, 113 mM
CsOH, 27 mM CsCl, 1 mM NaCl, 1 mM MgCl.sub.2, 1 mM EGTA, 10 mM TES.
pH 7.2 with CsOH. Filter sterilized before use.
Ion Transport Assay:
[0289] Another method to measure CFTR function is Ussings chamber
short circuit current measurement. Engineered or native epithelial
cells are grown to confluent monolayer on a semi-permeable filter
and sandwiched between two perspex blocks. The flow of chloride
ions via CFTR from one side of the epithelia to the other can be
quantified by measuring the flow of current whilst maintaining the
transepithelial potential at OmV. This is achieved using KCl filled
agar-based electrodes to both clamp the cellular monolayer and
measure the flow of currents.
Cell Culture:
[0290] FRT cells stably expressing .DELTA.F508-CFTR were cultured
on plastic in Coon's modified F-12 medium supplemented with 32 mM
NaHCO.sub.3, 10% v/v fetal bovine serum, 2 mM L-glutamine, 100 U/mL
penicillin, 100 .mu.g/mL streptomycin and 30 .mu.g/mL hygromycin B
as the growth medium. For Ussing chamber experiments, the cells
were grown as polarized epithelia on Snapwell permeable support
inserts (500000 cells/insert in growth medium) and cultured for 7
to 9 days. The inserts were fed with fresh Coon's modified F-12
growth medium every 48 hours, and 24 hours prior to Ussing chamber
experiment. To increase the .DELTA.F508 CFTR protein expression at
the cell surface, plates were incubated at 27.degree. C. for 48 h
before performing an Ussing chamber experiment.
Potentiator Assay:
[0291] Fischer Rat Thyroid (FRT) epithelial cells, stably
expressing human .DELTA.F508-CFTR were used as monolayer cultures
on permeable supports. Cl.sup.- current was measured using the
short circuit current technique, under an imposed basolateral to
apical Cl.sup.- gradient in Ussing chambers. To measure stable
Cl.sup.- currents, FRT cells were cultured for 48 h at 27.degree.
C. to facilitate the insertion of .DELTA.F508 CFTR into the plasma
membrane. Ussing chamber studies were likewise conducted at
27.degree. C. Under these conditions, the effects of cumulative
additions of test compounds on .DELTA.F508 CFTR currents could be
quantitated with both potency and efficacy endpoints. Compounds
were added to both the apical and basloalteral sides subsequent to
addition of 10 .mu.M forskolin. Efficacy of compounds was compared
to a known potentiator such as gensitein.
Solutions:
[0292] Basolateral Ringer solution (mM): 126 NaCl, 24 NaHCO.sub.3,
0.38 KH.sub.2PO.sub.4, 2.13 K.sub.2HPO.sub.4, 1 MgSO.sub.4, 1
CaCl.sub.2 and 10 glucose.
[0293] Apical Ringer solution (mM): 140 Na-gluconate, 1 MgSO.sub.4,
2 CaCl.sub.2, 1 HCl, 10 glucose and 24 NaHCO.sub.3.
[0294] Compounds can also be tested for their ability to stimulate
insertion of .DELTA.F508 CFTR into the cell membrane using the
above assays. For these assays the protocols were identical other
than cells were not cultured at low temperature (26 or 27.degree.
C.) but instead incubated with test compounds for 12-24 h prior to
assay.
[0295] Compounds of the Examples, herein below, generally have
EC.sub.50 values in the data measurements described above below 10
.mu.M. Table 1 provides a list of representative compounds with
their EC.sub.50 value.
TABLE-US-00001 TABLE 1 Example No EC.sub.50 .mu.M Example No
EC.sub.50 2 0.015 9 0.090 3 0.055 10 0.112 4 0.076 11 0.037 5 0.05
12 0.035 6 0.426 14 0.115 7 0.040 15 0.051 8 0.060 16 0.008 17
0.010
[0296] Compounds listed below are within the scope of the broadest
claim and the CFTR EC.sub.50 values in the data measurements
described above were above 5C.M: [0297]
3-amino-6-bromo-N-(imidazo[1,2-a]pyridin-2-ylmethyl)-5-(trifluoromethyl)p-
yrazine-2-carboxamide; [0298]
3-amino-6-bromo-N-((1-methyl-1H-imidazol-4-yl)methyl)-5-(trifluoromethyl)-
pyrazine-2-carboxamide; [0299]
2-(3-amino-6-bromo-5-(trifluoromethyl)picolinamido)acetic acid;
[0300]
3-amino-6-bromo-N-((1-methyl-1H-pyrazol-3-yl)methyl)-5-(trifluoromethyl)p-
yrazine-2-carboxamide; [0301]
3-amino-N-(2-(4-fluorophenyl)-2-oxoethyl)-6-(1-methyl-1H-indol-6-yl)-5-(t-
rifluoromethyl)picolinamide; [0302]
3-amino-6-bromo-N-((1-methyl-1H-imidazol-2-yl)methyl)-5-(trifluoromethyl)-
pyrazine-2-carboxamide; [0303]
6-((3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)oxy)-3-(2,5-dimethyl-1H-pyrrol--
1-yl)-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)pico-
linamide; [0304]
3-amino-6-(6-(3-(dimethylamino)propoxy)pyridin-3-yl)-N-(2-(4-fluorophenyl-
)-2-oxoethyl)-5-(trifluoromethyl)pyrazine-2-carboxamide; [0305]
(R)-3-amino-6-bromo-N-((4-methylpiperazin-2-yl)methyl)-5-(trifluoromethyl-
) pyrazine-2-carboxamide; [0306]
3-amino-6-bromo-N-((1-methyl-1H-imidazol-5-yl)methyl)-5-(trifluoromethyl)
pyrazine-2-carboxamide; [0307]
3-amino-6-(3-(N,N-dimethylsulfamoyl)phenyl)-N-(2-(4-fluorophenyl)-2-oxoet-
hyl)-5-(trifluoromethyl)picolinamide; [0308]
3-amino-6-bromo-N-isobutyl-N-methyl-5-(trifluoromethyl)
pyrazine-2-carboxamide; [0309]
3-amino-6-bromo-N-((1-methyl-1H-pyrazol-5-yl)methyl)-5-(trifluoromethyl)p-
yrazine-2-carboxamide; [0310]
6-bromo-3-(methylamino)-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(t-
rifluoromethyl)picolinamide; [0311]
(3-amino-6-bromo-5-(trifluoromethyl)pyrazin-2-yl)(4-methylpiperazin-1-yl)-
methanone; [0312]
3-amino-6-bromo-N-(2-(pyridin-4-yl)ethyl)-5-(trifluoromethyl)pyrazine-2-c-
arboxamide; [0313]
3-amino-N-(2-(4-fluorophenyl)-2-oxoethyl)-6-(1-oxo-1,2,3,4-tetrahydroisoq-
uinolin-6-yl)-5-(trifluoromethyl)picolinamide; [0314]
3-amino-6-(4-carbamoyl-2-methylphenyl)-N-(2-(4-fluorophenyl)-2-oxoethyl)--
5-(trifluoromethyl) picolinamide; [0315]
3-amino-6-bromo-N-(2-(pyridin-3-yl)ethyl)-5-(trifluoromethyl)pyrazine-2-c-
arboxamide; [0316]
3-amino-6-(3,4-dimethylphenyl)-N-(2-(4-fluorophenyl)-2-oxoethyl)-5-(trifl-
uoromethyl)picolinamide; [0317]
3-amino-N-benzyl-6-bromo-N-methyl-5-(trifluoromethyl)pyrazine-2-carboxami-
de; [0318]
3-amino-6-hydroxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)--
5-(trifluoromethyl)picolinamide; [0319]
3-amino-6-hydroxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluo-
romethyl)picolinamide; [0320]
(3-amino-6-bromo-5-(trifluoromethyl)pyrazin-2-yl)(4-methyl-3-phenylpipera-
zin-1-yl)methanone; [0321]
(S)-3-amino-6-bromo-N-((1-ethylpyrrolidin-2-yl)methyl)-5-(trifluoromethyl-
) pyrazine-2-carboxamide; and [0322]
3-amino-6-bromo-N-(imidazo[1,5-a]pyridin-1-ylmethyl)-5-(trifluoromethyl)
pyrazine-2-carboxamide.
[0323] The invention is illustrated by the following Examples.
EXAMPLES
General Conditions:
[0324] Mass spectra were run on LC-MS systems using electrospray
ionization. These were either Agilent 1100 HPLC/Micromass Platform
Mass Spectrometer combinations or Waters Acquity UPLC with SQD Mass
Spectrometer. [M+H]+ refers to mono-isotopic molecular weights.
[0325] NMR spectra were run on open access Bruker AVANCE 400 NMR
spectrometers using ICON-NMR. Spectra were measured at 298K and
were referenced using the solvent peak.
[0326] Optical rotations were measured at 589 nm and 546 nm using
an Optical activity AA-1000 polarimeter at 21'C.
[0327] The following examples are intended to illustrate the
invention and are not to be construed as being limitations thereon.
Temperatures are given in degrees centigrade.
[0328] If not mentioned otherwise, all evaporations are performed
under reduced pressure, preferably between about 15 mm Hg and 100
mm Hg (=20-133 mbar). The structure of final products,
intermediates and starting materials is confirmed by standard
analytical methods, e.g., microanalysis and spectroscopic
characteristics, e.g., MS, IR, and NMR.
[0329] Abbreviations used are those conventional in the art. If not
defined, the terms have their generally accepted meanings.
Abbreviations
[0330] app apparent [0331] ATP adenosine 5'-triphosphate [0332] BI
NAP racemic 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl [0333] BOC
tertiary butyl carboxy [0334] br broad [0335] d doublet [0336] dd
doublet of doublets [0337] DCM dichloromethane [0338] DIEA
diethylisopropylamine [0339] DIPEA diisopropylethylamine [0340] DMF
N,N-dimethylformamide [0341] DMSO dimethylsulfoxide [0342] DTT
dithiothreitol [0343] ESI electrospray ionization [0344] EtOAc
ethyl acetate [0345] eq equivalent [0346] h hour(s) [0347] HATU
2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate [0348] HPLC high pressure liquid chromatography
[0349] IR infrared spectroscopy [0350] LCMS liquid chromatography
and mass spectrometry [0351] MeOH methanol [0352] MS mass
spectrometry [0353] MW microwave [0354] m multiplet [0355] min
minutes [0356] ml milliliter(s) [0357] m/z mass to charge ratio
[0358] NMR nuclear magnetic resonance [0359] ppm parts per million
[0360] PS polymer supported [0361] rac racemic [0362] RT room
temperature [0363] Rt retention time [0364] s singlet [0365] SCX-2
strong cation exchange (e.g. Isolute.RTM. SCX-2 columns from
Biotage) [0366] t triplet [0367] TEA triethylamine [0368] TFA
trifluoroacetic acid [0369] THF tetrahydrofuran
[0370] Referring to the examples that follow, compounds of the
preferred embodiments were synthesized using the methods described
herein, or other methods, which are known in the art.
[0371] The various starting materials, intermediates, and compounds
of the preferred embodiments may be isolated and purified, where
appropriate, using conventional techniques such as precipitation,
filtration, crystallization, evaporation, distillation, and
chromatography. Unless otherwise stated, all starting materials are
obtained from commercial suppliers and used without further
purification. Salts may be prepared from compounds by known
salt-forming procedures.
[0372] It should be understood that the organic compounds according
to the preferred embodiments may exhibit the phenomenon of
tautomerism. As the chemical structures within this specification
can only represent one of the possible tautomeric forms, it should
be understood that the preferred embodiments encompasses any
tautomeric form of the drawn structure.
[0373] If not indicated otherwise, the analytical HPLC conditions
are as follows:
TABLE-US-00002 Method 10 minLC_v001 Column Waters BEH C18 100
.times. 2.1 mm, 1.7 .mu.m Column Temp. 50.degree. C. Eluents A:
H.sub.2O, B: acetonitrile, both containing 0.1% TFA Flow Rate 0.7
ml/min Gradient 0.25 min 5% B; 5% to 95% B in 7.75 min, 1.00 min
95% B Method 10 minLC_v002 Column Waters BEH C18 50 .times. 2.1 mm,
1.7 .mu.m Column 50.degree. C. Temperature Eluents A: H.sub.2O, B:
methanol, both containing 0.1% TFA Flow Rate 0.8 ml/min Gradient
0.20 min 5% B; 5% to 95% B in 7.80 min, 1.00 min 95% B Method 10
minLC_v003 Column Waters BEH C18 50 .times. 2.1 mm, 1.7 .mu.m
Column 50.degree. C. Temperature Eluents A: H.sub.2O, B:
acetonitrile, both containing 0.1% TFA Flow Rate 0.8 ml/min
Gradient 0.20 min 5% B; 5% to 95% B in 7.80 min, 1.00 min 95% B
Method 2 minLC_v001 Column Waters BEH C18 100 .times. 2.1 mm, 1.7
.mu.m Column Temp. 50.degree. C. Eluents A: H.sub.2O, B:
acetonitrile, both containing 0.1% TFA Flow Rate 0.7 ml/min
Gradient 0.25 min 5% B; 5% to 95% B in 1.00 min, 0.25 min 95% B
Method 2 minLC_v002 Column Waters BEH C18 50 .times. 2.1 mm, 1.7
.mu.m Column 50.degree. C. Temperature Eluents A: H.sub.2O, B:
methanol, both containing 0.1% TFA Flow Rate 0.8 ml/min Gradient
0.20 min 5% B; 5% to 95% B in 1.30 min, 0.25 min 95% B Method 2
minLC_v003 Column Waters BEH C18 50 .times. 2.1 mm, 1.7 .mu.m
Column 50.degree. C. Temperature Eluents A: H.sub.2O, B:
acetonitrile, both containing 0.1% TFA Flow Rate 0.8 ml/min
Gradient 0.20 min 5% B; 5% to 95% B in 1.30 min, 0.25 min 95% B
Method 10 minC18 Column: Gemini C18 100 .times. 3 mm, 3 micron
Column 50.degree. C. Temperature Eluents: A: H2O, B: Methanol, 0.1%
formic acid Flow rate: 1 ml/min Gradient: 0.00 min 0% B, 10.00 min
95% B Method AD25IPA_DEA Mobile Phase: 25% isopropanol + 0.1% v/v
DEA/75% CO.sub.2 Column: Chiralpak AD-H, 250 .times. 10 mm id, 5
.mu.m Detection: UV @ 220 nm Flow rate: 10 ml/min
[0374] Example compounds of the present invention include
Preparation of Final Compounds
Example 1.0
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
##STR00015##
[0376] 3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(Intermediate A) (397 mg, 1.392 mmol),
3-amino-1,1,1-trifluoro-2-methyl-propan-2-ol hydrochloride (250 mg,
1.392 mmol) and HATU (529 mg, 1.392 mmol) were dissolved in DMF (10
ml) and stirred at RT for 2 min. 4-Methylmorpholine (0.413 ml, 4.18
mmol) was added and stirring continued at RT for 3 h. The reaction
mixture was poured onto ice/water (100 ml) and extracted with EtOAc
(250 ml). The organic extract was washed with sat NH.sub.4Cl
solution (.about.50 ml), dried over MgSO.sub.4 and concentrated in
vacuo to give a pale brown oil. The oil was dissolved in CHCl.sub.3
(.about.3 ml) and loaded onto a 24 g ISCO (silica) column eluting
with iso-hexane:EtOAc to afford the title product; LC-MS Rt=1.46
mins; [M+H].sup.+ 410.1, Method 2minLC_v002. .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 8.30 (NH, t), 7.72 (1H, s), 7.29 (NH2, bs), 6.28
(OH, s), 3.68 (1H, dd), 3.47 (1H, dd), 1.24 (3H, s). .sup.19F NMR
(400 MHz, DMSO-d6) 5-62.71 (CF3, s), -80.48 (CF3, s).
[0377] The compounds of the following tabulated Examples (Table 2)
were prepared by a similar method to that of Example 1 from the
appropriate starting compound and amine. Single enantiomers were
prepared by using chiral amines or by separation of the product by
Supercritical Fluid Chromatography. The preparations of the
starting compounds and amines are described in the Intermediates
section, unless they are commercially available. DIPEA or TEA may
have been used in place of 4-methylmorpholine in some
reactions.
TABLE-US-00003 TABLE 2 Retention Time, Ex. Structure Name [M +
H].sup.+, 1H NMR 1.1 ##STR00016## 3-Amino-6-bromo-5-
trifluoromethyl- pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-
2-hydroxy-propyl)- amide (Separated by SFC, second eluted peak) R.t
3.26 mins; Method = AD25IPA_DEA 1H NMR (DMSO) .delta. 3.4 (1H, m),
3.6 (1H, m), 4.3 (1H, m), 6.5 (1H, s), 7.3 (2H, s), 7.7 (1H, s),
8.6 (1H, t), 1.2 ##STR00017## 3-Amino-6-bromo-5- trifluoromethyl-
pyridine-2-carboxylic acid (3,3,3-trifluoro-2-
hydroxy-propyl)-amide (Racemate) Rt 1.42 mins; [M + H].sup.+ 398
Method: 2minLC_v002 1H NMR (DMSO) .delta. 3.4 (1H, m), 3.6 (1H, m),
4.3 (1H, m), 6.5 (1H, d), 7.3 (2H, s), 7.7 (1H, s), 8.6 (1H, t),
1.3 ##STR00018## 3-Amino-6-bromo-5- trifluoromethyl-
pyridine-2-carboxylic acid ((S)-3,3,3- trifluoro-2-hydroxy-
propyl)-amide Prepared using (S)-3- Amino-1,1,1-trifluoro-
propan-2-ol Rt 1.41 mins; [M + H].sup.+ 398 Method: 2minLC_v002 1H
NMR (DMSO) .delta. 3.4 (1H, m), 3.6 (1H, m), 4.3 (1H, m), 6.5 (1H,
d), 7.3, (2H, s), 7.7 (1H, s), 8.6 (1H, t) 1.4 ##STR00019##
3-Amino-6-bromo-5- trifluoromethyl- pyridine-2-carboxylic acid
[(R)-1- (tetrahydro-furan-2- yl)methyl]-amide Prepared using
(R)-(-)- tetrahydrofurfuryl amine Rt 1.51 mins; [M + H].sup.+ 370
Method: 2minLC_v002 1H NMR (DMSO) .delta. 1.6 (1H, m), 1.9, (3H,
m), 3.4, (2H, m), 3.7, (1H, m), 3.8, (1H, m), 4.1, (1H, m), 7.3,
(2H, s), 7.7, (1H, s), 8.4, (1H, t) 1.5 ##STR00020##
3-Amino-6-bromo-5- trifluoromethyl- pyridine-2-carboxylic acid
([1,3]dioxolan-2- ylmethyl)-amide Rt 1.42 mins; [M + H].sup.+ 370
Method: 2minLC_v002 1H NMR (DMSO) .delta. 3.4, (2H, t), 3.8, (2H,
m), 3.9, (2H, m), 5.0, (1H, t), 7.3, (2H, br), 7.7, (1H, s), 8.4,
(1H, t), 1.6 ##STR00021## 3-Amino-6-bromo-5- trifluoromethyl-
pyridine-2-carboxylic acid [(S)-1- (tetrahydro-furan-2-
yl)methyl]-amide Prepared using (S)- (+)- Tetrahydrofurfurylamine
Rt 1.52 mins; [M + H].sup.+ 370 Method: 2minLC_v002. 1H NMR (DMSO)
1.6, (1H, m), 1.9, (3H, m), 3.3, (2H, m), 3.6, (1H, m), 3.8, (1H,
m), 4.0, (1H, m), 7.4, (2H, s), 7.7, (1H, s), 8.4, (1H, d) 1.7
##STR00022## 3-Amino-6-bromo-5- trifluoromethyl-
pyridine-2-carboxylic acid (tetrahydro-furan- 2-ylmethyl)-amide Rt
1.49 mins; [M + H].sup.+ 368 Method: 2minLC_v002. 1H NMR (DMSO)
.delta. 1.55, (1H, m), 1.8, (3H, m), 3.3, (2H, m), 3.6, (1H, m),
3.8, (1H, m), 4.0, (1H, m), 7.3, (2H, s), 7.7, (1H, s), 8.4, (1H,
t) 1.8 ##STR00023## 3-Amino-6-bromo-5- trifluoromethyl-
pyridine-2-carboxylic acid (2-methyl-2- piperidin-1-yl-propyl)-
amide Rt 1.14 mins; [M + H].sup.+ 423 Method: 2minLC_v002 1H NMR
(DMSO) .delta. 1.3, (6H, s), 1.4, (1H, m), 1.7, (3H, m), 1.9, (2H,
m), 2.9, (2H, m), 3.6, (2H, m), 3.7, (2H, m), 7.3, (2H, s), 7.7,
(1H, s), 8.7, (1H, t) 1.9 ##STR00024## 3-Amino-6-bromo-5-
trifluoromethyl- pyridine-2-carboxylic acid (2-hydroxy-
propyl)-amide Rt 4.06 mins; [M + H].sup.+ 344. Method: 10minLC_v002
1H NMR. ([400 MHz], [DMSO- d6]) .delta. 8.30 (1H, t), 7.69 (1H, s),
7.28 (2H, br s), 4.84 (1H, d), 3.78 (1H, m), 3.29 (1H, m), 3.14
(1H, m), 1.05 (3H, d). 1.10 ##STR00025## 3-Amino-6-bromo-5-
trifluoromethyl- pyridine-2-carboxylic acid (2-hydroxy-2-
methyl-propyl)-amide Rt 4.35 mins; [M + H].sup.+ 338. Method:
10minLC_v002 1H NMR. ([400 MHz], [DMSO- d6]) .delta. 8.14 (1H, t),
7.70 (1H, s), 7.29 (2H, br s), 4.70 (1H, s), 3.24 (1H, d), 1.10
(6H, s). 1.11 ##STR00026## 3-Amino-6-bromo-5- trifluoromethyl-
pyridine-2-carboxylic acid (2-methyl- tetrahydro-furan-2-
ylmethyl)-amide Rt 1.53 mins; [M + H].sup.+ 384 Method:
2minLC_v002. 1H NMR. ([400 MHz], [DMSO- d6]) .delta. 8.12 (1H, t),
7.70 (1H, s), 7.28 (2H, br s), 3.76 (2H, t), 3.33 (2H, d), 1.88
(2H, m), 1.80 (1H, m), 1.60 (1H, m), 1.13 (3H, s). 1.12
##STR00027## 3-Amino-6-bromo-5- trifluoromethyl-
pyridine-2-carboxylic acid (2-methoxy- ethyl)-amide Rt 1.43 mins;
[M + H].sup.+ 342; Method: 2minLC_v002. 1H NMR. ([400 MHz], [DMSO-
d6]) .delta. .quadrature..quadrature.8.41 (1H, t), 7.69 (1H, s),
7.28 (2H, br s), 3.44 (4H, m), 3.27 (3H, s). 1.13 ##STR00028##
3-Amino-6-bromo-5- trifluoromethyl- pyrazine-2-carboxylic acid
(2-methyl- tetrahydro-furan-2- ylmethyl)-amide Rt 1.52 mins; [M +
H].sup.+ 385; Method: 2minLC_v002. 1H NMR. ([400 MHz], [DMSO- d6])
.delta. .quadrature..quadrature.8.35 (1H, t), 8.09 (2H, br s), 3.76
(2H, t), 3.34 (2H, d), 1.86 (3H, m), 1.58 (1H, m), 1.13 (3H, s).
1.14 ##STR00029## 3-Amino-6-bromo-5- trifluoromethyl-
pyrazine-2-carboxylic acid [2-(4-fluoro- phenyl)-2-morpholin-
4-yl-ethyl]-amide Rt 4.29 mins; [M + H].sup.+ 492. Method:
10minLC_v002. .sup.1H NMR (400 MHz, MeOD) .delta..sub.H 7.61-7.64
(2H, m, 2 .times. Ar'H (AA'BB'X system)), 7.28-7.32 (2H, m, 2
.times. Ar'H (AA'BB'X system)), 4.65-4.73 (1H, br m,
NHCH.sub.AH.sub.BCH.sub.XN (Ar')), 4.31 (1H, dd.sub.ABX, J =
6.5/14.4 Hz, NHCH.sub.AH.sub.BCH.sub.XN(Ar')), 3.70- 4.14 (6H, m,
NHCH.sub.AH.sub.BCH.sub.XN (Ar') + 5 .times. morpholine CH),
3.00-3.30 (3H, m, 3 .times. morpholine CH). 1.15 ##STR00030##
3-Amino-6-bromo-5- trifluoromethyl- pyridine-2-carboxylic acid
[2-(4-fluoro- phenyl)-2-morpholin- 4-yl-ethyl]-amide Rt 4.39 mins;
[M + H].sup.+ 491 Method: 10minLC_v002. .sup.1H NMR (400 MHz, MeOD)
.delta..sub.H 8.37-8.38 (1H, m, ArC(O)NHCH.sub.2), 7.68 (1H, s,
ArH-1), 7.35 (2H, m (AA'BB'X system), 2 .times. Ar'H-2), 7.17-7.25
(4H, br s + m (AA'BB'X system), ArNH.sub.2 + 2 .times. Ar'H-3),
3.73-3.81 (2H, m, NHCH.sub.AH.sub.BCH(N)Ar' +
NHCH.sub.AH.sub.BCH(N)Ar'), 3.53- 3.58 (5H, morpholine 2 .times.
CH.sub.2 + NHCH.sub.AH.sub.BCH(N)Ar'), 2.34- 2.43 (4H, m, 2 .times.
morpholine CH.sub.2). 1.16 ##STR00031## 3-Amino-6-bromo-5-
trifluoromethyl- pyridine-2-carboxylic acid (2-morpholin-4-yl-
2-phenyl-ethyl)-amide Rt 4.20 mins; [M + H].sup.+ 473 Method
10minLC_v002. 1H NMR (400 MHz, DMSO- d6) .delta. 8.46 (1H, s
broad), 7.70 (1H, s), 7.32 (7H, m broad), 3.75 (2H, m broad), 3.59
(4H, broad), 2.40 (2H, broad), 2.30 (2H, broad). 1.17 ##STR00032##
3-Amino-6-bromo-5- trifluoromethyl- pyridine-2-carboxylic acid (2-
dimethylamino-2- phenyl-ethyl)-amide Rt 4.25 mins; [M + H].sup.+
431; Method; 10minLC_v002. 1H NMR (400 MHz, DMSO- d6) .delta. 10.20
(1H, s), 8.72 (1H, t), 7.71 (1H, s), 7.60 (2H, s broad), 7.50 (3H,
s broad) 7.30 (2H, s broad), 4.67 (1H, m), 4.19 (1H, qui), 3.83
(m), 2.80 (3H, d), 2.61 (3H, d). 1.18 ##STR00033##
3-Amino-6-bromo-5- trifluoromethyl- pyrazine-2-carboxylic acid
(3-methyl-2- morpholin-4-yl-butyl)- amide Rt 3.39 mins; [M +
H].sup.+ 442. Method 10minLC_v002. 1H NMR (400 MHz, DMSO- d6)
.delta. 9.03 (1H, s), 9.10 (1H, s), 8.12 (2H, s), 4.00-3.20 (12H,
broad), 1.10 (3H, broad), 1.00 (3H, broad). 1.19 ##STR00034##
3-Amino-6-bromo-5- trifluoromethyl- pyrazine-2-carboxylic acid
(2-methyl-2- morpholin-4-yl-propyl)- amide Rt 2.83 mins; [M +
H].sup.+ 428; Method 10minLC_v002. 1H NMR (400 MHz, DMSO- d6)
.delta. 9.04 (1H, s), 8.95 (1H, s), 8.10 (2H, s), 4.04 (2H, d),
3.75 (2H, t), 3.60 (4H + broad water signal underneath), 3.20 (2H,
q), 1.35 (6H, s). 1.20 ##STR00035## 3-Amino-6-bromo-5-
trifluoromethyl- pyrazine-2-carboxylic acid (1-morpholin-4-yl-
cyclohexylmethyl)- amide Rt 3.59 mins; [M + H].sup.+ 466. Method
10minLC_v002. 1H NMR (400 MHz, DMSO- d6) .delta. 9.00 (1H, broad),
8.90 (1H, broad), 8.10 (1H, s), 4.02- 3.35 (20H, very broad) 1.21
##STR00036## 3-Amino-6-bromo-5- trifluoromethyl-
pyrazine-2-carboxylic acid (2-morpholin-4-yl- 2-phenyl-ethyl)-amide
Rt 6.09 mins; [M + H].sup.+ 474 Method 10minC18 1.22 ##STR00037##
3-Amino-6-bromo-5- trifluoromethyl- pyrazine-2-carboxylic acid (2-
dimethylamino-2- phenyl-ethyl)-amide Rt 5.42 mins; [M + H].sup.+
432 Method 10minC18 1.23 ##STR00038## 3-Amino-6-bromo-5-
trifluoromethyl- pyrazine-2-carboxylic acid [2-(4-methoxy-
phenyl)-2-pyrrolidin-1- yl-ethyl]-amide Rt 5.64 mins; [M + H].sup.+
488 Method 10minC18 1.24 ##STR00039## 3-Amino-6-bromo-5-
trifluoromethyl- pyrazine-2-carboxylic acid [2-dimethylamino-
2-(4-methoxy-phenyl)- ethyl]-amide Rt 5.51 mins; [M + H].sup.+ 462;
Method 10minC18 1.25 ##STR00040## 3-Amino-6-(4-fluoro- phenyl)-5-
trifluoromethyl- pyridine-2-carboxylic acid (3,3,3-trifluoro-2-
hydroxy-2-methyl- propyl)-amide Rt 5.41 mins; [M + H].sup.+ 426;
Method 10minLC_v002. .sup.1H NMR .delta. 8.42 (1H, m), 7.72 (1H,
s), 7.5 (2H, m), 7.3 (2H, t), 7.22 (2H, br s), 6.24 (1H, s), 3.68
(1H, m), 3.46 (1H, m), 1.24 (3H, s) 1.26 ##STR00041## 3-Amino-5-
trifluoromethyl- pyridine-2-carboxylic acid (3,3,3-trifluoro-2-
hydroxy-2-methyl- propyl)-amide Rt 4.18 mins; [M + H].sup.+ 332;
Method 10minLC_v002. .sup.1H NMR .delta. 8.58 (1H, t), 8.1 (1H, s),
7.56 (1H, s), 7.2 (2H, br s), 6.29 (1H, s), 3.61-3.7 (1H, m),
3.42-3.5 (1H, m), 1.26 (3H, s). 1.27 ##STR00042##
3-Amino-6-(4-chloro- 2-methyl-phenyl)-5- trifluoromethyl-
pyridine-2-carboxylic acid ((R)-3,3,3- trifluoro-2-hydroxy-
propyl)-amide Prepared using (R)-3- amino-1,1,1-
trifluoropropan-2-ol Rt 1.59 mins; [M + H].sup.+ 442 Method:
2minLC_v002. 1H NMR. ([400 MHz], [DMSO- d6]) .delta. 8.54 (1H, br),
7.69 (1H, s), 7.41 (1H, d), 7.30 (1H, dd), 7.24 (2H, br s), 7.20
(1H, d), 6.40 (1H, br), 4.19 (1H, m), 3.54 (1H, m), 3.36 (1H, m),
2.01 (3H, s). 1.28 ##STR00043## 3-Amino-6-bromo-5- trifluoromethyl-
pyridine-2-carboxylic acid (3,3,3-trifluoro-2- hydroxy-2-
trifluoromethyl-propyl)- amide Rt 1.59 mins; [M + H].sup.+ 466;
Method 2minLC_v002. .sup.1H NMR (400 MHz, DMSO- d6) .delta. 8.50
(1H, t), 8.30 (1H, s), 7.72 (1H, s), 7.30 (2H, s), 4.00 (2H, d)
1.29 ##STR00044## 5-Amino-6'-methyl-3- trifluoromethyl-
[2,3']bipyridinyl-6- carboxylic acid (3,3,3- trifluoro-2-hydroxy-2-
methyl-propyl)-amide Rt 1.16 mins; [M + H].sup.+ 423; Method
2minLC_v002. .sup.1H NMR (400 MHz, DMSO- d6) .delta. 8.53 (1H, d),
8.45 (1H, t), 7.75 (1H, d), 7.71 (1H, s), 7.34 (1H, d), 7.25 (2H,
s), 6.21 (1H, s), 3.69 (1H, dd), 3.42 (1H, dd), 2.54 (3H, s), 1.22
(3H, s). 1.30 ##STR00045## Methyl 3-(3-amino-6- bromo-5-
(trifluoromethyl) picolinamido) propanoate. Rt 4.64 mins; [M +
H].sup.+ 372.1; Method 10minLC_v002. .sup.1H NMR (400 MHz, DMSO-
d6) .delta. 8.56 (1H, t), 7.68 (1H, s), 7.27 (2H, br s), 3.61 (3H,
s) 3.50 (2H, q), 2.60 (2H, t). 1.31 ##STR00046## 3-Amino-N-
(benzo[d]isoxazol-3- ylmethyl)-6-bromo-5- (trifluoromethyl)
picolinamide Rt 4.18 mins; [M + H].sup.+ 417.1; Method
10minLC_v002. .sup.1H NMR (400 MHz, DMSO- d6) .delta. 9.32 (NH, t),
7.96 (1H, dt), 7.74 (1H, dt), 7.70 (1H, s), 7.65-7.62 (1H, m),
7.40- 7.36 (1H, m), 7.29 (NH2, b s), 4.88 (2H, d) 1.32 ##STR00047##
3-Amino-6-(oxazol-2- yl)-N-(3,3,3-trifluoro-2- hydroxy-2-
methylpropyl)-5- (trifluoromethyl) picolinamide Rt 3.44 mins; [M +
H].sup.+ 399.1; Method 10minLC_v003. 1.33 ##STR00048## Single
enantiomer of 3-Amino-6-bromo-N- (3,3,3-trifluoro-2- methoxy-2-
methylpropyl)-5- (trifluoromethyl) picolinamide (Separated by SFC,
second eluted peak) 1H NMR (400 MHz, DMSO- d6) .delta. 8.24 (1H,
t), 7.72 (1H, s), 7.29 (2H, s), 3.65 (2H, m), 3.37 (3H, s), 1.35
(3H, s) 1.34 ##STR00049## Single enantiomer of
3-amino-N-(2-hydroxy- 3-methyl-2- (trifluoromethyl)butyl)-
6-methoxy-5- (trifluoromethyl) picolinamide (Separated by SFC,
first eluted peak) Rt 4.48 mins; [M + H].sup.+ 390.3; Method
10minLC_v003. .sup.1H NMR (400 MHz, DMSO- d6) .delta. 8.21 (1H, m),
7.69 (1H, s), 6.59 (2H, s), 6.26 (1H, s), 3.91 (3H, s), 3.68 (2H,
m), 2.02 (1H, m), 1.02 (6H, m) 1.35 ##STR00050## 3-Amino-6-
cyclopropyl-N-(3,3,3- trifluoro-2-hydroxy-2- methylpropyl)-5-
(trifluoromethyl) picolinamide Rt 1.23 mins; [M + H].sup.+ 372.2;
Method 2minLC_v003. .sup.1H NMR (400 MHz, DMSO- d6) .delta. 8.29
(1H, m), 7.56 (1H, s), 6.9 (2H, br s), 6.3 (1H, s), 3.62 (1H, m),
3.48 (1H, m), 2.1 (1H, m), 1.24 (3H, s), 0.9-1.1 (4H, m) 1.36
##STR00051## 3-Amino-6-methoxy- N-(3,3,3-trifluoro-2- hydroxy-2-
(trifluoromethyl)propyl)- 5-(trifluoro methyl) picolinamide Rt 4.27
mins; [M + H].sup.+ 416.3; Method 10minLC_v003. .sup.1H NMR (400
MHz, DMSO-d6) .delta. 8.39 (1H, t), 8.32 (1H, br s), 7.69 (1H, s),
6.70 (2H, br s), 3.99 (2H, d), 3.93 (3H, s), 1.37 ##STR00052##
Single enantiomer of 5-amino-N-(3,3,3- trifluoro-2-hydroxy-2-
methylpropyl)-3- (trifluoromethyl)-2,4'- bipyridine-6- carboxamide
(Separated by SFC, first eluted peak) Rt 0.86 mins; [M + H].sup.+
409.1; Method 2minLC_v003. .sup.1H NMR (400 MHz, DMSO-d6) .delta.
8.70 (2H, d), 8.45 (1H, t), 7.75 (1H, s), 7.50 (2H, d), 7.33 (2H,
s), 6.22 (1H, s), 3.69 (1H, dd), 3.43 (1H, dd), 1.21 (3H, s). 1.38
##STR00053## 3-Amino-6-bromo-5- trifluoromethyl-
pyridine-2-carboxylic acid (3-methyl-2-oxo- butyl)-amide Rt 1.18
mins; [M + H].sup.+ 368; Method 2minLC_v003. .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 8.64 (1H, t), 7.71 (1H, s), 7.29 (2H, broad s),
4.2 (2H, d), 2.7-2.8 (1H, m), 1.08 (6H, d, 2 .times. CH3). 1.39
##STR00054## 3-Amino-6-bromo-5- trifluoromethyl-
pyrazine-2-carboxylic acid [2-(4-fluoro- phenyl)-2-oxo-ethyl]-
amide .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.0 (1H, t, NH), 8.1
(4H, m, NH2, Ar--H), 7.4 (2H, t, Ar--H), 4.8 (2H, 5, CH2)
Example 2 and 3
[0378] These compounds namely, [0379]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide. (Ex. 2)
[0379] ##STR00055## [0380] and
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide. (Ex.3)
##STR00056##
[0380] are prepared by chiral separation of
3-amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide. (Example 1)
using Supercritical Fluid Chromatography under the following
conditions:
[0381] Mobile Phase: 12% isopropanol+0.1% DEA/88% CO.sub.2
[0382] Column: Chiralpak OJ-H, 250.times.10 mm id, 5 .mu.m
[0383] Detection: UV @ 220 nm
[0384] Flow rate: 10 ml/min
[0385] Sample concentration: 347 mg in 5 ml EtOH.
[0386] Injection volume: 50 .mu.l
Example 2: First Eluted Peak:
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
[0387] LC-MS: Rt=4.97 min [M+H].sup.+ 410.1/412.2 (Method
10minLC_v002).
[0388] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.30 (NH, t), 7.72
(1H, s), 7.29 (NH2, bs), 6.28 (OH, s), 3.68 (1H, dd), 3.47 (1H,
dd), 1.24 (3H, s)
[0389] .sup.19F NMR (400 MHz, DMSO-d6) d -62.70 (CF3, s), -80.47
(CF3, s)
[0390] Optical rotation [.alpha.].sup.21.sub.D at 589 nm
+14.4.degree. (c=0.522, MeOH).
Example 3: Second Eluted Peak:
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
[0391] LC-MS Rt=4.94 min [M+H].sup.+ 412.1 (Method
10minLC_v002).
[0392] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.30 (NH, t), 7.72
(1H, s), 7.29 (NH2, bs), 6.28 (OH, s), 3.68 (1H, dd), 3.47 (1H,
dd), 1.24 (3H, s)
[0393] .sup.19F NMR (400 MHz, DMSO-d6) d -62.70 (CF3, s), -80.48
(CF3, s).
[0394] The stereochemistry of this compound was confirmed by X-ray
crystallography.
Example 4, 5 and 6
[0395] This compound namely,
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide. (Ex. 4),
##STR00057##
was prepared according to the following procedure:
[0396] A solution comprising
3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
(Intermediate D)(4 g, 16.94 mmol) and
3-amino-1,1-trifluoro-2-methylpropan-2-ol hydrochloride
(Intermediate R) (3.04 g, 16.94 mmol) in NMP (188 ml) was treated
with HATU (7.73 g, 20.33 mmol) followed by dropwise addition (2 ml
portions) of DIPEA (8.88 ml, 50.8 mmol) over 1 hour. After stirring
for a further hour, the reaction mixture was poured into water (450
ml) and EtOAc (450 ml). The aqueous phase was acidified with 5M HCl
(50 ml) and the layers were separated. The organic portion was
washed with 2M NaOH (200 ml), water (4.times.200 ml), brine
(2.times.100 ml), dried over MgSO.sub.4, filtered and concentrated
in vacuo to afford a brown solid. Purification of the solid by
chromatography on silica (220 g pre-packed silica cartridge)
eluting with 0-50% EtOAc in iso-hexane afforded the racemate,
3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide (Ex. 4) as a
yellow solid; 1H NMR (400 MHz, DMSO-d6) .delta. 8.3 (1H, t), 7.7
(1H, s), 6.7 (2H, s), 6.2 (1H, s), 3.9 (3H, s), 3.7 (1H, m), 3.5
(1H, m), 1.2 (3H, s).
[0397] LC-MS: Rt 1.24 min; MS m/z 362.4 [M+H].sup.+; Method
2minLC_v003.
[0398] Chiral separation of the racemate by Supercritical Fluid
Chromatography was carried out using the following conditions to
afford the compounds listed hereinafter:
[0399] Mobile Phase: 12% 2-propanol+0.1% DEA/50% CO.sub.2
[0400] Column: Chiralcel OD-H, 250.times.10 mm id, 5 .mu.m (2
columns linked in series)
[0401] Detection: UV @ 220 nm
[0402] Flow rate: 10 ml/min
[0403] Sample concentration: 3.5 g in 30 ml EtOH
[0404] Injection volume: 100 .mu.l
[0405] Examples 5 and 6 are entantiomers.
Example 5: First Eluted Peak Rt=7.30 minutes.
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
##STR00058##
[0407] 1H NMR (400 MHz, DMSO-d6) .delta. 8.3 (1H, t), 7.6 (1H, s),
6.6 (2H, broad), 6.2 (1H, s), 3.9 (3H, s), 3.6 (1H, m), 3.5 (1H,
m), 1.3 (3H, s); LC-MS Rt=1.15 mins, [M+H].sup.+ 362.4 (Method
2minLC_v003).
[0408] Optical rotation [.alpha.].sup.21.sub.D at 589 nm
-20.83.degree. (c=0.513, MeOH).
[0409] The stereochemistry of this compound was confirmed by X-ray
crystallography.
Example 6: Second Eluted Peak Rt=8.29 minutes.
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
##STR00059##
[0411] 1H NMR (400 MHz, DMSO-d6) .delta. 8.3 (1H, t), 7.6 (1H, s),
6.6 (2H, broad), 6.2 (1H, s), 3.9 (3H, s), 3.6 (1H, m), 3.5 (1H,
m), 1.3 (3H, s); LC-MS Rt=1.15 mins [M+H].sup.+ 362.4 (Method
2minLC_v003).
[0412] Alternatively, Example 5 may be prepared according to the
following method: To a solution of
3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
(Intermediate D) (10 g, 42.3 mmol) and
(S)-3-amino-1,1,1-trifluoro-2-methylpropan-2-ol hydrochloride
(Intermediate RA)(7.60 g, 42.3 mmol) in NMP (400 ml) was added HATU
(19.3 g, 50.8 mmol) followed by dropwise addition of DIPEA (22.19
ml, 127 mmol) over .about.1 hr. After stirring at room temperature
for 30 min, the mixture was added to EtOAc (2 L), washed with 1M
NaOH (2.times.1 L), water (1 L), brine (1 L), dried (MgSO.sub.4)
and evaporated under reduced pressure to give the crude product as
a dark brown oil. Purification by chromatography on silica eluting
with a gradient of 1 to-25% of EtOAc in iso-hexane afforded a
yellow oil. Recrystallisation of the oil from iso-hexane/DCM
afforded 3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic
acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide as a
crystalline solid;
[0413] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.28 (1H, t), 7.66
(1H, s), 6.67 (2H, s), 6.27 (1H, s), 3.91 (3H, s), 3.65 (1H, m),
3.45 (1H, m), 1.24 (3H, s).
[0414] .sup.19F NMR (376 MHz, DMSO-d6) -62.58 ppm (s), -80.43 ppm
(s)
Example 7
3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
##STR00060##
[0416] A mixture comprising
3-amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide (Ex. 3)(100
mg, 0.244 mmol), 4-fluorophenylboronic acid (37.5 mg, 0.268 mmol)
and 1,1'bis(diphenylphosphoshio) ferrocenepalladium dichloride
(19.90 mg, 0.024 mmol) was suspended in THF (2 ml) and 1M
Cs.sub.2CO.sub.3 (0.667 ml). The vial was flushed with N.sub.2,
sealed and heated at 160.degree. C. using microwave radiation for
15 minutes. The mixture was partitioned between EtOAc (50 ml) and
water (50 ml). The organic portion was separated and washed with
brine (30 ml), dried (MgSO.sub.4), filtered through Celite.RTM.
(filter material) and concentrated in vacuo. The crude residue was
dissolved in DMSO (2 ml) and purified by mass directed LCMS using
MeCN/Water/0.1% TFA eluent to afford clean product. The product
fraction obtained as MeCN/Water/0.1% TFA solution was poured into
EtOAc (50 ml) and washed with saturated NaHCO.sub.3 (50 ml) to free
base the product. The organic portion were combined, dried
(MgSO.sub.4) and concentrated in vacuo to afford the title compound
as a pale orange crystalline solid; 1H NMR (400 MHz, DMSO-d6)
.delta. 8.4 (1H, m), 7.7 (1H, s), 7.49 (2H, m), 7.29 (2H, t), 7.2
(2H, br s), 6.22 (1H, s), 3.68 (1H, m), 3.44 (1H, m), 1.22 (3H, s);
LC-MS Rt 4.41 mins [M+H].sup.+ 426 (Method 10minLC_v003).
Example 8
3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
##STR00061##
[0418] This compound was prepared from
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide (Ex. 2)
analogously to Example 8. 1H NMR (400 MHz, DMSO-d6) .delta. 8.42
(1H, m), 7.7 (1H, s), 7.5 (2H, m), 7.3 (2H, t), 7.21 (2H, br s),
6.24 (1H, s), 3.68 (1H, m), 3.44 (1H, m), 1.22 (3H, s); LC-MS
Rt=4.39 mins [M+H].sup.+ 426 (Method 10minLC_v003).
Example 9 and 10
[0419] The enantiomers of
3-amino-6-(2,4-dichloro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide were
prepared from
3-Amino-6-(2,4-dichloro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid (Intermediate H) and
3-amino-1,1,1-trifluoro-2-methylpropan-2-ol hydrochloride
analogously to Example 1 and separated by chiral separation using
Supercritical Fluid Chromatography:
Example 9: First Eluted Peak. Entantiomer 1 of
3-Amino-6-(2,4-dichloro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
##STR00062##
[0421] 1H NMR (400 MHz, DMSO-d6) .delta. 8.38 (t, 1H), 7.83 (s,
1H), 7.78 (s, 1H), 7.60 (d, 1H), 7.54 (d, 1H), 7.39 (brs, 2H), 6.25
(br s, 1H). 3.71 (dd, 1H), 3.48 (dd, 1H), 1.26 (s, 3H); LC-MS
Rt=1.65 mins [M+H].sup.+ 476 (Method 2minLC_v002).
Example 10: Second Eluted peak. Enantiomer 2 of
3-Amino-6-(2,4-dichloro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
##STR00063##
[0423] 1H NMR (400 MHz, DMSO-d6) .delta. 8.38 (t, 1H), 7.83 (s,
1H), 7.78 (s, 1H), 7.60 (d, 1H), 7.54 (d, 1H), 7.39 (brs, 2H), 6.25
(br s, 1H). 3.71 (dd, 1H), 3.48 (dd, 1H), 1.26 (s, 3H); LC-MS Rt
1.65 mins [M+H].sup.+=476.1 (Method 2minLC_v002).
Example 11
3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid (2-hydroxy-2-methyl-propyl)-amide
##STR00064##
[0425] To a stirred suspension of
3-amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(2-hydroxy-2-methyl-propyl)-amide (Ex. 1.10) (180 mg, 0.505 mmol)
and 4-fluorophenylboronic acid (106 mg, 0.758 mmol) in a 2:1
mixture of toluene:EtOH (12 ml) under nitrogen was added 2M
Na.sub.2CO.sub.3(aq) (1.011 ml, 2.022 mmol) followed by
Pd(dppf)Cl.sub.2.CH.sub.2Cl.sub.2 adduct (41 mg, 0.051 mmol). The
reaction mixture was heated using microwave radiation at
140.degree. C. for 1 hour and then allowed to cool to RT. The
mixture was diluted with EtOAc (100 ml) and washed with water (100
ml). The organic phase was separated, filtered through Celite.RTM.
(filter material) dried (MgSO.sub.4) and concentrated in vacuo to
yield a brown oil/solid. Purification by chromatography on silica
eluting with MeOH/DCM yielded a yellow oil/solid. This was passed
through a 500 mg Isolute.RTM. Si-TMT cartridge
(2,4,6-trimercaptotriazine silica, pre-wetted with DCM) eluting
with 30% MeOH/DCM (50 ml) to afford a yellow oil/solid. The crude
product was dried in vacuo and slurried in .about.0.5 ml DCM. The
resulting suspension was removed by filtration and the filtrate was
evaporated to yield the title compound as a light yellow/brown
foam-like solid; LC-MS Rt=5.30 mins [M+H]+ 372 (Method
10minLC_v002).
[0426] 1H NMR (400 MHz, DMSO-d6), .delta. 8.29 (1H, t), 7.69 (1H,
s), 7.49 (2H, t), 7.29 (2H, t), 7.22 (2H, s), 4.63 (1H, s), 3.24
(2H, d), 1.08 (6H, s).
Example 12
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-propyl)-amide
##STR00065##
[0427] Step 1:
3-(2,5-Dimethyl-pyrrol-1-yl)-6-methoxy-5-trifluoromethyl-pyridine-2-carbo-
xylic acid (3,3,3-trifluoro-2-hydroxy-propyl)-amide
[0428] This compound was prepared from
3-(2,5-Dimethyl-pyrrol-1-yl)-6-methoxy-5-trifluoromethyl-pyridine-2-carbo-
xylic acid (Intermediate D2) and 3-amino-1,1,1-trifluoropropan-2-ol
analogously to Example 1; LC-MS Rt=1.50 mins [M+H].sup.+ 426
(Method 2minLC_v002).
Step 2: 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic
acid (3,3,3-trifluoro-2-hydroxy-propyl)-amide
[0429]
3-(2,5-Dimethyl-pyrrol-1-yl)-6-methoxy-5-trifluoromethyl-pyridine-2-
-carboxylic acid (3,3,3-trifluoro-2-hydroxy-propyl)-amide (350 mg,
0.823 mmol) was dissolved in EtOH (14 ml) and water (7 ml).
Hyroxylamine hydrochloride (572 mg, 8.23 mmol) was added followed
by TEA (167 mg, 1.646 mmol) and the mixture was heated at reflux
overnight. After cooling the RT, the mixture was purified by
reverse phase chromatography eluting with MeOH; water (0.1% TFA) to
afford the title compound as a pale yellow solid; LC-MS Rt=4.20 min
[M+H]+ 348.2 (Method 10minLC_v002)
[0430] 1H NMR (400 MHz, DMSO-d6) .delta. 8.47 (NH, t), 7.66 (1H,
s), 6.68 (NH2, bs), 6.51 (OH, d), 4.27-4.20 (1H, m), 3.93 (3H, s),
3.64-3.58 (1H, m), 3.44-3.37 (1H, m) 19F NMR (400 MHz, DMSO-d6) d
-62.67 (CF3, s), -77.05 (CF3, s), Trace TFA.
Example 14
5-Amino-6'-methyl-3-trifluoromethyl-[2,3']bipyridinyl-6-carboxylic
acid (3,3,3-trifluoro-2-hydroxy-2-trifluoromethyl-propyl)-amide
##STR00066##
[0432] This compound was prepared from
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-2-trifluoromethyl-propyl)-amide (Ex.
1.28) and 2-methylpyridine-5-boronic acid analogously to Example 8.
LC-MS Rt 1.28 min; 477[M+H]+; (Method 2minLC_v002); .sup.1H NMR
(400 MHz, MeOD) .delta. 8.50 (1H, s), 7.85 (1H, dd), 7.69 (1H, s),
7.40 (1H, d), 4.00 (2H, s), 2.62 (3H, s).
Example 15
5-Amino-6'-methyl-3-trifluoromethyl-[2,3']bipyridinyl-6-carboxylic
acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
##STR00067##
[0434] This compound was prepared by chiral separation of
5-amino-6'-methyl-3-trifluoromethyl-[2,3']bipyridinyl-6-carboxylic
acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide (Example
1.29) using Supercritical Fluid Chromatography; LC-MS Rt 3.15 min
[M+H]+ 423; (Method 10minLC_v002); 1H NMR (400 MHz, DMSO-d6)
.delta. 8.53 (1H, s), 8.49 (1H, t), 7.75 (1H, d), 7.71 (1H, s),
7.35 (1H, d), 7.25 (2H, s), 6.22 (1H, s), 3.69 (1H, dd), 3.42 (1H,
dd), 2.54 (3H, s), 1.22 (3H, s). SFC Retention Time: 4.87 min.
Example 16 and 17
3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide and
3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid
((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
##STR00068##
[0435] Step 1:
3-(2,5-Dimethyl-pyrrol-1-yl)-5,6-bis-trifluoromethyl-pyridine-2-carboxyli-
c acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
[0436] To a stirred solution of
3-(2,5-dimethyl-pyrrol-1-yl)-5,6-bis-trifluoromethyl-pyridine-2-carboxyli-
c acid (Intermediate M) (1.16 g, 3.29 mmol) in NMP (32 ml) was
added 3-Amino-1,1,1-trifluoro-2-methyl-propan-2-ol hydrochloride
(commercially available) (591 mg, 3.29 mmol) followed by HATU (1.25
g, 3.29 mmol) and NEt.sub.3 (918 ul, 6.59 mmol) and the reaction
mixture was left to stir at RT. After 1 h a further 0.2 equiv.
NEt.sub.3 was added. After 15 min a further 0.4 equiv. NEt.sub.3
and 0.2 equiv. amine were added. After 30 min a further 0.1 equiv
HATU was added. After 30 min most of the starting material had been
consumed. The reaction mixture was added to EtOAc (50 ml), washed
with 0.1M NaOH and the aqueous layer was back extracted with EtOAc
(2.times.50 ml). The combined organic extracts were washed with
water (2.times.150 ml), brine (100 ml), dried (MgSO.sub.4) and
concentrated in vacuo to give the crude product as an orange
oil.
[0437] The crude material was purified by chromatography on silica
eluting with 0-15% EtOAc in iso-hexane to afford the title product
as a yellow solid; LC-MS Rt 1.32 min; MS m/z 478.2 [M+H]+; Method
2minLC_v003.
Step 2: 3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
[0438] To a stirred solution of
3-(2,5-dimethyl-pyrrol-1-yl)-5,6-bis-trifluoromethyl-pyridine-2-carboxyli-
c acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide (985 mg,
2.064 mmol) in 2:1 EtOH/H.sub.2O (7.5 ml) was added hydroxylamine
hydrochloride (1.43 g, 20.64 mmol) followed by NEt.sub.3 (575 ml,
4.13 mmol). The reaction mixture was heated to reflux
(.about.98.degree. C.) for 11.5 hours and then allowed to cool to
RT. The solvent was removed in vacuo and the resulting residue was
partitioned between EtOAc (25 ml) and water (25 ml). The aqueous
layer was separated and extracted with EtOAc (2.times.25 ml) and
the combined organic extracts were washed with brine (50 ml), dried
(MgSO.sub.4) and concentrated in vacuo. The crude material was
purified by chromatography on silica eluting with 0-25% EtOAc in
iso-hexane to afford the title product as a pale yellow solid;
LC-MS: Rt 1.24 min; MS m/z 400.0 [M+H]+; Method 2minLC_v003.
Step 3: 3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide and
3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid
((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
##STR00069##
[0440] These compounds were prepared by chiral separation of
3-amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; Enantiomer 1:
LC-MS Rt 1.23 min; MS m/z 400.0 [M+H]+; Method 2minLC_v003. SFC
Retention Time 5.07 min.
[0441] Enantiomer 2: LC-MS Rt 1.23 min; MS m/z 400.0 [M+H]+; Method
2minLC_v003. SFC Retention Time 5.13 min.
Example 18
3-Amino-6-methoxy-N-(3,3,3-trifluoro-2-(4-methoxybenzylamino)-2-methyl
propyl)-5-(trifluoromethyl)picolinamide
##STR00070##
[0443] The title compound was prepared analogously to Example 1
from 3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
(Intermediate D) and
3,3,3-trifluoro-N2-(4-methoxybenzyl)-2-methylpropane-1,2-diamine
(Intermediate N). DIPEA was used in this reaction. 1H NMR (400 MHz,
DMSO-d6) .delta. 8.27 (1H, m), 7.68 (1H, s), 7.25 (2H, d), 6.83
(2H, d), 6.70 (2H, s), 3.85 (3H, s), 3.75 (2H, m), 3.72 (3H, s),
3.70 (1H, m), 3.47 (1H, m), 2.80 (1H, t), 1.24 (3H, s)
Example 19
3-Amino-N-(2-amino-3,3,3-trifluoro-2-methylpropyl)-6-methoxy-5-(trifluorom-
ethyl) picolinamide
##STR00071##
[0445] A mixture comprising
3-amino-6-methoxy-N-(3,3,3-trifluoro-2-(4-methoxybenzylamino)-2-methylpro-
pyl)-5-(trifluoromethyl)picolinamide (Ex. 18) (0.9 g, 1.873 mmo) in
TFA (50 ml) was heated to 50.degree. C. for 2 h. After cooling to
RT, the pH was adjusted to pH 12 using 2M NaOH. The product was
extracted with DCM and the organic extract was washed with water,
dried over MgSO.sub.4 and concentrated in vacuo. The crude product
was loaded onto a SCX-2 cartridge eluting with MeOH followed by 2M
NH3 in MeOH. The methanolic ammonia fractions were concentrated in
vacuo and dried under vacuum to afford the title compound. 1H NMR
(400 MHz, DMSO-d6) .delta. 8.35 (1H, m), 7.67 (1H, s), 6.67 (2H,
s), 3.93 (3H, s), 3.58 (1H, m), 3.40 (1H, m), 2.22 (2H, s), 1.14
(3H, s).
[0446] LC-MS Rt 0.94 min; MS m/z 361.2 [M+H]+; Method
2minLC_v003.
Example 20
3-Amino-6-(pyrrolidin-1-yl)-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-
-(trifluoromethyl)picolinamide
##STR00072##
[0447] Step 1:
3-(2,5-Dimethyl-1H-pyrrol-1-yl)-6-(pyrrolidin-1-yl)-N-(3,3,3-trifluoro-2--
hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide
[0448] The title compound was prepared from Intermediate DA
analogously to Example 1; LC-MS Rt 1.42 min; MS m/z 479.3 [M+H]+;
Method 2minLC_v003.
Step 2.
3-Amino-6-(pyrrolidin-1-yl)-N-(3,3,3-trifluoro-2-hydroxy-2-methylp-
ropyl)-5-(trifluoromethyl)picolinamide
[0449] This compound was prepared from
3-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(pyrrolidin-1-yl)-N-(3,3,3-trifluoro-2--
hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide analogously
to Intermediate D (final step). The resulting racemate was
separated by SFC to afford the title compound; First eluted
peak:
[0450] 1H NMR (400 MHz, DMSO-d6) .delta. 8.24 (1H, m), 7.6 (1H, s),
6.4 (2H, br s), 6.32 (1H, s), 3.64 (1H, m), 3.48 (1H, m), 3.35
(4H), 1.88 (4H, m), 1.25 (3H, s);
[0451] LC-MS Rt 3.87 min; MS m/z 401.3 [M+H]+; Method
10minLC_v003.
Example 21
[0452]
(S)-3-amino-6-ethoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-
-(trifluoro methyl)picolinamide
##STR00073##
[0453] The title compound was prepared from Intermediate DB and
Intermediate R analogously to Example 20; 1H NMR (400 MHz, DMSO-d6)
.delta. 8.3 (1H, t), 7.7 (1H, s), 6.6 (2H, broad), 6.3 (1H, s), 4.4
(2H, q), 3.6 (1H, mult), 3.5 (1H, mult), 1.3 (3H, t), 1.2 (3H,
s).
[0454] LC-MS Rt 1.20 min; MS m/z 376.2 [M+H]+; Method
2minLC_v003.
Example 22
3-Amino-6-bromo-N-(2-morpholinoethyl)-5-(trifluoromethyl)pyrazine-2-carbox-
amide
##STR00074##
[0456] To a stirred solution of
3-amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(Intermediate C) (250 mg, 0.874 mmol) in NMP (8 ml) was added
4-(2-aminoethyl)morphonline (138 ul, 1.049 mmol) followed by DIPEA
(763 ul, 4.37 mmol). To this solution was then added HATU (499 mg,
1.311 mmol) in portions and the reaction mixture was left to stir
at RT for 1 hour. A further 1 equiv. of 4-(2-aminoethyl)morphonline
was added. After a further 1.5 hr, 0.5 equiv. HATU (166 mg, 0.425
mmol) was added and the RM was left to stir for a further 30 min.
The mixture was added to EtOAc (50 ml) and washed with 0.1M NaOH
(50 ml). The aqueous layer was back extracted with EtOAc (50 ml).
The combined organics were washed with water (50 ml), brine (50
ml), dried over magnesium sulfate and evaporated under reduced
pressure to give a brown oil (418 mg). The crude product was
purified by chromatography (Biotage-silica 20 g/70 ml column, 3:1
EtOAc/iso-hexane). The resulting yellow residue was loaded onto an
SCX-2 cartridge (10 g) that had been pre-wetted with MeOH. The
cartridge was washed with MeOH (140 ml) and eluted with 3.5M
ammonia in methanol solution (70 ml). The appropriate fractions
were evaporated under reduced pressure to give a solid. This solid
was dissolved in EtOAc and filtered under vacuum. The filtrate was
evaporated under reduced pressure and then dried in vacuo to afford
the title compound as a yellow solid;
[0457] LC-MS: Rt 2.61 min; MS m/z 398.2 [M+H]+; Method
10minLC_v002
[0458] 1H NMR (400 MHz, DMSO-d6) .delta. 8.70 (1H, s), 8.10 (2H,
s), 3.58 (4H. t), 3.40 (2H, q), 2.45 (2H, m), 2.40 (4H, s).
Example 23
N-(2-(1H-imidazol-2-yl)propyl)-3-amino-6-bromo-5-(trifluoromethyl)pyrazine-
-2-carboxamide
##STR00075##
[0460] The title compound was prepared from
3-amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(Intermediate C) and 2-(1H-imidazol-2-yl)propan-1-amine (prepared
according to the procedure of Steffens, Robert; Schunack, Walter.
Histamine analogs, XXVI. Racemic histamine H1-agonists. Archiv der
Pharmazie (Weinheim, Germany) (1984), 317(9), 771-6; 1H NMR (400
MHz, DMSO-d6) .delta. 11.8 (1H, s), 9.0 (1H, t), 8.1 (2H, s), 7.0
(1H, s), 6.8 (1H, s), 3.55 (2H, m), 3.15 (1H, m), 1.2 (3H, d).
LC-MS [M+H]+ 393.0/395.1
Example 24a and 24b
Enantiomers of
3-amino-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5,6-bis(trifluoromet-
hyl) pyrazine-2-carboxamide
##STR00076##
[0462] The title compound was prepared from Intermediate BA and
3-amino-1,1,1-trifluoro-2-methylpropan-2-ol analogously to Example
4. Chiral separation of the racemate by Supercritical Fluid
Chromatography afforded the title compound;
Example 24a: First Eluted Peak: Enantiomer 1 of
3-amino-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5,6-bis(trifluoromet-
hyl) pyrazine-2-carboxamide
[0463] 1H NMR (400 MHz, DMSO-d6) .delta. 8.61-8.74 (1H, broad
hump), 8.5-8.61 (1H, broad hump), 8.46 (1H, t), 6.3 (1H, s), 3.69
(1H, m), 3.5 (1H, m), 1.29 (3H, s)
[0464] LC-MS: Rt 4.23 min; MS m/z 401.2 [M+H]+; Method
10minLC_v003.
Example 24b: Second eluted peak: Enantiomer 2 of
3-amino-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5,6-bis(trifluoromet-
hyl) pyrazine-2-carboxamide
[0465] 1H NMR (400 MHz, DMSO-d6) .delta. 8.61-8.76 (1H, broad
hump), 8.5-8.60 (1H, broad hump), 8.46 (1H, t), 6.3 (1H, s), 3.69
(1H, m), 3.5 (1H, m), 1.29 (3H, s)
[0466] LC-MS: Rt 4.24 min; MS m/z 401.2 [M+H]+; Method
10minLC_v003.
[0467] Optical rotation [.alpha.].sup.21.sub.D at 589
nm+22.0.degree. (c=0.517, MeOH).
Example 25
3-Amino-6-(1-methyl-1H-pyrazol-4-yl)-N-(3,3,3-trifluoro-2-hydroxy-2-methyl
propyl)-5-(trifluoromethyl)picolinamide
##STR00077##
[0468] Step 1:
3-Amino-6-(1-methyl-1H-pyrazol-4-yl)-5-(trifluoromethyl)picolinic
acid
[0469] 3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
methyl ester (Intermediate A4) (500 mg, 1.672 mmol),
PdCl.sub.2(dppf).CH.sub.2Cl.sub.2 adduct (205 mg, 0.251 mmol),
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(383 mg, 1.839 mmol) and Cs.sub.2CO.sub.3 (6.69 ml, 6.69 mmol) in
THF (12 ml) under N.sub.2, was heated using microwave radiation at
150.degree. C. for 10 minutes. 2M NaOH (5 ml) was added and the
mixture was stirred at RT overnight. The mixture was filtered
through Celite.RTM. (filter material) and the organic solvent was
removed. The resulting aqueous layer was washed with EtOAc and
acidified to pH 1. The product was extracted with DCM and
concentrated in vacuo to afford the title compound;
Step 2;
3-Amino-6-(1-methyl-1H-pyrazol-4-yl)-N-(3,3,3-trifluoro-2-hydroxy--
2-methylpropyl)-5-(trifluoromethyl)picolinamide
[0470] The title compound was prepared from
3-amino-6-(1-methyl-1H-pyrazol-4-yl)-5-(trifluoro methyl)picolinic
acid and 3-amino-1,1,1-trifluoro-2-methylpropan-2-ol analogously to
Example 4 1H NMR (400 MHz, Methanol-d4) .delta. 7.97 (1H, s), 7.85
(1H, s), 7.60 (1H, s), 3.97 (3H, s), 3.77 (1H, m), 3.56 (1H, m),
1.37 (3H, s)
[0471] LC-MS: Rt 3.22 min; MS m/z 412.3 [M+H]+; Method
10minLC_v003.
Example 26
3-Amino-6-furan-2-yl-5-trifluoromethyl-pyrazine-2-carboxylic acid
[2-(2-methoxy-phenyl)-ethyl]-amide
##STR00078##
[0473] The title compound was prepared from
3-amino-6-furan-2-yl-5-trifluoromethyl-pyrazine-2-carboxylic acid
(Intermediate PA) and the appropriate amine; MS m/z
406.93[M+H]+
Preparation of Intermediates
Intermediate A
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
##STR00079##
[0474] Intermediate A1:
2-Bromo-3-nitro-5-trifluoromethyl-pyridine
[0475] 3-Nitro-5-(trifluoromethyl)pyridin-2-ol (31.00 g, 149 mmol)
was dissolved in acetonitrile (250 ml) to give a dark brown
solution. Phosphorus(V) oxybromide (85 g, 298 mmol) was added and
the mixture was heated at reflux for 4.5 hours and then stirred at
RT overnight. The reaction mixture was quenched by pouring into
vigorously stirring water (600 ml) containing sodium
hydrogencarbonate (110 g). The dark brown mixture was extracted
with DCM (3.times.200 ml) and the organic phase was washed with
water (200 ml) and brine (100 ml), dried (MgSO.sub.4) and
concentrated in vacuo to afford the title product as a brown oil.
.sup.1H-NMR: [400 MHz, CDCl.sub.3, .delta..sub.H 8.87 (1H, d, J=1.4
Hz, ArH), 8.39 (1H, d, J=1.9 Hz, ArH).
Intermediate A2:
3-Nitro-5-trifluoromethyl-pyridine-2-carbonitrile
[0476] 2-Bromo-3-nitro-5-trifluoromethyl-pyridine (10.00 g, 36.87
mmol) was dissolved in toluene (250 ml) with stirring to give a
pale yellow solution. Tetrabutylammonium bromide (11.90 g, 36.9
mmol) was added followed by copper(I) cyanide (9.92 g, 111 mmol)
and the mixture was heated at reflux for 10 h. After cooling to RT,
the reaction mixture was partitioned between water (750 ml) and
EtOAc (750 ml). The organic fractions were combined, washed with
water (2.times.250 ml) and brine (100 ml), dried (MgSO.sub.4) and
concentrated in vacuo to afford the title product. .sup.1H-NMR:
[400 MHz, DMSO-d.sub.6 .delta..sub.H 9.55 (1H, m, ArH), 9.24 (1H,
m, ArH)
Intermediate A3: 3-Amino-5-trifluoromethyl-pyridine-2-carboxylic
acid methyl ester
[0477] 3-Nitro-5-trifluoromethyl-pyridine-2-carbonitrile (6.5 g,
29.9 mmol) was dissolved in EtOAc (150 ml) to give a pale yellow
solution and placed under an atmosphere of nitrogen. 10% Palladium
on activated carbon (3.19 g, 2.99 mmol) was added and the reaction
mixture stirred under an atmosphere of hydrogen for 18 hours. The
reaction mixture was filtered and concentrated in vacuo. The crude
residue was dissolved in HCl conc. (45 ml) and heated to reflux for
24 hours. The reaction mixture was allowed to cool to RT and
concentrated in vacuo. The solid was dissolved in MeOH (300 ml) and
sulfuric acid (14.4 ml) was added. The resulting solution was
heated at reflux for 48 hours. The reaction was allowed to cool to
RT, then neutralised by addition of 10% NaHCO.sub.3(aq) (600 ml).
The product was extracted into DCM (3.times.200 ml) and the
combined organic phases were washed with water (200 ml), brine (50
ml), (MgSO.sub.4) and concentrated in vacuo. The resulting solid
was purified by chromatography on silica: Eluant gradient:
isohexane (500 ml), 10% EtOAc in isohexane (1000 ml), 20% EtOAc in
isohexane (1500 ml) to afford the titled compound as a pale yellow
solid .sup.1H-NMR: [400 MHz, DMSO-d.sub.6, .delta..sub.H 8.13 (1H,
d, J=1.7 Hz, ArH), 7.60 (1H, d, J=1.3 Hz, ArH), 7.01 (2H, br,
NH.sub.2), 3.85 (3H, s, ArOCH.sub.3), m/z 221.1 [M+H].sup.+
Intermediate A4:
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid methyl
ester
[0478] 3-Amino-5-trifluoromethyl-pyridine-2-carboxylic acid methyl
ester (9.49 g, 43.16 mmol) was suspended in water (300 ml).
Sulfuric acid (4.60 ml, 86 mmol) was added followed by dropwise
addition over 30 minutes of a solution of bromine (2.222 ml, 43.1
mmol) in acetic acid (29.6 ml, 517 mmol). The reaction mixture was
stirred at RT for 18 hours. A further 100 ml of water was added,
followed by a further 0.25 equivalents of the bromine/AcOH mixture
(550 .mu.L bromine in 7.4 ml AcOH) and the reaction mixture stirred
at RT for an additional 90 minutes. The reaction mixture was
diluted with 500 ml water and neutralised by addition of solid
NaHCO.sub.3 (.about.85 g). The suspension was extracted with DCM
(3.times.300 ml) and the combined organic phases washed with
sat.NaHCO.sub.3(aq) (250 ml), water (250 ml) and brine (100 ml),
dried (MgSO.sub.4) and concentrated in vacuo. The crude material
was recrystallised from boiling MeOH (.about.300 ml) to give the
title product as a pale orange solid m/z 301.0 [M+H].sup.+ 1H-NMR:
[400 MHz, DMSO-d.sub.6 .delta..sub.H 7.77 (1H, s, ArH), 7.17 (2H,
s, NH.sub.2), 3.86 (3H, s, ArCO.sub.2CH.sub.3).
Intermediate A:
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
[0479] 3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
methyl ester (1.40 g, 4.68 mmol) was suspended in MeOH (15 ml);
Sodium hydroxide (2.0 M aqueous solution) (14.04 ml, 28.1 mmol) was
added and the suspension was stirred at RT overnight. The mixture
was concentrated in vacuo and the resulting residue was dissolved
in water (100 ml) and then acidifed by the addition of 5.0M
HCl(aq). The product was extracted into ethyl acetate (2.times.75
ml) and the combined organic extracts were washed with water (50
ml), brine (25 ml), dried (MgSO.sub.4) and concentrated in vacuo to
afford the title product as a yellow solid. .sup.1H-NMR: [400 MHz,
DMSO-d.sub.6, .delta..sub.H 13.24 (1H, br s, CO.sub.2H), 7.74 (1H,
s, ArH), 7.17 92H, br s ArNH.sub.2). m/z 285.1, 287.1
[M+H].sup.+
Intermediate B
3-Amino-5-trifluoromethyl-pyrazine-2-carboxylic acid ethyl
ester
##STR00080##
[0480] Intermediate B1: Carbamimidoyl-nitroso-acetic acid ethyl
ester
[0481] To a solution of 2M ammonia in Ethanol (152 ml, 0.304 mmol)
at 0.degree. C. to 5.degree. C., ethyl ethoxycarbonylacetimidate
HCl (25 g, 0.127 mmol) was added over 30 minutes. The reaction was
stirred vigorously at this temperature for 3 hours, after which a
solution of sodium nitrite in water (9.63 g, 0.139 mmol) was added
in a single portion. The pH of the mixture was adjusted to pH6 with
the addition of 5N HCl. The reaction mixture was left to stir at RT
overnight. The yellow precipitate formed was filtered under vacuum,
washed with water and dried to give the title compound;
[0482] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.1 (2H, br s), 7.6
(2H, br s), 4.3 (2H, q), 1.3 (3H, t).
Intermediate B2: Amino-carbamimidoyl-acetic acid ethyl ester
[0483] To a solution of carbamimidoyl-nitroso-acetic acid ethyl
ester (5.5 g, 31.4 mmol) in ethanol/5M HCl (1:1 ratio, 250 ml) was
added 10% Pd/C (1.3 g). The reaction mixture was hydrogenated
(H.sub.2(g)) at low pressure over 2 nights. The Pd/C was filtered
through Celite.RTM. (filter material) and the filtrate reduced in
vacuo to give the title compound as a white solid. This was taken
through to the next step as crude.
Intermediate B: 3-Amino-5-trifluoromethyl-pyrazine-2-carboxylic
acid ethyl ester
[0484] To a mixture of amino-carbamimidoyl-acetic acid ethyl ester
(2 g, 9.22 mmol) and water (50 ml), a 20% aqueous solution of
trifluoropyruvic aldehyde (2.32 g, 18.43 mmol) was added. To this
mixture, sodium acetate (5.29 g, 64.52 mmol) was added (pH of the
reaction mixture was pH5). The reaction mixture was left to stir at
RT overnight. The resultant precipitate was filtered under vacuum
purification by chromatography on silica eluting with iso-hexane:
EtOAc (gradient of 0 to 10% EtOAc) afforded the title compound
[0485] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.4 (1H, s), 7.8 (2H,
br s), 4.4 (2H, q), 1.4 (3H, t).
Intermediate BA
3-Amino-5,6-bis(trifluoromethyl)pyrazine-2-carboxylic acid
##STR00081##
[0486] Step 1: Ethyl
3-amino-5,6-bis(trifluoromethyl)pyrazine-2-carboxylate
[0487] The title compound was prepared from
amino-carbamimidoyl-acetic acid ethyl ester (Intermediate B2) and
1,1,1,4,4,4-hexafluorobutane-2,3-dione analogously to Intermediate
B; 10 LCMS Rt=4.72 minutes, [M+H]+ 304.2/326.1 Method
10minLC_v002.
Step 2: 3-Amino-5,6-bis(trifluoromethyl)pyrazine-2-carboxylic
acid
[0488] To a stirring solution of ethyl
3-amino-5,6-bis(trifluoromethyl)pyrazine-2-carboxylate (300 mg,
0.990 mmol) in EtOH (10 ml), 2M NaOH (0.495 ml, 0.990 mmol) was
added dropwise over 1 minute. After stirring at RT for 30 minutes
the reaction mixture was poured into water (30 ml) and the pH was
adjusted to pH 4 by addition of 1M HCl. The mixture was extracted
with EtOAc (2.times.50 ml) and the combined organic extracts were
washed with brine (30 ml), dried over MgSO.sub.4 (5 g), filtered
and concentrated in vacuo to afford the title compound as an off
white crystalline solid;
[0489] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.6-9.2 (2H, broad
hump), 7.8-8.3 (2H, broad hump), 4.4 (2H, q), 1.32 (3H, t).
Intermediate C
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
##STR00082##
[0490] Intermediate C1:
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid ethyl
ester
[0491] To a solution of
3-amino-5-trifluoromethyl-pyrazine-2-carboxylic acid ethyl ester
(Intermediate B) (30 mg, 0.13 mmol) in acetic acid (5 ml), sodium
carbonate (15 mg, 0.14 mmol) was added. To this mixture, half the
contents of a solution of bromine (7 .mu.L, 0.13 mmol) in acetic
acid (5 ml) were added, followed by the addition of sodium
carbonate ((15 mg, 0.14 mmol). The remaining solution of bromine in
acetic acid was added and the reaction mixture was left to stir at
RT for 2 hours. The mixture was diluted with water and the
resulting yellow precipitate was filtered under vacuum to afford
the title compound.
Intermediate C:
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
[0492] To a stirring solution of
3-amino-5-trifluoromethyl-pyrazine-2-carboxylic acid ethyl ester
(10 g, 31.8 mmol) in ethanol (20 ml), 2M NaOH (20 ml, 31.8 mmol)
was added. The resulting solution was stirred at RT for 5 minutes
and poured into water (50 ml). The pH was adjusted to pH6 with the
addition of 1M HCl. The resulting suspension was filtered under
vacuum, washed with water (20 ml) and dried to afford the title
compound; MS m/z 287[M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 7.98 (2H, s).
Intermediate D
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
##STR00083##
[0493] Intermediate D1:
6-Bromo-3-(2,5-dimethyl-pyrrol-1-yl)-5-trifluoromethyl-pyridine-2-carboxy-
lic acid methyl ester
##STR00084##
[0495] 3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
methyl ester (Intermediate A4) (2 g, 6.69 mmol) was suspended in
toluene (8 ml), and treated with p-toluenesulfonic acid (TsOH)
(0.115 g, 0.669 mmol) and acetonylacetone (0.941 ml, 8.03 mmol).
The reaction mixture was heated at reflux for 2 hours (using
Dean-Stark apparatus) and allowed to cool to RT overnight. The
resulting dark red/black solution was concentrated in vacuo to
remove toluene and the crude residue diluted with EtOAc (200 ml),
washed with NaHCO.sub.3 (50 ml), dried (MgSO.sub.4) and
concentrated in vacuo to give a brown solid. Purification of the
solid by chromatography on silica eluting with EtOAc/iso-hexane
afforded the title compound; LC-MS Rt=5.58 min [M+H]+ 377/379
(Method 10minLC_v002).
[0496] 1H NMR (400 MHz, DMSO-d6) .delta. 8.50 (1H, s), 7.77 (2H,
s), 5.83 (3H, s), 1.90 (6H, s); 19F NMR (400 MHz, DMSO-d6) .delta.
-62.26 (CF3, s).
Intermediate D2:
3-(2,5-Dimethyl-pyrrol-1-yl)-6-methoxy-5-trifluoromethyl-pyridine-2-carbo-
xylic acid
##STR00085##
[0498]
6-Bromo-3-(2,5-dimethyl-pyrrol-1-yl)-5-trifluoromethyl-pyridine-2-c-
arboxylic acid methyl ester (2 g, 5.30 mmol) was dissolved in MeOH
(40 ml) and treated with 2M NaOH (20 ml) to give a suspension which
was stirred at RT for 1 h to afford a clear solution. The solvent
was removed in vacuo and the resulting residue was acidified to pH1
with 5M HCl. The mixture was extracted with EtOAc (200 ml) and the
organic extract was dried (MgSO.sub.4) and concentrated in vacuo to
afford the title compound as a dark brown solid which was used in
the next step without further purification; LC-MS Rt=1.50 min
[M+H].sup.+ 315.2.1/316.2 (Method 2minLC_v002); 1H NMR (400 MHz,
DMSO-d6) .delta.14.42-12.61 (COOH, b), 8.25 (1H, s), 5.84 (2H, s),
4.13 (3H, s), 1.97 (6H, s); 19F NMR (400 MHz, DMSO-d6) .delta.
-62.43 (CF3, s).
Intermediate D:
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
[0499]
3-(2,5-Dimethyl-pyrrol-1-yl)-6-methoxy-5-trifluoromethyl-pyridine-2-
-carboxylic acid (2.1 g, 6.68 mmol) was dissolved in EtOH (40 ml)
and water (20 ml). To this mixture was added TEA (2.79 ml, 20.05
mmol) followed by hydroxylamine hydrochloride (4.64 g, 66.8
mmol).
[0500] The resulting mixture was heated at reflux for 5 hours.
After cooling to RT, the mixture was diluted with EtOAc (100 ml)
and washed with aqueous HCl (1M, 100 ml). The aqueous phase was
back extracted with EtOAc (100 ml) and the combined organic phases
washed with brine (100 ml), dried (MgSO4) and concentrated in vacuo
to afford the product as an orange solid. The material can be used
crude or recrystallised from isohexane-EtOAc (10:1) LC-MS Rt=1.0
min [M+H]+ 237 (Method 2minLC_v003)
[0501] 1H NMR (400 MHz, DMSO-d6) .delta. 8.5 (NH2, b), 7.70 (1H,
s), 3.89 (3H, s).
Intermediate DA
3-(2,5-Dimethyl-1H-pyrrol-1-yl)-6-(pyrrolidin-1-yl)-5-(trifluoromethyl)pic-
olinic acid
##STR00086##
[0502] Step 1:
6-Bromo-3-(2,5-dimethyl-1H-pyrrol-1-yl)-5-(trifiuoromethyl)picolinic
acid
[0503]
6-Bromo-3-(2,5-dimethyl-pyrrol-1-yl)-5-trifluoromethyl-pyridine-2-c-
arboxylic acid methyl ester (1.9 g, 5.04 mmol) and 2M NaOH (2.52
ml, 5.04 mmol) in THF (10 ml) was stirred at RT for 1 hour. The
reaction mixture was poured into water (50 ml) and the pH was
adjusted to pH 4 by addition of 1M HCl. The mixture was extracted
with EtOAc (2.times.50 ml) and the organic portion was washed with
brine (30 ml), dried over MgSO.sub.4 (5 g), filtered and
concentrated to give the title compound as a crystalline orange
solid; LC_MS Rt=1.21 min [M+H]+ 363.1 (Method 2minLC_v003).
Step 2.
3-(2,5-Dimethyl-1H-pyrrol-1-yl)-6-(pyrrolidin-1-yl)-5-(trifluorome-
thyl)picolinic acid
[0504] To a stirring solution of
6-bromo-3-(2,5-dimethyl-1H-pyrrol-1-yl)-5-(trifluoromethyl)
picolinic acid (300 mg, 0.826 mmol) in THF (1 ml), pyrrolidine
(0.136 ml, 1.652 mmol) was added. The orange solution was stirred
at RT overnight. The reaction mixture was partitioned between 0.5M
HCl (30 ml) and EtOAc (30 ml) and shaken. The organic portion was
separated and washed with brine (30 ml), dried over MgSO.sub.4,
filtered and concentrated in vacuo to give a red oil. The crude
product was purified on silica eluting with 0-40% EtOAc in
iso-hexane to afford the title product;
[0505] 1H NMR (400 MHz, DMSO d6) b 13.45 (1H, br s), 7.88 (1H, s),
5.74 (2H, s), 3.58 (5H, br s), 1.88-2.0 (11H, unresolved
peaks).
Intermediate DB
3-(2,5-Dimethyl-1H-pyrrol-1-yl)-6-ethoxy-5-(trifluoromethyl)picolinic
acid
##STR00087##
[0506] Step 1: Methyl
3-(2,5-dimethyl-1H-pyrrol-1-yl)-6-methoxy-5-(trifluoromethyl)picolinate
[0507]
3-(2,5-Dimethyl-pyrrol-1-yl)-6-methoxy-5-trifluoromethyl-pyridine-2-
-carboxylic acid (Intermediate D2)(500 mg, 1.591 mmol) in methanol
(15.91 ml) was treated with H.sub.2SO.sub.4 (0.0424 ml, 0.795 mmol)
and the solution was heated at reflux for overnight.
[0508] The solvent removed was removed in vacuo and the resulting
brown oil was neutralised to pH 7 using saturated sodium
bicarbonate. The mixture was extracted with EtOAc (20 ml) and the
combined organic extracts were washed with water (20 ml), brine (20
ml), passed though a phase separator and concentrated in vacuo.
Purification of the crude product by chromatography on silica
eluting with iso-hexane: EtOAc (gradient of 0 to 10% EtOAc)
afforded the title compound as an off-white powder.
[0509] 1H NMR (400 MHz, DMSO-d6) .delta. 8.3 (1H, s), 5.8 (2H, s),
4.1 (3H, s), 3.6 (3H, s), 1.9 (6H, s).
Step 2: Methyl
3-(2,5-dimethyl-1H-pyrrol-1-yl)-6-hydroxy-5-(trifluoromethyl)picolinate
[0510] Methyl
3-(2,5-dimethyl-1H-pyrrol-1-yl)-6-methoxy-5-(trifluoromethyl)picolinate
(100 mg, 0.305 mmol) in acetonitrile (3.05 ml) was treated with KI
(202 mg, 1.218 mmol) and TMS-Chloride (0.156 ml, 1.221 mmol) and
heated at reflux for 6 hours. The solvent removed was in vacuo and
the crude product was dissolved in EtOAc (20 ml) and washed with
water (2.times.10 ml) and brine (10 ml), dried over a phase
separator and concentrated in vacuo. Purification of the crude
product by chromatography on silica eluting with iso-hexane: EtOAc
(gradient of 0 to 30% EtOAc) afforded the title compound as an
yellow powder. LC-MS Rt=1.11 mins [M+H]+ 315.4 (Method
2minLC_v003).
Step 3: Methyl
3-(2,5-dimethyl-1H-pyrrol-1-yl)-6-ethoxy-5-(trifluoromethyl)picolinate
[0511] Methyl
3-(2,5-dimethyl-1H-pyrrol-1-yl)-6-hydroxy-5-(trifluoromethyl)picolinate
(62 mg, 0.168 mmol) in 1,4-dioxane (1.5 ml) (dry) was treated with
EtOH (0.020 ml, 0.335 mmol) and triphenylphosphine (88 mg, 0.335
mmol) and the solution stirred. DEAD (0.053 ml, 0.335 mmol) was
added dropwise and the reaction mixture stirred at room temperature
for 2 hours. The solvent was removed in vacuo and purification of
the crude product by chromatography on silica eluting with
iso-hexane: EtOAc (gradient of 0 to 10% EtOAc) afforded the title
compound;
[0512] 1H NMR (400 MHz, DMSO-d6) .delta. 8.3 (1H, s), 5.8 (2H, s),
4.5 (2H, q), 3.6 (3H, s), 1.9 (6H, s), 1.4 (3H, t).
Step 4.
3-(2,5-Dimethyl-1H-pyrrol-1-yl)-6-ethoxy-5-(trifluoromethyl)picoli-
nic acid
[0513] Methyl
3-(2,5-dimethyl-1H-pyrrol-1-yl)-6-ethoxy-5-(trifluoromethyl)picolinate
(140 mg, 0.409 mmol) was dissolved in THF (2.045 ml). NaOH (0.613
ml, 1.226 mmol) was added and heated at reflux for 6 hours. The
solvent was removed in vacuo and the resulting mixture was diluted
with EtOAc (25 ml) was acidified to pH 1 using HCl (5M). The
organic portion washed with brine, dried using a phase separator
and concentrated in vacuo to afford the title compound as a yellow
oil.
[0514] LC-MS Rt=1.26 mins [M+H]+ 329.2 Method 2minLC_v003.
Intermediate E
3-Amino-5-trifluoromethyl-pyridine-2-carboxylic acid
##STR00088##
[0516] To a stirring solution of
3-Amino-5-trifluoromethyl-pyridine-2-carboxylic acid methyl ester
(Intermediate A3) (1 g, 4.54 mmol) in MeOH (20 ml) was added 2M
NaOH (0.182 g, 4.54 mmol). The orange solution was stirred at RT
for 1 minute and then into water (10 ml). The solution was
acidified to pH1 with the addition of 1M HCl and the product was
extracted with EtOAc (150 ml). The organic portions were combined,
washed with brine (50 ml), dried over MgSO.sub.4 and concentrated
in vacuo to afford the title compound as an orange solid; LC-MS
Rt=0.82 mins [M+H]+ 207.1 (Method 2minLC_v002); 1H NMR (400 MHz,
DMSO-d6) .delta. 13.9 (1H, broad hump), 8.11 (1H, s), 7.59 (1H, s),
7.08 (2H, broad hump) (trace of EtOAc present but correlates to
proposed structure).
Intermediate G
3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid
##STR00089##
[0518] A mixture comprising
3-amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(Intermediate A) (1 g, 3.51 mmol), 4-fluorophenylboronic acid
(0.736 g, 5.26 mmol) and 1,1'Bis(diphenylphosphoshio)ferrocene
palladium dichloride (0.286 g, 0.351 mmol) and 1.0M
Cs.sub.2C.sub.03 (3.3 ml) in THF (10 ml) was heated to reflux for
10 hours. After cooling to RT, the mixture was partitioned between
DCM (100 ml) and 1 M NaOH (2.times.100 ml). The aqueous phase was
acidified with 5M HCl and the resulting milky solution was
extracted into DCM (2.times.100 ml). The organic portion was
separated, dried (MgSO.sub.4) and concentrated in vacuo to afford
the product as a crude oil. The crude material was purified by
flash chromatography on silica cartridge eluting with a gradient of
DCM: MeOH from 0% to 10% MeOH to afford the title product as a pale
yellow solid;
[0519] .sup.1H NMR (DMSO-d6, 400 MHz) .delta. 12.9 (1H, br s,
COOH), 7.7 (1H, s, CH, Ar--H), 7.4 (2H, m, Ar--H), 7.25 (2H, m,
Ar--H), 7.1 (2H, br s, NH2).
Intermediate GA
3-Amino-6-cyclopropyl-5-(trifluoromethyl)picolinic acid
##STR00090##
[0520] Step 1: 3-Amino-6-cyclopropyl-5-(trifluoromethyl)picolinic
acid
[0521] A microwave vial was charged with
amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid methyl
ester (Intermediate A4) (0.5 g, 1.754 mmol), cyclopropylboronic
acid (0.753 g, 8.77 mmol), and 1,1'Bis(diphenylphosphosphino)
ferrocene palladium dichloride (0.143 g, 0.175 mmol). The mixture
was taken up as a solution in THF (6 ml) and flushed with N.sub.2,
sealed and heated using microwave radiation at 150.degree. C. for
20 minutes. The reaction mixture was filtered through Celite.RTM.
(filter material) and washed through with EtOAc (20 ml). The
filtrate was partitioned between EtOAc (30 ml) and water (50 ml).
The phases were separated and the organic portion was washed with
brine (30 ml), dried over MgSO.sub.4, filtered and concentrated
under vacuum.
[0522] The crude material was taken up in EtOAc (20 ml) and dry
loaded onto silica (2-3 g). Material then purified on the
Combiflash Rf Teledyne ISCO System 100% Isohexane to 60%
EtOAc:Isohexane to afford semi pure material which was used without
further purification.
Step 2: 3-Amino-6-cyclopropyl-5-(trifluoromethyl)picolinic acid
[0523] To a stirring solution of
3-amino-6-cyclopropyl-5-(trifluoromethyl)picolinic acid (472 mg,
1.814 mmol) in THF (10 ml), 2M NaOH (10 ml, 20.00 mmol) was added.
The orange solution was stirred at RT for 2 days. The reaction
mixture was poured into water (30 ml) and the pH adjusted to pH6
with the addition of 1M HCl. The product was extracted with EtOAc
(50 ml) and the organic portion was dried over MgSO.sub.4, filtered
and concentrated in vacuo to give the title compound as a
red/orange oil. LC-MS Rt=1.10 mins [M+H]+ 247.1 (Method
2minLC_v003);
Intermediate H
3-Amino-6-(2,4-dichloro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid
##STR00091##
[0524] Intermediate H1:
3-Amino-6-(2,4-dichloro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid methyl ester
[0525] 3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
methyl ester (Intermediate A4) (3 g, 10.03 mmol),
2,4-dichlorophenylboronic acid (2.297 g, 12.04 mmol), potassium
phosphate (4.26 g, 20.06 mmol) and Fibrecat.RTM. 1034A (Johnson
Matthey, polymer supported palladium complex) (500 mg, 10.03 mmol)
were suspended in toluene (50 ml) and water (15 ml). The reaction
mixture was heated to 110.degree. C. under vigorous stirring for 3
hours. The mixture was allowed to cool to RT and EtOAc (100 ml) was
added. The organic layer was separated and washed with brine (15
ml). MP-TMT (macroporous polystyrene-bound trimercaptotriazine, 3
g, Polymern labs) was added and stirred for 1 hour at RT.
MgSO.sub.4 was added and the suspension filtered off. The filtrate
was concentrated in vacuo and purification of the residue by
reverse phase chromatography (130 g C18 column) eluting with
water/MeOH afforded the title compound as a white solid; LS-MS
Rt=1.55 mins [M+H]+ 365 (Method 2minLC_v002).
Intermediate H:
3-Amino-6-(2,4-dichloro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid
[0526]
3-Amino-6-(2,4-dichloro-phenyl)-5-trifluoromethyl-pyridine-2-carbox-
ylic acid methyl ester (0.9 g, 2.465 mmol) was suspended in MeOH
(15 ml) and NaOH 2M (2.465 ml, 4.93 mmol) was added under stirring.
1,4-Dioxane (15.00 ml) was added and the solution was left standing
at RT over night. The solvent was removed in vacuo and the
resulting residue was dissolved in water (10 ml) and carefully
acidified to pH4 with slow addition of 2M HCl (2 ml) whilst
stirring. The mixture was extracted with EtOAc (20 ml) and the
organic portion was washed with brine and concentrated in vacuo.
The residue was purified by reverse phase chromatography (130 g C18
column) eluting with water/MeOH to afford the title compound; LS-MS
Rt=1.57 mins [M+H]+ 351.0 (Method 2minLC_v002).
Intermediate I
3-Amino-6-(4-chloro-2-methyl-phenyl)-5-trifluoromethyl-pyridine-2-carboxyl-
ic acid methyl ester
##STR00092##
[0528] This compound was prepared from
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid methyl
ester (Intermediate A4) and 4-chloro-2-methylphenylboronic acid
analogously to Intermediate H; LC-MS Rt=1.53 mins, [M+H].sup.+ 331
(Method 2minLC_v002).
Intermediate J
2-Aminomethyl-1,1,1,3,3,3-hexafluoro-propan-2-ol
[0529] To a stirred mixture of 35% ammonium solution (1 ml) and
diethyl ether (1 ml) was added
3,3,3-trifluoro-2-(trifluoromethyl)-1,2-propenoxide (500 mg, 2.78
mmol) dropwise and the reaction mixture was left to stir at RT for
3 hours. The reaction mixture was separated and the aqueous layer
was extracted with diethyl ether (2.times.3 ml). The combined
organic portions were dried (MgSO.sub.4) and concentrated in vacuo
to give a white crystalline solid; 1H NMR (400 MHz, DMSO-d6)
.delta. 4.20 (broad), 3.30 (broad), 3.15 (s), 3.02 (s), 2.50 (s,
DMSO). 19F NMR (400 MHz, DMSO-d6) .delta. -85 (CF3), -84.5
(CF3).
Intermediate K
5-Amino-6'-methyl-3-(trifluoromethyl)-2,3'-bipyridine-6-carboxylic
acid
##STR00093##
[0530] Intermediate K1:
5-Amino-6'-methyl-3-trifluoromethyl-[2,3']bipyridinyl-6-carboxylic
acid methyl ester
[0531] This compound was prepared from
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid methyl
ester (Intermediate A4) and 2-methylpyridine-5-boronic acid
analogously to
3-amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid (Intermediate G); LC-MS Rt 0.96 min [M+H]+ 312 (Method
2minLC_v002); 1H NMR (400 MHz, DMSO-d6) .delta. 8.41 (1H, s), 7.79
(1H, s), 7.69 (1H, dd), 7.32 (1H, d), 7.10 (2H, s), 3.82 (3H, s),
2.52 (3H, s).
Intermediate K:
5-Amino-6'-methyl-3-(trifluoromethyl)-2,3'-bipyridine-6-carboxylic
acid
[0532] This compound was prepared from:
5-Amino-6'-methyl-3-trifluoromethyl-[2,3']bipyridinyl-6-carboxylic
acid methyl ester analogously to
3-amino-6-(4-chloro-2-methyl-phenyl)-5-trifluoromethyl-pyridine-2-carboxy-
lic acid methyl ester (Intermediate I); LC-MS Rt 0.90 min; [M+H]+
298 (Method 2minLC_v002); 1H NMR (400 MHz, DMSO-d6) .delta. 12.90
(1H, broad), 8.45 (1H, s), 7.72 (2H), 7.32 (1H, d), 7.12 (2H,
broad), 2.51 (3H).
Intermediate KA
5-Amino-3-(trifluoromethyl)-2,4'-bipyridine-6-carboxylic acid
##STR00094##
[0534] The title compound was prepared analogously to Intermediate
K using the appropriate boronic acid in step 1; 1H NMR (400 MHz,
DMSO-d6) .delta. 13.00 (1H, broad), 8.65 (2H, d), 7.65 (1H, s),
7.43 (2H, d), 7.18 (2H, broad).
Intermediate M
3-(2,5-Dimethyl-pyrrol-1-yl)-5,6-bis-trifluoromethyl-pyridine-2-carboxylic
acid
##STR00095##
[0535] Intermediate M1:
3-(2,5-Dimethyl-pyrrol-1-yl)-5,6-bis-trifluoromethyl-pyridine-2-carboxyli-
c acid methyl ester
[0536] A stirred mixture of KF (2.12 g, 5.62 mmol) and CuI (0.490
g, 8.43 mmol) was heated in a sealed 10.0-20.0 ml microwave vial
under vacuum until a slight greenish colour began to appear. The
vial was then placed under nitrogen to cool. A solution
6-bromo-3-(2,5-dimethyl-pyrrol-1-yl)-5-trifluoromethyl-pyridine-2-carboxy-
lic acid methyl ester (Intermediate D) (2.64 ml, 16.86 mmol) in 1:1
dry DMF/dry NMP (14 ml) was then added, followed by TMS-CF.sub.3
(2.64 ml, 16.86 mmol). A new septum was then used to seal the vial
and the reaction mixture was heated using microwave radiation with
stirring at 100.degree. C. for 3 h and allowed to cool. The mixture
was added to 5M NH3 solution (50 ml) and then extracted with
diethyl ether (4.times.50 ml). The combined organic extracts were
washed with 5M NH.sub.3 solution (3.times.20 ml), 1M HCl (50 ml),
sat. sodium bicarbonate solution (2.times.50 ml), brine (50 ml),
dried (MgSO.sub.4) and concentrated in vacuo to give a brown oil.
The crude material was purified by chromatography on silica eluting
with Iso-hexane/EtOAc, 0-10% to afford the title compound as an
orange solid; LC-MS Rt 1.37 min; MS m/z 367.1 [M+H]+; Method
2minLC_v003.
Intermediate M:
3-(2,5-Dimethyl-pyrrol-1-yl)-5,6-bis-trifluoromethyl-pyridine-2-carboxyli-
c acid
[0537] To a stirred solution
3-(2,5-dimethyl-pyrrol-1-yl)-5,6-bis-trifluoromethyl-pyridine-2-carboxyli-
c acid methyl ester (1.28 g, 3.49 mmol) in methanol (25 ml) was
added 1M NaOH (7 ml, 6.99 mmol) and the reaction mixture was left
to stir at RT for 30 min. The solvent was removed in vacuo and
water (20 ml) was added to the remaining residue. The pH was
adjusted to pH 4/5 by the addition of 1M HCl. The mixture was
extracted with EtOAc (3.times.20 ml) and the combined organic
extracts were washed with brine (30 ml), dried (MgSO.sub.4) and
concentrated in vacuo and dried in a vacuum oven (50.degree. C.)
overnight to give the crude title product as an orange solid which
was used without further purification; LC-MS: Rt 1.23 min; MS m/z
353.1 [M+H]+; Method 2minLC_v003.
Intermediate N
3,3,3-Trifluoro-N2-(4-methoxybenzyl)-2-methyl
propane-1,2-diamine
##STR00096##
[0538] Step 1:
1-(4-methoxyphenyl)-N-(1,1,1-trifluoropropan-2-ylidene)methanamine
[0539] To a stirring solution of trifluoroacetone (7.75 g, 69.2
mmol) in diethyl ether (60 ml) at -40.degree. C. was added
4-methoxybenzyl amine (9.49 g, 69.2 mmol) and triethylamine (14 g,
138 mmol) in diethyl ether (40 ml). A cooled (0.degree. C.) mixture
of TiCl.sub.4 (6.56 g, 34.6 mmol) in hexane (40 ml) at was added
dropwise over 10 minutes and the resulting mixture was allowed to
warm up to ambient temperature over 20 mins and stirred at
50.degree. C. for 2.5 h. The inorganic precipitate was removed by
filtration and washed with diethyl ether. The filtrate was
concentrated in vacuo to afford a yellow oil. Purification of the
crude product by chromatography on silica eluting with 0% to 25%
EtOAc in iso-hexane afforded the title product.
Step 2. 3,3,3-trifluoro-2-(4-methoxybenzylamino)-2-methyl
propanenitrile
[0540] To a cooled (0.degree. C.) solution of
1-(4-methoxyphenyl)-N-(1,1,1-trifluoropropan-2-ylidene)methanamine
(4.41 g, 19.07 mmol) in DCM (100 ml) was added cyanotrimethylsilane
(2.84 g, 28.6 mmol) and magnesium bromide. The mixture was stirred
at RT for 90 h and then diluted with sat. NaHCO.sub.3 (200 ml).
After stirring at RT for 1 h, the organic phase was separated,
washed with a further portion of sat. NaHCO.sub.3 (100 ml), dried
over MgSO.sub.4 and concentrated in vacuo to afford the title
compound.
Step 3:
3,3,3-trifluoro-N2-(4-methoxybenzyl)-2-methylpropane-1,2-diamine
[0541] To a cooled (0.degree. C.) solution of
3,3,3-trifluoro-2-(4-methoxybenzylamino)-2-methyl propanenitrile
(1.5 g, 5.81 mmol) in dry diether ether (50 ml) was added LiAlH4
(11.62 ml of a 2M solution in THF) and the resulting mixture was
stirred at RT overnight. The reaction mixture was hydrolyzed by
successive addition of water 15% KOH, and water. The resulting
precipitate was filtered on Celite.RTM. (filter material) and the
organic portion was washed with water, dried over MgSO.sub.4 and
concentrated under reduced pressure to afford the title product; 1H
NMR (400 MHz, Methanol-d4) b 7.97 (1H, s), 7.85 (1H, s), 7.60 (1H,
s), 3.97 (3H, s), 3.77 (1H, m), 3.56 (1H, m), 1.37 (3H, s)
[0542] LC-MS: Rt 3.22 min; MS m/z 412.3 [M+H]+; Method
10minLC_v003.
Intermediate O
Benzo[d]isoxazol-3-ylmethanamine
##STR00097##
[0544] The title compound was prepared according to the procedure
of Pigini, Maria; Giannella, Mario; Gualtieri, Fulvio; Melchiorre,
Carlo; Bolle, Paola; Angelucci, Luciano. Analogs with a
1,2-benzisoxazole nucleus of biologically active indole
derivatives. III. Tryptamine and gramine isosteres. European
Journal of Medicinal Chemistry (1975), 10(1), 29-32 (Compound 11
page 31-32).
Intermediate P
Methyl 3-amino-6-(oxazol-2-yl)-5-(trifluoromethyl)picolinate
[0545] A solution of
3-amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid methyl
ester (Intermediate A4) (500 mg, 1.672 mmol),
2-(tributylstannyl)oxazole (0.704 ml, 3.34 mmol) and
tetrakis(triphenylphosphine)palladium(0) (193 mg, 0.167 mmol) in
dioxane (10 ml) was heated at reflux for 13 hours. After cooling to
room temperature over 8 hours, the solvent was evaporated and the
resulting residue triturated with hot methanol to remove a yellow
solid impurity. The remaining crude material was used without
further purification. LC-MS: Rt 0.95 min; MS m/z 288 [M+H]+; Method
2minLC_v003.
Intermediate PA
3-Amino-6-furan-2-yl-5-trifluoromethyl-pyrazine-2-carboxylic
acid
##STR00098##
[0546] Step 1:
3-Amino-6-furan-2-yl-5-trifluoromethyl-pyrazine-2-carboxylic
acid
[0547] The title compound was prepared from
3-amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid ethyl
ester (Intermediate C1) and tributyltin-2-furylstannane analogously
to methyl 3-amino-6-(oxazol-2-yl)-5-(trifluoromethyl)picolinate
(Intermediate P)
Step 2:
3-Amino-6-furan-2-yl-5-trifluoromethyl-pyrazine-2-carboxylic
acid
[0548] The title compound was prepared from
3-amino-6-furan-2-yl-5-trifluoromethyl-pyrazine-2-carboxylic acid
and 6M NaOH analogously to
3-amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(Intermediate C, final step).
Intermediate Q
2-Hydroxy-3-methyl-2-(trifluoromethyl)butan-1-aminium chloride
##STR00099##
[0549] Step 1:
1,1,1-Trifluoro-3-methyl-2-(nitromethyl)butan-2-ol
[0550] A cooled (0.degree. C.) solution of lithium hydroxide (0.048
g, 2.015 mmol) in water (20 ml) was stirred and treated with
nitromethane (1.23 g, 20.15 mmol),
1,1,1-trifluoro-3-methylbutan-2-one (3.11 g, 22.17 mmol),
cetyltrimethylammonium Chloride (0.871 g, 2.72 mmol) and MgSO.sub.4
(0.485 g, 4.03 mmol). The white suspension was stirred at 0.degree.
C. for 1 hr, then at RT for 2 days. The resulting biphasic mixture
was separated and the more dense lower layer was collected and
dissolved in diethyl ether (30 ml). The mixture was dried over
MgSO.sub.4, filtered and concentrated in vacuo to give a pale
yellow oil. The oil was taken up in diethyl ether (10 ml) and
passed through a pre-packed SCX-2 cartridge eluting with 100%
diethyl ether. The filtrate was concentrated in vacuo to afford the
title compound as a colourless oil. .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 4.74 (1H, d), 4.59 (1H, d), 4.29 (1H, s), 2.29
(1H, m), 1.1 (6H, two sets of unresolved doublets)
Step 2: 2-Hydroxy-3-methyl-2-(trifluoromethyl)butan-1-aminium
chloride
[0551] To a solution of
1,1,1-trifluoro-3-methyl-2-(nitromethyl)butan-2-ol (753 mg, 3.74
mmol) in EtOH (10 ml) in a 25 ml medium pressure glass
hydrogenation vessel under N.sub.2, 10% Pd on carbon (39.8 mg,
0.374 mmol) was added. The vessel was flushed with N.sub.2,
followed by H.sub.2 (22.64 mg, 11.23 mmol) at 5 bar pressure and
stirred at RT for 6 days. The mixture was filtered through
Celite.RTM. and washed through with EtOH (30 ml), followed by DCM
(10 ml). The filtrate was concentrated under vacuum to give a
colourless oil. The crude product was taken up in methanol (20 ml)
and treated with a 1.25M HCl in methanol solution. The resulting
colourless solution was stirred at RT for 1 hour and concentrated
under vacuum to afford the title compound;
[0552] 1H NMR (400 MHz, DMSO-d6) .delta. 8.04 (3H, broad peak),
6.74 (1H, s), 3.58 (broad peak), 3.6 (2H, m), 2.12 (1H, m), 0.99
(6H).
Intermediate R
3-Amino-1,1,1-trifluoro-2-methylpropan-2-ol hydrochloride
##STR00100##
[0553] Step 1: 1,1,1-trifluoro-2-methyl-3-nitropropan-2-ol
[0554] To LiOH (0.193 g, 8.06 mmol) in a 3-neck round bottom flask
was added water (25 ml), nitromethane (3.76 ml, 81 mmol) and
trifluoroacetone (7.95 ml, 89 mmol).
[0555] Cetyltrimethylammonium chloride (3.8 g, 10.88 mmol) and
MgSO.sub.4 (1.9 g, 16.12 mmol) were added and the resulting yellow
solution stirred at 20-25.degree. C. for 2 days. The reaction
mixture was poured into diethyl ether (120 ml) and washed with
water (3.times.200 ml) and brine (1.times.100 ml). The organic
portion was dried over MgSO.sub.4 and concentrated in vacuo to
afford the title compound as a yellow liquid. 1H NMR (CDCl.sub.3,
400 MHz): b 4.7 (1H d), .delta. 4.5 (1H, d), b 3.7 (1H, broad), b
1.6 (3H, s). Step 2. 3-Amino-1,1,1-trifluoro-2-methylpropan-2-ol
hydrochloride
[0556] Pd/C was added (1 g) to a 200 ml glass vessel. Ethanol (50
ml, dry) was added cautiously under an atmosphere of CO.sub.2.
1,1,1-Trifluoro-2-methyl-3-nitropropan-2-ol (10 g, 57.8 mmol) was
dissolved in ethanol (50 ml, dry) and added to the glass vessel.
The reaction mixture was put under a positive pressure of hydrogen
(5 bar) at room temperature and hydrogenated for 2 days. The
reaction mixture was filtered through Celite.RTM. (filter material)
and washed with excess ethanol. The solvent was removed in vacuo to
yield a colourless oil. The oil was dissolved in MeOH (50 ml) and
treated dropwise with HCl (1M) in MeOH (30 ml). The solution was
left to stir for 30 minutes and concentrated in vacuo azeotroping
with MeCN to afford the title compound as a waxy white solid; 1H
NMR (DMSO-d6, 400 MHz) b 8.3 (3H, broad s), 6.9 (1H, broad), 3.0
(2H, q), 1.4 (3H, s).
Intermediate RA
(S)-3-Amino-1,1,1-trifluoro-2-methyl propan-2-ol hydrochloride
##STR00101##
[0557] Step 1: Benzyl
3,3,3-trifluoro-2-hydroxy-2-methylpropylcarbamate
[0558] To a stirring suspension of
amino-1,1,1-trifluoro-2-methylpropan-2-ol hydrochloride
(Intermediate R) (1.5 g, 8.35 mmol) in DCM (50 ml) was added TEA
93.54 g, 35.0 mmol) followed by benzyl 2,5-dioxopyrrolidin-1-yl
carbonate (1.983 g, 7.96 mmol). The mixture was stirred at RT for 6
hours and then diluted with water. The organic portion was
separated using a phase separator and concentrated in vacuo.
Purification by chromatography on silica eluting with 0-70% EtOAc
in iso-hexane afforded the title product; 1H NMR (400 MHz, DMSO-d6)
.delta. 7.34 (6H, m), 5.98 (1H, s), 5.05 (2H, s), 3.31 (1H, m),
3.18 (1H, m), 1.21 (3H. s) LC-MS: Rt 1.05 min; MS m/z 278.1 [M+H]+;
Method 2minLC_v003.
Step 2. Separation of Enantiomers of benzyl
3,3,3-trifluoro-2-hydroxy-2-methyl propylcarbamate
[0559] Benzyl 3,3,3-trifluoro-2-hydroxy-2-methylpropylcarbamate
(1.7 g) was dissolved in 2-propanol (10 ml) and purified using the
following chromatographic conditions:
[0560] Mobile Phase: 10% 2-propanol/90% CO.sub.2
[0561] Column: 2.times. Chiralcel OJ-H, 250.times.10 mm id, 5 .mu.m
(columns coupled in series)
[0562] Detection: UV @ 220 nm
[0563] Flow rate: 10 ml/min
[0564] Sample concentration: 1.7 g in 10 ml 2-propanol
[0565] Injection volume: 75 .mu.l
[0566] First eluted peak: Rt=6.94 minutes (R)-benzyl
3,3,3-trifluoro-2-hydroxy-2-methyl propylcarbamate
[0567] Second eluted peak: Rt=8.04 minutes (S)-benzyl
3,3,3-trifluoro-2-hydroxy-2-methyl propylcarbamate (Stereochemistry
confirmed by analysis of final compound prepared by subsequent
steps)
Step 3: (S)-3-Amino-1,1,1-trifluoro-2-methylpropan-2-ol
hydrochloride
[0568] A mixture comprising (S)-benzyl
3,3,3-trifluoro-2-hydroxy-2-methyl propylcarbamate in EtOH (165 ml)
was pumped through a H-Cube (hydrogenation reactor, 1-2 ml/min, 1
bar pressure, RT) for 8 hours using a 10% palladium on carbon
catalyst cartridge. 1.25 M HCl in methanol (130 ml) was added to
the mixture was stirred for 30 mins. The solvent was removed in
vacuo azeotroping with MeCN to afford the title product as a white
powder; 1H NMR (400 MHz, DMSO-d6) .delta. 8.3 (3H, broad), 6.8 (1H,
s), 3.0 (2H, s), 1.5 (3H, s).
[0569] Alternatively, racemic
3-Amino-1,1,1-trifluoro-2-methylpropan-2-ol can be resolved into
separate enantiomers by recrystallistion with either (S)-Mandelic
acid or L-tartaric acid in isopropanol or ethanol.
Intermediate S
2-Aminomethyl-1,1,1,3,3,3-hexafluoro-propan-2-ol
[0570] 3,3,3-Trifluoro-2-(trifluoromethyl)-1,2-propenoxide (1 g,
5.55 mmol) was added to a stirred solution of aqueous ammonia
solution (0.88 g/ml, 3 ml) and diethyl ether (3 ml). The resulting
colourless solution was stirred at room temperature for 3 hours.
The biphasic mixture was separated and and the aqueous portion was
further extracted with diethyl ether (2.times.5 ml). The combined
organic layers were dried over MgSO.sub.4 and concentrated in vacuo
(no heating) to afford the title compound as a white crystalline
solid which was used without further purification; 1H NMR (400 MHz,
DMSO-d6) signals unassigned b 4.20 (broad), 3.15 (s).
Intermediate T
3,3,3-Trifluoro-2-methoxy-2-methylpropan-1-amine
##STR00102##
[0571] Step 1:
2-(3,3,3-Trifluoro-2-hydroxy-2-methylpropyl)isoindoline-1,3-dione
[0572] A mixture comprising
3,3,3-trifluoro-2-hydroxy-2-methyl-propyl-ammonium (0.9 g),
phthalic anhydride (1.039 g) and DIPEA (2.188 ml) in chloroform (30
ml) was heated at 70.degree. C. for 5 hours. After cooling to RT,
the mixture was washed with water and passed through a phase
separator. The organic phase was reduced to dryness. The crude
product was purified by chromatography on silica, eluting in a 0%
to 30% iso-hexane:EtOAc removed to give the title product; 1H NMR
(400 MHz, Methanol-d4) .delta. 7.92 (2H, m), 7.85 (2H, m), 3.95
(2H, m), 1.36 (3H, s).
Step 2.
2-(3,3,3-Trifluoro-2-methoxy-2-methylpropyl)isoindoline-1,3-dione
[0573] To a stirring solution of
2-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl) isoindoline-1,3-dione
(250 mg, 0.915 mmol)) at 0.degree. C. in THF (8 ml), NaH (80 mg, 2
mmol) was added. After 30 minutes methyl iodide (1.299, 9.15 mmol)
was added. The reaction mixture was left stirring in a ice-bath and
allowed to warm to 25.degree. C. over 3.5 hours. The reaction was
quenched with sat. NH.sub.4Cl and the mixture extracted with DCM.
The organic extract was separated using a phase seperator and
purification by chromatography on silica, eluting in a 0% to 30%
iso-hexane:EtOAc afforded the title product; 1H NMR (400 MHz,
Methanol-d4) .delta. 7.91 (2H, m), 7.85 (2H, m), 3.97 (2H, m), 3.44
(3H, s), 1.42 (3H, s); LC-MS: Rt 1.17 min; MS m/z 288.10 [M+H]+;
Method 2minLC_v003.
Step 3: 3,3,3-Trifluoro-2-methoxy-2-methylpropan-1-amine
[0574] A mixture comprising
2-(3,3,3-trifluoro-2-methoxy-2-methylpropyl)isoindoline-1,3-dione
(272 mg, 0.95 mmol) and hydrazine (0.033 ml, 1.045 mmol) was
stirred at 75.degree. C. for 4 hours. After cooling to RT, the
mixture was filtered and the filtrate was concentrated in vacuo to
afford the title product which was used without further
purification (no characterisation data available).
[0575] From the foregoing it will be appreciated that, although
specific embodiments of the invention have been described herein
for purposes of illustration, various modifications may be made
without deviating from the spirit and scope of the invention.
Accordingly, the invention is not limited except as by the appended
claims.
EMBODIMENTS/CONSISTORY CLAUSES
Embodiment 1
[0576] A compounds according to Formula I:
##STR00103##
or pharmaceutically acceptable salts thereof, wherein: A is N or
CR.sup.4a; R.sup.1 is H; C.sub.1-C.sub.8 alkyl optionally
substituted by one or more halogen atoms; C.sub.2-C.sub.8 alkenyl;
C.sub.2-C.sub.8 alkynyl; C.sub.3-C.sub.10 cycloalkyl;
C.sub.5-C.sub.10 cycloalkenyl; --C.sub.1-C.sub.4
alkyl-C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.8 alkoxy optionally
substituted by one or more halogen atoms; halogen;
SO.sub.2NR.sup.8R.sup.9; SO.sub.2R.sup.10; S--C.sub.1-C.sub.8alkyl
optionally substituted by one or more halogen atoms;
S--C.sub.6-C.sub.14 aryl; --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; CN;
NR.sup.11R.sup.12; CONR.sup.13R.sup.14; NR.sup.13SO.sub.2R.sup.15;
NR.sup.13C(O)R.sup.15 and CO.sub.2R.sup.15, wherein the cycloalkyl,
cycloalkenyl, aryl and heterocyclyl groups are each optionally
substituted by one or more Z substituents; R.sup.2 is
C.sub.1-C.sub.4 haloalkyl; R.sup.3, R.sup.4 and R.sup.4a are each
independently H or C.sub.1-C.sub.8 alkyl optionally substituted by
one or more halogen atoms; R.sup.5 and R.sup.6 are each
independently H; C.sub.1-C.sub.8 alkyl optionally substituted by
one or more halogen atoms; C.sub.2-C.sub.8 alkenyl; C.sub.2-C.sub.8
alkynyl; C.sub.3-C.sub.10 cycloalkyl; C.sub.5-C.sub.10
cycloalkenyl; --C.sub.1-C.sub.4 alkyl-C.sub.3-C.sub.8 cycloalkyl;
C.sub.1-C.sub.8 alkoxy optionally substituted by one or more
halogen atoms; OH; CN; halogen; --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; or
--(C.sub.0-C.sub.4 alkyl)-CO.sub.2R.sup.15, wherein the cycloalkyl,
cycloalkenyl, --(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl and
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group
groups are each optionally substituted by one or more Z
substituents; or R.sup.5 and R.sup.6 are each independently a group
of the formula:
--(CH.sub.2).sub.m--NR.sup.17R.sup.18; or
R.sup.5 and R.sup.6 are each independently a group of the
formula:
--(CH.sub.2).sub.m--OR.sup.4; or
R.sup.4 and R.sup.5 together with the carbon atoms to which they
are bound form a 3 to 8 membered carbocyclic ring system; or
R.sup.5 and R.sup.6 together with the carbon atoms to which they
are bound form a 5 to 8 membered carbocyclic ring system or a 5 to
8 membered heterocyclic ring system containing one or more
heteroatoms selected from N, O and S, wherein the ring system is
optionally substituted by one or more Z substituents; R.sup.4,
R.sup.5 and R.sup.6 cannot all be the same; m is 0, 1, 2 or 3;
R.sup.8, R.sup.11, R.sup.13 and R.sup.17 are each independently H,
C.sub.1-C.sub.8 alkyl optionally substituted by one or more halogen
atoms, C.sub.3-C.sub.10 cycloalkyl or --(C.sub.1-C.sub.4
alkyl)-C.sub.3-C.sub.8 cycloalkyl; R.sup.9, R.sup.10, R.sup.12,
R.sup.14, R.sup.5, R.sup.16 and R.sup.18 are each independently H;
C.sub.1-C.sub.8 alkyl optionally substituted by one or more halogen
atoms; C.sub.2-C.sub.8 alkenyl; C.sub.2-C.sub.8 alkynyl;
C.sub.3-C.sub.10 cycloalkyl; C.sub.5-C.sub.10 cycloalkenyl;
--C.sub.1-C.sub.4 alkyl-C.sub.3-C.sub.8 cycloalkyl;
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl; or
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group,
wherein the heterocyclic group contains at least one heteroatom
selected from N, O and S, wherein the cycloalkyl, cycloalkenyl,
aryl and heterocyclyl groups are each optionally substituted by one
or more Z substituents; or R.sup.8 and R.sup.9, R.sup.11 and
R.sup.12, R.sup.13 and R.sup.14, and R.sup.17 and R.sup.18 together
with the nitrogen atom to which they are attached may form a 4 to
14 membered heterocyclic group optionally substituted by one or
more Z substituents; Z is independently OH, aryl, O-aryl, benzyl,
O-benzyl, C.sub.1-C.sub.6 alkyl optionally substituted by one or
more OH groups or NH.sub.2 groups, C.sub.1-C.sub.6 alkyl optionally
substituted by one or more halogen atoms, C.sub.1-C.sub.6 alkoxy
optionally substituted by one or more OH groups or C.sub.1-C.sub.4
alkoxy, NR.sup.18(SO.sub.2)R.sup.21, (SO.sub.2)NR.sup.19R.sup.21,
(SO.sub.2)R.sup.21, NR.sup.18C(O)R.sup.21, C(O)NR.sup.19R.sup.21,
NR.sup.18C(O)NR.sup.19R.sup.21, NR.sup.18C(O)OR.sup.19,
NR.sup.19R.sup.21, C(O)OR.sup.19, C(O)R.sup.19, SR.sup.19,
OR.sup.19, oxo, CN, NO.sub.2, halogen or a 3 to 14 membered
heterocyclic group, wherein the heterocyclic group contains at
least one heteroatom selected from N, O and S; R.sup.19 and
R.sup.21 are each independently H; C.sub.1-C.sub.8 alkyl;
C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.4 alkoxy-C.sub.1-C.sub.4
alkyl; (C.sub.0-C.sub.4 alkyl)-aryl optionally substituted by one
or more groups selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkoxy and halogen; (C.sub.0-C.sub.4 alkyl)-3- to 14-membered
heterocyclic group, the heterocyclic group including one or more
heteroatoms selected from N, O and S, optionally substituted by one
or more groups selected from halogen, oxo, C.sub.1-C.sub.6 alkyl
and C(O)C.sub.1-C.sub.6 alkyl; (C.sub.0-C.sub.4 alkyl)-O-aryl
optionally substituted by one or more groups selected from
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy and halogen; and
(C.sub.0-C.sub.4 alkyl)-O-3- to 14-membered heterocyclic group, the
heterocyclic group including one or more heteroatoms selected from
N, O and S, optionally substituted by one or more groups selected
from halogen, C.sub.1-C.sub.6 alkyl or C(O)C.sub.1-C.sub.6 alkyl;
wherein the alkyl groups are optionally substituted by one or more
halogen atoms, C.sub.1-C.sub.4 alkoxy, C(O)NH.sub.2,
C(O)NHC.sub.1-C.sub.6 alkyl or C(O)N(C.sub.1-C.sub.6 alkyl).sub.2;
or R.sup.19 and R.sup.21 together with the nitrogen atom to which
they attached form a 5- to 10-membered heterocyclic group, the
heterocyclic group including one or more further heteroatoms
selected from N, O and S, the heterocyclic group being optionally
substituted by one or more substituents selected from OH; halogen;
aryl; 5- to 10-membered heterocyclic group including one or more
heteroatoms selected from N, O and S; S(O).sub.2-aryl;
S(O).sub.2--C.sub.1-C.sub.6 alkyl; C.sub.1-C.sub.6 alkyl optionally
substituted by one or more halogen atoms; C.sub.1-C.sub.6 alkoxy
optionally substituted by one or more OH groups or C.sub.1-C.sub.4
alkoxy; and C(O)OC.sub.1-C.sub.6 alkyl, wherein the aryl and
heterocyclic substituent groups are themselves optionally
substituted by C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl or
C.sub.1-C.sub.6 alkoxy.
Embodiment 2
[0577] The compound of Formula I
##STR00104##
or pharmaceutically acceptable salts thereof, wherein:
A is N or CR.sup.4a;
[0578] R.sup.1 is H; C.sub.1-C.sub.8 alkyl optionally substituted
by one or more halogen atoms; C.sub.2-C.sub.8 alkenyl;
C.sub.2-C.sub.8 alkynyl; C.sub.3-C.sub.10 cycloalkyl;
C.sub.5-C.sub.10 cycloalkenyl; --C.sub.1-C.sub.4
alkyl-C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.8 alkoxy optionally
substituted by one or more halogen atoms; halogen;
SO.sub.2NR.sup.8R.sup.9; SO.sub.2R.sup.10; S--C.sub.1-C.sub.8alkyl
optionally substituted by one or more halogen atoms;
S--C.sub.6-C.sub.14 aryl; CN; NR.sup.11R.sup.12;
C(O)NR.sup.13R.sup.14; NR.sup.13SO.sub.2R.sup.15;
NR.sup.13C(O)R.sup.15, CO.sub.2R.sup.15, --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; or --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; wherein
the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are each
optionally substituted by one or more Z substituents; R.sup.2 is
C.sub.1-C.sub.4 haloalkyl; R.sup.3 and R.sup.4a are each
independently H or C.sub.1-C.sub.8 alkyl optionally substituted by
one or more halogen atoms; R.sup.4 is H, or C.sub.1-C.sub.8 alkyl
optional substituted with one or more halogen; R.sup.5 is
--(CH.sub.2).sub.m--NR.sup.17R.sup.18, --(CH.sub.2).sub.m--OR';
C.sub.1-C.sub.8 alkoxy optionally substituted by one or more
halogen atoms; --(C.sub.0-C.sub.4 alkyl)-CO.sub.2R.sup.15;
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl or -3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; wherein
the --(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl and
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group are
each optionally substituted by one or more Z substituents; R.sup.6
is C.sub.1-C.sub.8 alkyl optionally substituted by one or more
halogen atoms; C.sub.3-C.sub.10 cycloalkyl; --C.sub.1-C.sub.4
alkyl-C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.8 alkoxy optionally
substituted by one or more halogen atoms; OH; CN; halogen;
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl; or
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group,
wherein the heterocyclic group contains at least one heteroatom
selected from N, O and S; wherein the cycloalkyl, cycloalkenyl,
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl and
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group are
each optionally substituted by one or more Z substituents; or
R.sup.6 is H, and R.sup.5 is --(CH.sub.2).sub.m--NR.sup.17R.sup.18,
--(CH.sub.2).sub.m--OR', C.sub.1-C.sub.8 alkoxy optionally
substituted by one or more halogen atoms; --(C.sub.0-C.sub.4
alkyl)-CO.sub.6--C.sub.14 aryl; --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; or
--(C.sub.0-C.sub.4 alkyl)-CO.sub.2R.sup.15, wherein
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl and
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group
groups are each optionally substituted by one or more Z
substituents; or R.sup.4 and R.sup.6 together with the carbon atoms
to which they are bound form a 3 to 8 membered carbocyclic ring
system; or R.sup.4 and R.sup.5 together form an oxo group (C.dbd.O)
and R.sup.6 is C.sub.1-C.sub.4 alkyl optionally substituted by one
or more halogen atoms; C.sub.1-C.sub.4 alkoxy optionally
substituted by one or more halogen atoms; --(C.sub.0-C.sub.4
alkyl)-CO.sub.6--C.sub.14 aryl; or --(C.sub.0-C.sub.4 alkyl)-3 to
14 membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S, wherein
the aryl and heterocyclyl groups are each optionally substituted by
one or more Z substituents; or R.sup.5 and R.sup.6 together with
the carbon atoms to which they are bound a 5 to 8 membered
heterocyclic ring system containing one or more heteroatoms
selected from N, O and S, wherein the ring system is optionally
substituted by one or more Z substituents; or R.sup.4 and R.sup.5
and R.sup.6 together with the carbon atoms to which they are bound
form a 5 to 8 membered heterocyclic ring system containing one or
more heteroatoms selected from N, O and S, wherein the ring system
is optionally substituted by one or more Z substituents; R' is H,
or C.sub.1-C.sub.8 alkyl optional substituted with one or more
halogen; m is 0, 1, 2 or 3; R.sup.8, R.sup.11, R.sup.13 and
R.sup.17 are each independently H, C.sub.1-C.sub.8 alkyl optionally
substituted by one or more halogen atoms, C.sub.3-C.sub.10
cycloalkyl or --(C.sub.1-C.sub.4 alkyl)-C.sub.3-C.sub.8 cycloalkyl;
R.sup.9, R.sup.10, R.sup.12, R.sup.14, R.sup.15, R.sup.16 and
R.sup.18 are each independently H; C.sub.1-C.sub.8 alkyl optionally
substituted by one or more halogen atoms; C.sub.2-C.sub.8 alkenyl;
C.sub.2-C.sub.8 alkynyl; C.sub.3-C.sub.10 cycloalkyl;
C.sub.5-C.sub.10 cycloalkenyl; --C.sub.1-C.sub.4
alkyl-C.sub.3-C.sub.8 cycloalkyl; --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; or --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S, wherein
the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are each
optionally substituted by one or more Z substituents; or R.sup.8
and R.sup.9, R.sup.11 and R.sup.12, R.sup.13 and R.sup.14, and
R.sup.17 and R.sup.18 together with the nitrogen atom to which they
are attached may form a 4 to 14 membered heterocyclic group
optionally substituted by one or more Z substituents; Z is
independently OH, aryl, O-aryl, benzyl, O-benzyl, C.sub.1-C.sub.6
alkyl optionally substituted by one or more OH groups or NH.sub.2
groups, C.sub.1-C.sub.6 alkyl optionally substituted by one or more
halogen atoms, C.sub.1-C.sub.6 alkoxy optionally substituted by one
or more OH groups or C.sub.1-C.sub.4 alkoxy,
NR.sup.18(SO.sub.2)R.sup.21, (SO.sub.2)NR.sup.19R.sup.21,
(SO.sub.2)R.sup.21, NR.sup.18C(O)R.sup.21, C(O)NR.sup.19R.sup.21,
NR.sup.18C(O)NR.sup.19R.sup.21, NR.sup.18C(O)OR.sup.19,
NR.sup.19R.sup.21, C(O)OR.sup.19, C(O)R.sup.19, SR.sup.19,
OR.sup.19, oxo, CN, NO.sub.2, halogen or a 3 to 14 membered
heterocyclic group, wherein the heterocyclic group contains at
least one heteroatom selected from N, O and S; R.sup.19 and
R.sup.21 are each independently H; C.sub.1-C.sub.8 alkyl;
C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.4 alkoxy-C.sub.1-C.sub.4
alkyl; (C.sub.0-C.sub.4 alkyl)-aryl optionally substituted by one
or more groups selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkoxy and halogen; (C.sub.0-C.sub.4 alkyl)-3- to 14-membered
heterocyclic group, the heterocyclic group including one or more
heteroatoms selected from N, O and S, optionally substituted by one
or more groups selected from halogen, oxo, C.sub.1-C.sub.6 alkyl
and C(O)C.sub.1-C.sub.6 alkyl; (C.sub.0-C.sub.4 alkyl)-O-aryl
optionally substituted by one or more groups selected from
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy and halogen; and
(C.sub.0-C.sub.4 alkyl)-O-3- to 14-membered heterocyclic group, the
heterocyclic group including one or more heteroatoms selected from
N, O and S, optionally substituted by one or more groups selected
from halogen, C.sub.1-C.sub.6 alkyl or C(O)C.sub.1-C.sub.6 alkyl;
wherein the alkyl groups are optionally substituted by one or more
halogen atoms, C.sub.1-C.sub.4 alkoxy, C(O)NH.sub.2,
C(O)NHC.sub.1-C.sub.6 alkyl or C(O)N(C.sub.1-C.sub.6 alkyl).sub.2;
or R.sup.19 and R.sup.21 together with the nitrogen atom to which
they attached form a 5- to 10-membered heterocyclic group, the
heterocyclic group including one or more further heteroatoms
selected from N, O and S, the heterocyclic group being optionally
substituted by one or more substituents selected from OH; halogen;
aryl; 5- to 10-membered heterocyclic group including one or more
heteroatoms selected from N, O and S; S(O).sub.2-aryl;
S(O).sub.2--C.sub.1-C.sub.6 alkyl; C.sub.1-C.sub.6 alkyl optionally
substituted by one or more halogen atoms; C.sub.1-C.sub.6 alkoxy
optionally substituted by one or more OH groups or C.sub.1-C.sub.4
alkoxy; and C(O)OC.sub.1-C.sub.6 alkyl, wherein the aryl and
heterocyclic substituent groups are themselves optionally
substituted by C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl or
C.sub.1-C.sub.6 alkoxy.
Embodiment 3
[0579] The compound according to embodiment 1 or 2, wherein [0580]
R.sup.1 is H; C.sub.1-C.sub.4 alkyl optionally substituted by one
or more halogen atoms; C.sub.1-C.sub.4 alkoxy optionally
substituted by one or more halogen atoms; halogen; C.sub.6-C.sub.14
aryl; --(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic
group, wherein the heterocyclic group contains at least one
heteroatom selected from N, O and S; or --NR.sup.11R.sup.12,
wherein the aryl and heterocyclic groups are each optionally
substituted by one or more Z substituents.
Embodiment 4
[0581] The compound according to embodiment 1 to 3, wherein [0582]
R.sup.1 is C.sub.1-C.sub.4 alkyl optional substituted by one or
more halogen atoms.
Embodiment 5
[0583] The compound according to embodiment 1 to 4, wherein [0584]
R.sup.1 is --CH.sub.3 or CF.sub.3.
Embodiment 6
[0585] The compound according to embodiment 1, 2 or 3, wherein
[0586] R.sup.1 is C.sub.1-C.sub.4 alkoxy optional substituted by
one or more halogen atoms.
Embodiment 7
[0587] The compound according to embodiment 1, 2, 3 or 6, wherein
[0588] R.sup.1 is --OCH.sub.3, --OCH.sub.2CH.sub.3 or
--OCF.sub.3.
Embodiment 8
[0589] The compound according to embodiments 1, 2 or 3, wherein
R.sup.1 is aryl, wherein aryl is phenyl optionally substituted by
one or more Z substituents, Embodiment 9: The compound according to
embodiment 1, 2, 3 or 8, wherein R.sup.1 is 4-fluorophenyl,
4-chloro-2-methylphenyl, or 2,4-dichlorophenyl.
Embodiment 10
[0590] The compound according to embodiment 1, 2 or 3, wherein
R.sup.1 is pyridyl, oxazole, pyrrolidine or pyrazole and is
optionally substituted by one or more Z substituents.
Embodiment 11
[0591] The compound according to embodiment 1, 2, 3 or 10, wherein
R.sup.1 is 1-methyl-4-pyridyl, oxzaoyl-2-yl,
1-methyl-1H-pyrazole-4-yl or pyrrolidin-1 yl.
Embodiment 12
[0592] The compound according to embodiment 1 to 11, wherein
R.sup.1 is Br, --CH.sub.3, --CF.sub.3, --OCH.sub.3,
--OCH.sub.2CH.sub.3, --OCF.sub.3, 4-fluorophenyl,
4-chloro-2-methylphenyl, 2,4-dichlorophenyl, 1-methyl-4-pyridyl,
1-methyl-1H-pyrazole-4-yl, oxzaoyl-2-yl, or pyrrolidin-1yl.
Embodiment 13
[0593] The compound according to embodiment 1 to 12, wherein
R.sup.5 provides a heteroatom two carbons from the amide nitrogen,
wherein the heteroatom is oxygen or nitrogen.
Embodiment 14
[0594] The compound according to embodiment 1 to 13, wherein [0595]
R.sup.4 is H or C.sub.1-C.sub.4 alkyl optionally substituted by one
or more halogen atoms; [0596] R.sup.5 is C.sub.1-C.sub.4 alkoxy
optionally substituted by one or more halogen atoms;
--(CH.sub.2).sub.m--NR.sup.17R.sup.18; --(CH.sub.2).sub.m--OR', or
OH; [0597] R' is H, or C.sub.1-C.sub.4 alkyl optional substituted
with one or more halogen; [0598] m is 0, 1 or 2; [0599] R.sup.6 is
C.sub.1-C.sub.4 alkyl optionally substituted by one or more halogen
atoms; C.sub.1-C.sub.4 alkoxy optionally substituted by one or more
halogen atoms; OH; CN; halogen; --(C.sub.0-C.sub.4 alkyl)-C.sub.6
aryl; or --(C.sub.0-C.sub.4 alkyl)-5 to 6 membered heterocyclic
group, wherein the heterocyclic group contains at least one
heteroatom selected from N, O and S, wherein the aryl and
heterocyclyl groups are each optionally substituted by one or more
Z substituents; or [0600] R.sup.4 and R.sup.6 together with the
carbon atoms to which they are bound form a 3 to 8 membered
carbocyclic ring system; or [0601] R.sup.5 and R.sup.6 together
with the carbon atoms to which they are bound a 5 to 8 membered
heterocyclic ring system containing one or more heteroatoms
selected from N, O and S, wherein the ring system is optionally
substituted by one or more Z substituents; [0602] R.sup.17 and
R.sup.18 are each independently H; or C.sub.1-C.sub.4 alkyl
optionally substituted by one or more halogen atoms.
Embodiment 15
[0603] The compound according to any proceeding embodiment, wherein
[0604] R.sup.3 is H; [0605] R.sup.4 is H or Me; [0606] R.sup.4a is
H; [0607] R.sup.5 is --(CH.sub.2).sub.m--NR.sup.17R.sup.18;
--(CH.sub.2).sub.m--OR'; or OH; [0608] m is 0, or 1; [0609] R' is
H; [0610] R.sup.6 is C.sub.1-C.sub.4 alkyl optionally substituted
by one or more halogen atoms; or [0611] R.sup.5 and R.sup.6
together with the carbon atoms to which they are bound form a 5 to
6 membered heterocyclic ring system containing one or more
heteroatoms selected from N, O and S, wherein the ring system is
optionally substituted by one or more Z substituents; and [0612]
R.sup.17 and R.sup.18 are each independently H; or C.sub.1-C.sub.4
alkyl optionally substituted by one or more halogen atoms.
Embodiment 16
[0613] The compound according to any proceeding embodiment, wherein
[0614] R.sup.3 is H; [0615] R.sup.4 is H or Me; [0616] R.sup.4a is
H; [0617] R.sup.5 is --NR.sup.17R.sup.18; or OH; [0618] R.sup.6 is
C.sub.1-C.sub.4 alkyl optionally substituted by one or more halogen
atoms; or [0619] R.sup.5 and R.sup.6 together with the carbon atoms
to which they are bound form a 5 to 6 membered heterocyclic ring
system containing one or more heteroatoms selected from N, O and S,
wherein the ring system is optionally substituted by one or more Z
substituents; and [0620] R.sup.17 and R.sup.18 are each
independently H; or C.sub.1-C.sub.4 alkyl optionally substituted by
one or more halogen atoms.
Embodiment 17
[0621] The compound according to any proceeding claim, wherein
[0622] R.sup.3 is H; [0623] R.sup.4 is H or Me; [0624] R.sup.4a is
H; [0625] R.sup.5 is --NR.sup.17R.sup.18; or OH; [0626] R.sup.6 is
C.sub.1-C.sub.4 alkyl optionally substituted by one or more halogen
atoms; and [0627] R.sup.17 and R.sup.18 are each independently H;
or C.sub.1-C.sub.4 alkyl optionally substituted by one or more
halogen atoms.
Embodiment 18
[0628] The compound according to embodiment 1 to 13, wherein [0629]
R.sup.3 is H; [0630] R.sup.4a is H; [0631] R.sup.4 and R.sup.5 form
an oxo group; [0632] R.sup.6 is C.sub.1-C.sub.4 alkyl optionally
substituted by one or more halogen atoms; C.sub.1-C.sub.4 alkoxy
optionally substituted by one or more halogen atoms; phenyl; or 5
to 6 membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S, wherein
the phenyl and heterocyclyl groups are each optionally substituted
by one or more Z substituents.
Embodiment 19
[0633] The compound according to embodiment 1 to 13 or 18, wherein
[0634] R.sup.3 is H; [0635] R.sup.4a is H; [0636] R.sup.4 and
R.sup.5 form an oxo group; [0637] R.sup.6 is C.sub.1-C.sub.4 alkyl
optionally substituted by one or more halogen atoms; or phenyl,
wherein the phenyl is optionally substituted by one or more Z
substituents; [0638] Z is independently OH, C.sub.1-C.sub.4 alkyl
optionally substituted by one or more OH groups or NH.sub.2 groups,
C.sub.1-C.sub.4 alkyl optionally substituted by one or more halogen
atoms, C.sub.1-C.sub.4 alkoxy optionally substituted by one or more
OH groups or C.sub.1-C.sub.4 alkoxy, C(O)OR.sup.19, C(O)R.sup.19,
OR.sup.19, CN, or halogen; [0639] R.sup.19 is H; C.sub.1-C.sub.4
alkyl; C.sub.3-C.sub.6 cycloalkyl; or C.sub.1-C.sub.4
alkoxy-C.sub.1-C.sub.4 alkyl, wherein all alkyl are optionally
substituted with halogens.
Embodiment 20
[0640] The compound according to embodiment 1 to 13 or 18 to 19,
wherein [0641] R.sup.3 is H; [0642] R.sup.4a is H; [0643] R.sup.4
and R.sup.5 form an oxo group; [0644] R.sup.6 is C.sub.1-C.sub.4
alkyl optionally substituted by one or more halogen atoms; or
phenyl, [0645] wherein the phenyl is optionally substituted by one
or more Z substituents; [0646] Z is independently, C.sub.1-C.sub.4
alkyl optionally substituted by one or more halogen atoms,
C.sub.1-C.sub.4 alkoxy or halogen.
Embodiment 21
[0647] The compound according to embodiment 1 to 13, wherein the
compound is represented by formula II,
##STR00105##
or a pharmaceutically acceptable salt thereof, wherein, R.sup.101
is selected from the following:
##STR00106## ##STR00107##
Embodiment 22
[0648] The compound according to embodiment 21, wherein [0649]
R.sup.3 is H;
R.sup.101 is
##STR00108##
[0650] Embodiment 23
[0651] The compound according to embodiment 21, wherein [0652]
R.sup.3 is H;
##STR00109##
[0652] R.sup.101 is
Embodiment 24
[0653] The compound according to embodiment 21, wherein [0654]
R.sup.3 is H;
R.sup.101 is
##STR00110##
[0655] Embodiment 25
[0656] The compound according to embodiment 21, wherein [0657]
R.sup.3 is H;
R.sup.101 is
##STR00111##
[0658] Embodiment 26
[0659] The compound according to embodiment 1 to 13, wherein [0660]
R.sup.3 is H; [0661] R.sup.101 is --(C.sub.1-C.sub.2 alkyl)-5 to 10
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S, wherein
the aryl and heterocyclyl groups are each optionally substituted by
one or more Z substituents.
Embodiment 27
[0662] The compound according to embodiment 21 or 26, wherein
[0663] R.sup.3 is H;
R.sup.101 is
##STR00112##
[0664] Embodiment 28
[0665] The compound of formula III
##STR00113##
or pharmaceutically acceptable salts thereof, wherein:
A is N or CR.sup.4a;
X is NR.sup.y or O;
[0666] R.sup.1 is C.sub.1-C.sub.8 alkyl optionally substituted by
one or more halogen atoms; C.sub.3-C.sub.10 cycloalkyl;
--C.sub.1-C.sub.4 alkyl-C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.8
alkoxy optionally substituted by one or more halogen atoms;
halogen; CN; NR.sup.11R.sup.12; C(O)NR.sup.13R.sup.14;
NR.sup.13C(O)R.sup.15, CO.sub.2R.sup.15, --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; or --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; wherein
the cycloalkyl, aryl and heterocyclyl groups are each optionally
substituted by one or more Z substituents; R.sup.2 is
C.sub.1-C.sub.4 haloalkyl; R.sup.3 and R.sup.4a are each
independently H or C.sub.1-C.sub.8 alkyl optionally substituted by
one or more halogen atoms; R.sup.4 is H, or C.sub.1-C.sub.8 alkyl
optional substituted with one or more halogen; R.sup.5a is H,
C.sub.1-C.sub.8 alkyl optional substituted with one or more
halogen, --(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl or -3 to
14 membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; wherein
the --(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl and
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group are
each optionally substituted by one or more Z substituents; R.sup.y
is H, C.sub.1-C.sub.8 alkyl optional substituted with one or more
halogen, --(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl or -3 to
14 membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; wherein
the --(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl and
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group are
each optionally substituted by one or more Z substituents; R.sup.6
is C.sub.1-C.sub.8 alkyl optionally substituted by one or more
halogen atoms; C.sub.3-C.sub.10 cycloalkyl; --C.sub.1-C.sub.4
alkyl-C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.8 alkoxy optionally
substituted by one or more halogen atoms; OH; CN; halogen;
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl; or
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group,
wherein the heterocyclic group contains at least one heteroatom
selected from N, O and S; wherein the cycloalkyl, cycloalkenyl,
--(C.sub.0-C.sub.4 alkyl)-C.sub.6-C.sub.14 aryl and
--(C.sub.0-C.sub.4 alkyl)-3 to 14 membered heterocyclic group are
each optionally substituted by one or more Z substituents; or
R.sup.4 and R.sup.6 together with the carbon atoms to which they
are bound form a 3 to 8 membered carbocyclic ring system; or
R.sup.5a and R.sup.6 together with the atoms to which they are
bound a 5 to 8 membered heterocyclic ring system containing one or
more heteroatoms selected from N, O and S, wherein the ring system
is optionally substituted by one or more Z substituents; or
R.sup.5a and R.sup.y together with the atoms to which they are
bound a 5 to 8 membered heterocyclic ring system containing one or
more heteroatoms selected from N, O and S, wherein the ring system
is optionally substituted by one or more Z substituents; R.sup.11
and R.sup.13 are each independently H, C.sub.1-C.sub.8 alkyl
optionally substituted by one or more halogen atoms,
C.sub.3-C.sub.10 cycloalkyl or --(C.sub.1-C.sub.4
alkyl)-C.sub.3-C.sub.8 cycloalkyl; R.sup.12, R.sup.14, and R.sup.15
are each independently H; C.sub.1-C.sub.8 alkyl optionally
substituted by one or more halogen atoms; C.sub.2-C.sub.8 alkenyl;
C.sub.2-C.sub.8 alkynyl; C.sub.3-C.sub.10 cycloalkyl;
C.sub.5-C.sub.10 cycloalkenyl; --C.sub.1-C.sub.4
alkyl-C.sub.3-C.sub.8 cycloalkyl; --(C.sub.0-C.sub.4
alkyl)-C.sub.6-C.sub.14 aryl; or --(C.sub.0-C.sub.4 alkyl)-3 to 14
membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S, wherein
the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are each
optionally substituted by one or more Z substituents; or R.sup.11
and R.sup.12, and R.sup.13 and R.sup.14 together with the nitrogen
atom to which they are attached may form a 4 to 14 membered
heterocyclic group optionally substituted by one or more Z
substituents; Z is independently OH, aryl, O-aryl, benzyl,
O-benzyl, C.sub.1-C.sub.6 alkyl optionally substituted by one or
more OH groups or NH.sub.2 groups, C.sub.1-C.sub.6 alkyl optionally
substituted by one or more halogen atoms, C.sub.1-C.sub.6 alkoxy
optionally substituted by one or more OH groups or C.sub.1-C.sub.4
alkoxy, NR.sup.18(SO.sub.2)R.sup.21, (SO.sub.2)NR.sup.19R.sup.21,
(SO.sub.2)R.sup.21, NR.sup.18C(O)R.sup.21, C(O)NR.sup.19R.sup.21,
NR.sup.18C(O)NR.sup.19R.sup.21, NR.sup.18C(O)OR.sup.19,
NR.sup.19R.sup.21, C(O)OR.sup.19, C(O)R.sup.19, SR.sup.19,
OR.sup.19, oxo, CN, NO.sub.2, halogen or a 3 to 14 membered
heterocyclic group, wherein the heterocyclic group contains at
least one heteroatom selected from N, O and S; R.sup.19 and
R.sup.21 are each independently H; C.sub.1-C.sub.8 alkyl;
C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.4 alkoxy-C.sub.1-C.sub.4
alkyl; (C.sub.0-C.sub.4 alkyl)-aryl optionally substituted by one
or more groups selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkoxy and halogen; (C.sub.0-C.sub.4 alkyl)-3- to 14-membered
heterocyclic group, the heterocyclic group including one or more
heteroatoms selected from N, O and S, optionally substituted by one
or more groups selected from halogen, oxo, C.sub.1-C.sub.6 alkyl
and C(O)C.sub.1-C.sub.6 alkyl; (C.sub.0-C.sub.4 alkyl)-O-aryl
optionally substituted by one or more groups selected from
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy and halogen; and
(C.sub.0-C.sub.4 alkyl)-O-3- to 14-membered heterocyclic group, the
heterocyclic group including one or more heteroatoms selected from
N, O and S, optionally substituted by one or more groups selected
from halogen, C.sub.1-C.sub.6 alkyl or C(O)C.sub.1-C.sub.6 alkyl;
wherein the alkyl groups are optionally substituted by one or more
halogen atoms, C.sub.1-C.sub.4 alkoxy, C(O)NH.sub.2,
C(O)NHC.sub.1-C.sub.6 alkyl or C(O)N(C.sub.1-C.sub.6 alkyl).sub.2;
or R.sup.19 and R.sup.21 together with the nitrogen atom to which
they attached form a 5- to 10-membered heterocyclic group, the
heterocyclic group including one or more further heteroatoms
selected from N, O and S, the heterocyclic group being optionally
substituted by one or more substituents selected from OH; halogen;
aryl; 5- to 10-membered heterocyclic group including one or more
heteroatoms selected from N, O and S; S(O).sub.2-aryl;
S(O).sub.2--C.sub.1-C.sub.6 alkyl; C.sub.1-C.sub.6 alkyl optionally
substituted by one or more halogen atoms; C.sub.1-C.sub.6 alkoxy
optionally substituted by one or more OH groups or C.sub.1-C.sub.4
alkoxy; and C(O)OC.sub.1-C.sub.6 alkyl, wherein the aryl and
heterocyclic substituent groups are themselves optionally
substituted by C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl or
C.sub.1-C.sub.6 alkoxy.
Embodiment 29
[0667] The compound according to embodiment 28, wherein
A is N or CR.sup.4a;
X is NR.sup.y or O;
[0668] R.sup.1 is C.sub.1-C.sub.4 alkyl optionally substituted by
one or more halogen atoms; C.sub.1-C.sub.4 alkoxy optionally
substituted by one or more halogen atoms; halogen;
--(C.sub.0-C.sub.4 alkyl)-C.sub.6 aryl; or --(C.sub.0-C.sub.4
alkyl)-5 to 6 membered heterocyclic group, wherein the heterocyclic
group contains at least one heteroatom selected from N, O and S;
wherein the cycloalkyl, aryl and heterocyclyl groups are each
optionally substituted by one or more Z substituents; R.sup.2 is
C.sub.1-C.sub.4 haloalkyl; R.sup.3 and R.sup.4a are H; R.sup.4 is
H, or C.sub.1-C.sub.4 alkyl optional substituted with one or more
halogen; R.sup.5a is H, C.sub.1-C.sub.4 alkyl optional substituted
with one or more halogen, --(C.sub.0-C.sub.4 alkyl)-C.sub.6 aryl or
-5 to 8 membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; wherein
the --(C.sub.0-C.sub.4 alkyl)-C.sub.6 aryl and -5 to 8 membered
heterocyclic group are each optionally substituted by one or more Z
substituents; R.sup.y is H, C.sub.1-C.sub.4 alkyl optional
substituted with one or more halogen, --(C.sub.0-C.sub.4
alkyl)-C.sub.6 aryl or -5 to 8 membered heterocyclic group, wherein
the heterocyclic group contains at least one heteroatom selected
from N, O and S; wherein the --(C.sub.0-C.sub.4 alkyl)-C.sub.6 aryl
and -5 to 8 membered heterocyclic group are each optionally
substituted by one or more Z substituents; R.sup.6 is
C.sub.1-C.sub.4 alkyl optionally substituted by one or more halogen
atoms; C.sub.1-C.sub.4 alkoxy optionally substituted by one or more
halogen atoms; OH; CN; --(C.sub.0-C.sub.4 alkyl)-C.sub.6 aryl; or
-5 to 8 membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; wherein
the --C.sub.6 aryl and -5 to 8 membered heterocyclic group are each
optionally substituted by one or more Z substituents; or R.sup.4
and R.sup.6 together with the carbon atoms to which they are bound
form a 3 to 8 membered carbocyclic ring system; or R.sup.5a and
R.sup.6 together with the atoms to which they are bound a 5 to 8
membered heterocyclic group containing one or more heteroatoms
selected from N, O and S, wherein the heterocyclic group is
optionally substituted by one or more Z substituents; or R.sup.5a
and R.sup.y together with the atoms to which they are bound a 5 to
8 membered heterocyclic ring system containing one or more
heteroatoms selected from N, O and S, wherein the ring system is
optionally substituted by one or more Z substituents; Z is
independently OH, aryl, O-aryl, C.sub.1-C.sub.6 alkyl optionally
substituted by one or more OH groups or NH.sub.2 groups,
C.sub.1-C.sub.6 alkyl optionally substituted by one or more halogen
atoms, C.sub.1-C.sub.6 alkoxy optionally substituted by one or more
OH groups or C.sub.1-C.sub.4 alkoxy, NR.sup.18C(O)R.sup.21,
C(O)NR.sup.19R.sup.21, NR.sup.19R.sup.21, C(O)OR.sup.19,
C(O)R.sup.19, SR.sup.19, OR.sup.19, oxo, CN, NO.sub.2, halogen or a
5 to 8 membered heterocyclic group, wherein the heterocyclic group
contains at least one heteroatom selected from N, O and S; wherein
the heterocyclic group is option substituted by halogen,
C.sub.1-C.sub.4 alkyl optionally substituted by halogen,
C.sub.1-C.sub.4 alkoxy or --CN; R.sup.18 is H or C.sub.1-C.sub.4
alkyl; R.sup.19 and R.sup.21 are each independently H;
C.sub.1-C.sub.8 alkyl; C.sub.3-C.sub.8 cycloalkyl; C.sub.1-C.sub.4
alkoxy-C.sub.1-C.sub.4 alkyl; (C.sub.0-C.sub.4 alkyl)-aryl
optionally substituted by one or more groups selected from
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy and halogen;
(C.sub.0-C.sub.4 alkyl)-3- to 14-membered heterocyclic group, the
heterocyclic group including one or more heteroatoms selected from
N, O and S, optionally substituted by one or more groups selected
from halogen, oxo, C.sub.1-C.sub.6 alkyl and C(O)C.sub.1-C.sub.6
alkyl; (C.sub.0-C.sub.4 alkyl)-O-aryl optionally substituted by one
or more groups selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkoxy and halogen; and (C.sub.0-C.sub.4 alkyl)-O-3- to 14-membered
heterocyclic group, the heterocyclic group including one or more
heteroatoms selected from N, O and S, optionally substituted by one
or more groups selected from halogen, C.sub.1-C.sub.6 alkyl or
C(O)C.sub.1-C.sub.6 alkyl; wherein the alkyl groups are optionally
substituted by one or more halogen atoms, C.sub.1-C.sub.4 alkoxy,
C(O)NH.sub.2, C(O)NHC.sub.1-C.sub.6 alkyl or C(O)N(C.sub.1-C.sub.6
alkyl).sub.2; or R.sup.19 and R.sup.21 together with the nitrogen
atom to which they attached form a 5- to 10-membered heterocyclic
group, the heterocyclic group including one or more further
heteroatoms selected from N, O and S, the heterocyclic group being
optionally substituted by one or more substituents selected from
OH; halogen; aryl; 5- to 10-membered heterocyclic group including
one or more heteroatoms selected from N, O and S; S(O).sub.2-aryl;
S(O).sub.2--C.sub.1-C.sub.6 alkyl; C.sub.1-C.sub.6 alkyl optionally
substituted by one or more halogen atoms; C.sub.1-C.sub.6 alkoxy
optionally substituted by one or more OH groups or C.sub.1-C.sub.4
alkoxy; and C(O)OC.sub.1-C.sub.6 alkyl, wherein the aryl and
heterocyclic substituent groups are themselves optionally
substituted by C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl or
C.sub.1-C.sub.6 alkoxy.
Embodiment 30
[0669] The compound according to embodiment 28 or 29, wherein
A is N or CR.sup.4a;
X is NR.sup.y or O;
[0670] R.sup.1 is C.sub.1-C.sub.4 alkyl optionally substituted by
one or more halogen atoms; C.sub.1-C.sub.4 alkoxy optionally
substituted by one or more halogen atoms; or halogen; R.sup.2 is
CF.sub.3; R.sup.3 and R.sup.4a are H; R.sup.4 is H, or
C.sub.1-C.sub.4 alkyl optional substituted with one or more
halogen; R.sup.5a is H, C.sub.1-C.sub.4 alkyl optional substituted
with one or more halogen, R.sup.y is H, C.sub.1-C.sub.4 alkyl
optional substituted with one or more halogen, R.sup.6 is
C.sub.1-C.sub.4 alkyl optionally substituted by one or more halogen
atoms; C.sub.1-C.sub.4 alkoxy optionally substituted by one or more
halogen atoms; OH; CN; or R.sup.4 and R.sup.6 together with the
carbon atoms to which they are bound form a 3 to 6 membered
carbocyclic ring system; or R.sup.5a and R.sup.6 together with the
atoms to which they are bound a 5 to 8 membered heterocyclic group
containing one or more heteroatoms selected from N, O and S,
wherein the heterocyclic group is optionally substituted by one or
more Z substituents; or R.sup.5a and R.sup.y together with the
atoms to which they are bound a 5 to 8 membered heterocyclic ring
system containing one or more heteroatoms selected from N, O and S,
wherein the ring system is optionally substituted by one or more Z
substituents; Z is independently OH, C.sub.1-C.sub.6 alkyl
optionally substituted by one or more OH groups or NH.sub.2 groups,
C.sub.1-C.sub.6 alkyl optionally substituted by one or more halogen
atoms, C.sub.1-C.sub.6 alkoxy optionally substituted by one or more
OH groups or C.sub.1-C.sub.4 alkoxy, NR.sup.19R.sup.21,
C(O)OR.sup.19, C(O)R.sup.19, SR.sup.19, OR.sup.19, oxo, CN,
NO.sub.2, or halogen; R.sup.19 is H; C.sub.1-C.sub.8 alkyl;
(C.sub.0-C.sub.4 alkyl)-aryl optionally substituted by one or more
groups selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy
and halogen; (C.sub.0-C.sub.4 alkyl)-3- to 14-membered heterocyclic
group, the heterocyclic group including one or more heteroatoms
selected from N, O and S, optionally substituted by one or more
groups selected from halogen, oxo, C.sub.1-C.sub.6 alkyl and
C(O)C.sub.1-C.sub.6 alkyl; (C.sub.0-C.sub.4 alkyl)-O-aryl
optionally substituted by one or more groups selected from
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy and halogen; and
(C.sub.0-C.sub.4 alkyl)-O-3- to 14-membered heterocyclic group, the
heterocyclic group including one or more heteroatoms selected from
N, O and S, optionally substituted by one or more groups selected
from halogen, C.sub.1-C.sub.6 alkyl or C(O)C.sub.1-C.sub.6 alkyl;
wherein the alkyl groups are optionally substituted by one or more
halogen atoms, C.sub.1-C.sub.4 alkoxy, C(O)NH.sub.2,
C(O)NHC.sub.1-C.sub.6 alkyl or C(O)N(C.sub.1-C.sub.6 alkyl).sub.2;
or R.sup.19 and R.sup.21 together with the nitrogen atom to which
they attached form a 5- to 6-membered heterocyclic group, the
heterocyclic group including one or more further heteroatoms
selected from N, O and S, the heterocyclic group being optionally
substituted by one or more substituents selected from OH; halogen;
aryl; 5- to 10-membered heterocyclic group including one or more
heteroatoms selected from N, O and S; S(O).sub.2-aryl;
S(O).sub.2--C.sub.1-C.sub.6 alkyl; C.sub.1-C.sub.6 alkyl optionally
substituted by one or more halogen atoms; C.sub.1-C.sub.6 alkoxy
optionally substituted by one or more OH groups or C.sub.1-C.sub.4
alkoxy; and C(O)OC.sub.1-C.sub.6 alkyl, wherein the aryl and
heterocyclic substituent groups are themselves optionally
substituted by C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl or
C.sub.1-C.sub.6 alkoxy.
Embodiment 31
[0671] The compound according to embodiment 28 to 30, wherein
A is N or CR.sup.4a;
X is NR.sup.y or O;
[0672] R.sup.1 is C.sub.1-C.sub.4 alkyl optionally substituted by
one or more halogen atoms; C.sub.1-C.sub.4 alkoxy optionally
substituted by one or more halogen atoms; or halogen; R.sup.2 is
CF.sub.3; R.sup.3 and R.sup.4a are H; R.sup.4 is H, or
C.sub.1-C.sub.4 alkyl optional substituted with one or more
halogen; R.sup.5a is H, C.sub.1-C.sub.4 alkyl optional substituted
with one or more halogen, R.sup.y is H, C.sub.1-C.sub.4 alkyl
optional substituted with one or more halogen, R.sup.6 is
C.sub.1-C.sub.4 alkyl optionally substituted by one or more halogen
atoms; C.sub.1-C.sub.4 alkoxy optionally substituted by one or more
halogen atoms; OH; CN; or R.sup.5a and R.sup.6 together with the
atoms to which they are bound a 5 to 8 membered heterocyclic group
containing one or more heteroatoms selected from N, O and S,
wherein the heterocyclic group is optionally substituted by one or
more Z substituents; or R.sup.5a and R.sup.y together with the
atoms to which they are bound a 5 to 8 membered heterocyclic ring
system containing one or more heteroatoms selected from N, O and S,
wherein the ring system is optionally substituted by one or more Z
substituents; Z is independently OH, C.sub.1-C.sub.6 alkyl
optionally substituted by one or more OH groups or NH.sub.2 groups,
C.sub.1-C.sub.6 alkyl optionally substituted by one or more halogen
atoms, C.sub.1-C.sub.6 alkoxy optionally substituted by one or more
OH groups or C.sub.1-C.sub.4 alkoxy, oxo, CN, NO.sub.2, or
halogen;
Embodiment 32
[0673] The compound according to any of the proceeding embodiments,
A is N.
Embodiment 33
[0674] The compound to embodiments 1 to 31, wherein A is
CR.sup.4a.
Embodiment 34
[0675] The compound according to embodiment 33, wherein A is
CR.sup.4a and R.sup.4a is H.
Embodiment 35
[0676] The compound according to any proceeding embodiment, wherein
R.sup.2 is CF.sub.3CF.sub.2--, (CF.sub.3).sub.2CH--,
CH.sub.3--CF.sub.2--, CF.sub.3CF.sub.2--, CF.sub.3, CF.sub.2H--,
CH.sub.3--CCl.sub.2--, CF.sub.3CFCClH--, CBr.sub.3,
CBr.sub.2H--CF.sub.3CF.sub.2CHCF.sub.3 or
CF.sub.3CF.sub.2CF.sub.2CF.sub.2--.
Embodiment 36
[0677] The compound according to any proceeding embodiment, wherein
R.sup.2 is CF.sub.3.
Embodiment 37
[0678] The compound according to any proceeding embodiment, wherein
the compound is a substantially pure enantiomer with the S
configuration.
Embodiment 38
[0679] The compound according to embodiment 1 to 36, wherein the
compound is a substantially pure enantiomer with the R
configuration.
Embodiment 39
[0680] The compound according to embodiment 2, 21 or 28, wherein
the compound is represented by: [0681]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0682]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-propyl)-amide; [0683]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-propyl)-amide; [0684]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
[(R)-1-(tetrahydro-furan-2-yl)methyl]-amide; [0685]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
([1,3]dioxolan-2-ylmethyl)-amide; [0686]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
[(S)-1-(tetrahydro-furan-2-yl)methyl]-amide; [0687]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(tetrahydro-furan-2-ylmethyl)-amide; [0688]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(2-methyl-2-piperidin-1-yl-propyl)-amide; [0689]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(2-hydroxy-propyl)-amide; [0690]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(2-hydroxy-2-methyl-propyl)-amide; [0691]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(2-methyl-tetrahydro-furan-2-yl-methyl)-amide; [0692]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(2-methoxy-ethyl)-amide; [0693]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
[2-(4-fluoro-phenyl)-2-morpholin-4-yl-ethyl]-amide; [0694]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(2-morpholin-4-yl-2-phenyl-ethyl)-amide; [0695]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(2-dimethylamino-2-phenyl-ethyl)-amide; [0696]
3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0697]
3-Amino-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0698]
3-Amino-6-(4-chloro-2-methyl-phenyl)-5-trifluoromethyl-pyridine-2-carboxy-
lic acid ((R)-3,3,3-trifluoro-2-hydroxy-propyl)-amide; [0699]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-2-trifluoromethyl-propyl)-amide; [0700]
5-Amino-6'-methyl-3-trifluoromethyl-[2,3']bipyridinyl-6-carboxylic
acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0701]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0702]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0703]
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0704]
3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0705]
3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0706]
3-amino-6-(2,4-dichloro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0707]
3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid (2-hydroxy-2-methyl-propyl)-amide; [0708]
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-propyl)-amide; [0709]
5-Amino-6'-methyl-3-trifluoromethyl-[2,3']bipyridinyl-6-carboxylic
acid (3,3,3-trifluoro-2-hydroxy-2-trifluoromethyl-propyl)-amide;
[0710]
5-Amino-6'-methyl-3-trifluoromethyl-[2,3']bipyridinyl-6-carboxylic
acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0711]
3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0712]
3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid
((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0713]
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0714]
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0715]
Methyl
3-(3-amino-6-bromo-5-(trifluoromethyl)picolinamido)propanoate;
[0716]
3-Amino-N-(benzo[d]isoxazol-3-ylmethyl)-6-bromo-5-(trifluoromethyl)
picolinamide; [0717]
3-Amino-6-(oxazol-2-yl)-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(t-
rifluoromethyl)picolinamide; [0718]
3-Amino-6-bromo-N-(3,3,3-trifluoro-2-methoxy-2-methylpropyl)-5-(trifluoro-
methyl)picolinamide; [0719]
3-amino-N-(2-hydroxy-3-methyl-2-(trifluoromethyl)butyl)-6-methoxy-5-(trif-
luoromethyl)picolinamide; [0720]
3-Amino-6-cyclopropyl-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(tri-
fluoromethyl)picolinamide; [0721]
3-Amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-(trifluoromethyl)propyl)-
-5-(trifluoro methyl) picolinamide; [0722]
5-amino-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-3-(trifluoromethyl)--
2,4'-bipyridine-6-carboxamide; [0723]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(3-methyl-2-oxo-butyl)-amide; [0724]
3-Amino-6-(1-methyl-1H-pyrazol-4-yl)-N-(3,3,3-trifluoro-2-hydroxy-2-methy-
lpropyl)-5-(trifluoromethyl)picolinamide; [0725]
(S)-3-amino-6-ethoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trif-
luoro [0726] methyl)picolinamide; [0727]
3-Amino-6-(pyrrolidin-1-yl)-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)--
5-(trifluoromethyl)picolinamide; [0728]
3-Amino-N-(2-amino-3,3,3-trifluoro-2-methylpropyl)-6-methoxy-5-(trifluoro-
methyl) picolinamide; or [0729]
3-Amino-6-methoxy-N-(3,3,3-trifluoro-2-(4-methoxybenzylamino)-2-methylpro-
pyl)-5-(trifluoromethyl)picolinamide.
Embodiment 40
[0730] The compound according to embodiment 39, wherein the
compound is [0731]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
[(R)-1-(tetrahydro-furan-2-yl)methyl]-amide; [0732]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
([1,3]dioxolan-2-ylmethyl)-amide; [0733]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
[(S)-1-(tetrahydro-furan-2-yl)methyl]-amide; [0734]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(tetrahydro-furan-2-ylmethyl)-amide; or [0735]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(2-methyl-tetrahydro-furan-2-yl-methyl)-amide.
Embodiment 41
[0736] The compound according to embodiment 2, 21 or 28, wherein
the compound is [0737]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
[2-(4-fluoro-phenyl)-2-morpholin-4-yl-ethyl]-amide; [0738]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
[2-(4-fluoro-phenyl)-2-morpholin-4-yl-ethyl]-amide; [0739]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(2-morpholin-4-yl-2-phenyl-ethyl)-amide; [0740]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(2-dimethylamino-2-phenyl-ethyl)-amide; [0741]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(3-methyl-2-morpholin-4-yl-butyl)-amide; [0742]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(2-methyl-2-morpholin-4-yl-propyl)-amide; [0743]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(1-morpholin-4-yl-cyclohexylmethyl)-amide; [0744]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(2-morpholin-4-yl-2-phenyl-ethyl)-amide; [0745]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(2-dimethylamino-2-phenyl-ethyl)-amide; [0746]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
[2-(4-methoxy-phenyl)-2-pyrrolidin-1-yl-ethyl]-amide; [0747]
3-Amino-N-(2-amino-3,3,3-trifluoro-2-methylpropyl)-6-methoxy-5-(trifluoro-
methyl) picolinamide; or [0748]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
[2-dimethylamino-2-(4-methoxy-phenyl)-ethyl]-amide.
Embodiment 42
[0749] The compound according to embodiment 2, 21 or 28, wherein
the compound is [0750]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(2-methyl-tetrahydro-furan-2-yl-methyl)-amide; [0751]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
[2-(4-fluoro-phenyl)-2-morpholin-4-yl-ethyl]-amide; [0752]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(3-methyl-2-morpholin-4-yl-butyl)-amide; [0753]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(2-methyl-2-morpholin-4-yl-propyl)-amide; [0754]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(1-morpholin-4-yl-cyclohexylmethyl)-amide; [0755]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(2-morpholin-4-yl-2-phenyl-ethyl)-amide; [0756]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
(2-dimethylamino-2-phenyl-ethyl)-amide; [0757]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
[2-(4-methoxy-phenyl)-2-pyrrolidin-1-yl-ethyl]-amide; [0758]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
[2-dimethylamino-2-(4-methoxy-phenyl)-ethyl]-amide; [0759]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
[2-(4-fluoro-phenyl)-2-oxo-ethyl]-amide; [0760]
3-Amino-6-furan-2-yl-5-trifluoromethyl-pyrazine-2-carboxylic acid
[2-(2-methoxy-phenyl)-ethyl]-amide; [0761]
3-amino-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5,6-bis(trifluoromet-
hyl) pyrazine-2-carboxamide; [0762]
N-(2-(1H-imidazol-2-yl)propyl)-3-amino-6-bromo-5-(trifluoromethyl)pyrazin-
e-2-carboxamide; [0763]
3-Amino-6-bromo-N-(2-morpholinoethyl)-5-(trifluoromethyl)pyrazine-2-carbo-
xamide; or [0764]
3-Amino-6-bromo-5-trifluoromethyl-pyrazine-2-carboxylic acid
[2-(4-fluoro-phenyl)-2-oxo-ethyl]-amide.
Embodiment 43
[0765] The compound according to embodiment 39, wherein the
compound is [0766]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0767]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
(3,3,3-trifluoro-2-hydroxy-propyl)-amide; [0768]
3-Amino-6-bromo-5-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-propyl)-amide; [0769]
3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0770]
3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid
((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0771]
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0772]
3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0773]
3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0774]
3-amino-6-(2,4-dichloro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide; [0775]
3-Amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic
acid (2-hydroxy-2-methyl-propyl)-amide; or [0776]
3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid
((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide.
Embodiment 44
[0777] Use of a compound according to embodiment 1 to 43 in the
manufacture of a medicament for use in the treatment of an
inflammatory or obstructive airways disease or mucosal
hydration.
Embodiment 45
[0778] Use of a compound according to embodiment 1 to 43 in the
manufacture of a medicament for use in the treatment of a disease
mediated by CFTR.
Embodiment 46
[0779] Use of a compound according to embodiment 42 in the
manufacture of a medicament for use in the treatment of a disease
mediated by CFTR, wherein the disease is CF or COPD.
Embodiment 47
[0780] Use of a compound according to embodiment 1 to 43 in the
manufacture of a medicament for use in the treatment of cystic
fibrosis.
Embodiment 48
[0781] A pharmaceutical composition for treating a disease or
disorder mediated by CFTR, comprising: [0782] the compound
according to embodiment 1 to 43 and [0783] one or more
pharmaceutically acceptable excipients.
Embodiment 49
[0784] A pharmaceutical composition, according to embodiment 48,
wherein the disease or disorder is cystic fibrosis or COPD.
Embodiment 49
[0785] A pharmaceutical composition, according to embodiment 49,
wherein the disease or disorder is cystic fibrosis.
Embodiment 50
[0786] A pharmaceutical combination, comprising: [0787] a first
active comprising the compound according to embodiment 1 to 43 and
[0788] a second active selected from osmotic agents, ENaC blockers,
anti-inflammatory agents, bronchodilatory agents, antihistamine
agents, anti-tussive agents, antibiotic agents and DNase drug
substances, wherein the first and second actives may be in the same
or different pharmaceutical composition.
Embodiment 51
[0789] A pharmaceutical combination according to embodiment 50,
wherein the second active agent is an EnaC blocker.
Embodiment 52
[0790] A process for the preparation of compounds of formula (I),
comprising:
##STR00114## [0791] reacting a compound 1 with compound 2 in a
peptide coupling reaction,
##STR00115##
[0791] wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and
R.sup.6 are as defined herein and P is a suitable amino protecting
group; [0792] removing protecting groups and isolating the compound
of formula I.
Embodiment 53
[0793] The process according to embodiment 48, wherein the peptide
coupling condition is HATU in an aprotic solvent.
* * * * *